| # | Thr. | #G | #C | GO BP | GO CC | GO MF | KEGG | miRNA | CHR |
| 1 | 4/2 | 8 | 5 | VEGF signaling pathway (2.3e-02/3.7e-02/ 2/50) | |||||
| 2 | 4/2 | 32 | 5 | response to external stimulus (1.6e-03/1.5e+00/ 9/ 364) | extracellular space (6.3e-06/8.5e-01/ 9/ 237) | growth factor activity (3.3e-02/3.5e-01/ 4/91) | |||
| 3 | 4/2 | 12 | 5 | xenobiotic metabolic process (8.4e-05/1.6e-02/ 3/ 13) | glucuronosyltransferase activity (1.1e-04/1.4e-02/ 3/12) | Pentose and glucuronate interconversions (8.9e-05/1.9e-02/ 3/13) | |||
| 4 | 4/2 | 39 | 8 | regulation of bone mineralization (2.2e-03/5.2e-02/ 3/ 13) | extracellular region (5.2e-03/3.1e+00/ 11/ 673) | ||||
| 5 | 4/2 | 13 | 3 | proteinaceous extracellular matrix (3.5e-02/2.3e-01/ 3/ 153) | |||||
| 6 | 4/2 | 12 | 4 | ||||||
| 7 | 4/2 | 5 | 3 | cellular calcium ion homeostasis (2.8e-02/3.3e-02/ 2/ 60) | G-protein-coupled receptor binding (1.1e-02/1.5e-02/ 2/29) | ||||
| 8 | 4/2 | 22 | 6 | ||||||
| 9 | 4/2 | 31 | 7 | regulation of bone mineralization (1.4e-03/4.3e-02/ 3/ 13) | |||||
| 10 | 4/2 | 6 | 4 | cell maturation (1.2e-02/1.9e-02/ 2/ 27) | |||||
| 11 | 4/2 | 31 | 5 | extracellular region (1.2e-04/2.5e+00/ 12/ 673) | Wnt signaling pathway (2.8e-02/4.1e-01/ 4/109) | ||||
| 12 | 4/2 | 11 | 6 | ||||||
| 13 | 4/2 | 9 | 7 | antibacterial humoral response (4.5e-02/8.3e-04/ 1/ 1) | phagocytic vesicle membrane (2.7e-02/1.0e-03/ 1/ 1) | ||||
| 14 | 4/2 | 21 | 5 | translational elongation (4.6e-06/1.9e-01/ 6/ 91) | cytosolic ribosome (7.0e-07/1.6e-01/ 6/ 70) | structural constituent of ribosome (5.3e-05/2.5e-01/ 6/121) | Ribosome (6.9e-03/2.5e-01/ 4/68) | ||
| 15 | 4/2 | 30 | 7 | ||||||
| 16 | 4/2 | 7 | 5 | ||||||
| 17 | 4/2 | 27 | 3 | Focal adhesion (5.0e-02/5.1e-01/ 4/151) | |||||
| 18 | 4/2 | 7 | 5 | thiamin diphosphate biosynthetic process (3.4e-02/5.6e-04/ 1/ 1) | neurofilament (3.8e-02/1.5e-03/ 1/ 3) | ||||
| 19 | 4/2 | 26 | 3 | ||||||
| 20 | 4/2 | 5 | 6 | positive regulation of multicellular organismal process (3.4e-02/3.8e-02/ 2/ 69) | extracellular space (8.7e-03/1.5e-01/ 3/ 237) | ||||
| 21 | 4/2 | 4 | 3 | detection of hormone stimulus (3.4e-02/5.6e-04/ 1/ 1) | cytokine activity (4.1e-02/3.7e-02/ 2/71) | ||||
| 22 | 4/2 | 24 | 6 | vesicle-mediated transport (2.7e-02/1.0e+00/ 6/ 355) | cytoplasmic vesicle (8.3e-03/9.4e-01/ 6/ 319) | ||||
| 23 | 4/2 | 10 | 4 | ||||||
| 24 | 4/2 | 4 | 4 | regulation of isoprenoid metabolic process (3.4e-02/5.6e-04/ 1/ 1) | collagen type XV (1.5e-02/5.1e-04/ 1/ 1) | ||||
| 25 | 4/1.8 | 23 | 3 | positive regulation of cytokine biosynthetic process (4.6e-02/4.5e-02/ 2/ 19) | membrane (3.6e-03/7.6e+00/ 16/3116) | transmembrane receptor activity (2.0e-02/8.9e-01/ 6/324) | |||
| 26 | 4/1.8 | 14 | 8 | ||||||
| 27 | 4/1.8 | 8 | 5 | ||||||
| 28 | 4/1.8 | 8 | 6 | response to external stimulus (3.8e-03/2.5e-01/ 4/ 364) | extracellular space (2.4e-02/2.1e-01/ 3/ 237) | ||||
| 29 | 4/1.8 | 4 | 6 | positive regulation of nitric oxide biosynthetic process (1.8e-03/6.1e-03/ 2/ 11) | syntrophin complex (1.5e-02/5.1e-04/ 1/ 1) | cytokine activity (4.1e-02/3.7e-02/ 2/71) | |||
| 30 | 4/1.8 | 31 | 10 | response to external stimulus (1.2e-04/1.4e+00/ 10/ 364) | extracellular region part (1.2e-05/1.3e+00/ 10/ 376) | growth factor activity (2.4e-02/3.1e-01/ 4/91) | |||
| 31 | 4/1.8 | 30 | 3 | regulation of monooxygenase activity (2.8e-02/3.1e-02/ 2/ 8) | extracellular region (2.3e-04/2.2e+00/ 11/ 673) | ||||
| 32 | 4/1.8 | 22 | 8 | ||||||
| 33 | 4/1.8 | 18 | 5 | antigen processing and presentation of peptide or polysaccharide antigen via MHC class II (1.9e-04/2.1e-02/ 3/ 11) | MHC class II protein complex (2.6e-05/1.6e-02/ 3/ 7) | Asthma (2.0e-03/5.3e-02/ 3/11) | |||
| 34 | 4/1.8 | 6 | 7 | CMP-N-acetylneuraminate monooxygenase activity (4.2e-02/5.2e-04/ 1/1) | |||||
| 35 | 4/1.8 | 5 | 7 | hindgut morphogenesis (3.4e-02/5.6e-04/ 1/ 1) | trans-octaprenyltranstransferase activity (4.2e-02/5.2e-04/ 1/1) | ||||
| 36 | 4/1.8 | 21 | 9 | patterning of blood vessels (2.2e-02/2.6e-02/ 2/ 10) | melanosome (2.5e-02/2.0e-01/ 3/ 77) | ATP-dependent RNA helicase activity (4.9e-02/3.9e-02/ 2/15) | |||
| 37 | 4/1.8 | 4 | 7 | ||||||
| 38 | 4/1.8 | 5 | 6 | regulation of ARF protein signal transduction (1.0e-02/1.7e-02/ 2/ 31) | inositol pentakisphosphate 2-kinase activity (4.9e-02/6.6e-04/ 1/1) | ||||
| 39 | 4/1.8 | 21 | 5 | organic anion transport (1.3e-02/1.9e-02/ 2/ 8) | bile acid transmembrane transporter activity (2.8e-03/6.7e-03/ 2/3) | ||||
| 40 | 4/1.8 | 13 | 4 | ||||||
| 41 | 4/1.6 | 6 | 12 | synaptic vesicle targeting (4.0e-02/6.9e-04/ 1/ 1) | pseudopodium (3.8e-02/1.5e-03/ 1/ 3) | ||||
| 42 | 4/1.6 | 5 | 13 | regulation of axon diameter (3.4e-02/5.6e-04/ 1/ 1) | neurofilament (4.5e-02/1.9e-03/ 1/ 3) | ||||
| 43 | 4/1.6 | 7 | 8 | ||||||
| 44 | 4/1.6 | 27 | 12 | multicellular organismal development (2.4e-04/3.3e+00/ 13/1257) | extracellular region (2.3e-02/2.2e+00/ 8/ 673) | ||||
| 45 | 4/1.6 | 9 | 8 | ||||||
| 46 | 4/1.6 | 19 | 5 | ||||||
| 47 | 4/1.6 | 4 | 8 | negative regulation of vascular endothelial growth factor receptor signaling pathway (3.4e-02/5.6e-04/ 1/ 1) | desmosome (4.7e-02/2.0e-03/ 1/ 4) | chemoattractant activity (4.2e-02/5.2e-04/ 1/1) | |||
| 48 | 4/1.6 | 8 | 7 | nucleosome assembly (5.5e-04/3.3e-02/ 3/ 40) | nucleosome (2.4e-05/1.6e-02/ 3/ 21) | Systemic lupus erythematosus (3.9e-05/8.0e-02/ 4/54) | |||
| 49 | 4/1.6 | 6 | 12 | 16 (2.8e-02/ 0.2665/ 4/413) | |||||
| 50 | 4/1.6 | 46 | 10 | multicellular organismal process (2.6e-02/7.6e+00/ 17/1611) | extracellular region (6.6e-03/3.7e+00/ 12/ 673) | transmembrane receptor activity (1.8e-02/1.6e+00/ 8/324) | |||
| 51 | 4/1.6 | 4 | 11 | ||||||
| 52 | 4/1.6 | 4 | 8 | vitamin D binding (4.2e-02/5.2e-04/ 1/1) | |||||
| 53 | 4/1.6 | 13 | 8 | ||||||
| 54 | 4/1.6 | 4 | 8 | benzoate metabolic process (3.4e-02/5.6e-04/ 1/ 1) | kynureninase activity (4.2e-02/5.2e-04/ 1/1) | Tetrachloroethene degradation (4.1e-02/7.4e-04/ 1/1) | |||
| 55 | 4/1.6 | 9 | 9 | ||||||
| 56 | 4/1.6 | 5 | 8 | A band (3.2e-02/1.3e-03/ 1/ 2) | myosin II heavy chain binding (4.9e-02/6.6e-04/ 1/1) | ||||
| 57 | 4/1.4 | 5 | 10 | cell adhesion (3.2e-02/2.0e-01/ 3/ 368) | |||||
| 58 | 4/1.4 | 4 | 14 | synaptic vesicle docking during exocytosis (4.5e-02/8.3e-04/ 1/ 3) | |||||
| 59 | 4/1.4 | 30 | 13 | behavior (3.6e-04/6.3e-01/ 7/ 161) | extracellular region part (1.1e-06/1.3e+00/ 11/ 376) | cytokine activity (1.2e-02/2.4e-01/ 4/71) | Cytokine-cytokine receptor interaction (7.8e-03/5.1e-01/ 5/115) | ||
| 60 | 4/1.4 | 35 | 13 | nervous system development (6.2e-03/1.5e+00/ 8/ 402) | |||||
| 61 | 4/1.4 | 24 | 9 | translational elongation (1.5e-08/2.4e-01/ 8/ 91) | ribosome (3.9e-07/4.2e-01/ 8/ 149) | structural constituent of ribosome (9.2e-06/3.0e-01/ 7/121) | Ribosome (6.5e-04/2.8e-01/ 5/68) | ||
| 62 | 4/1.4 | 8 | 15 | A band (4.2e-02/1.8e-03/ 1/ 2) | |||||
| 63 | 4/1.4 | 13 | 12 | proteinaceous extracellular matrix (2.2e-02/2.0e-01/ 3/ 153) | |||||
| 64 | 4/1.4 | 7 | 11 | synaptic vesicle targeting (4.5e-02/8.3e-04/ 1/ 1) | gamma-glutamyltransferase activity (2.0e-04/1.6e-03/ 2/2) | ||||
| 65 | 4/1.4 | 4 | 14 | transcription factor TFIIA complex (3.8e-02/1.5e-03/ 1/ 3) | |||||
| 66 | 4/1.2 | 12 | 12 | ||||||
| 67 | 4/1.2 | 5 | 22 | dopamine receptor binding (4.2e-02/5.2e-04/ 1/1) | |||||
| 68 | 4/1.2 | 27 | 16 | behavior (1.3e-04/5.4e-01/ 7/ 161) | extracellular space (1.5e-06/7.3e-01/ 9/ 237) | cytokine activity (6.8e-03/2.0e-01/ 4/71) | Cytokine-cytokine receptor interaction (5.2e-03/4.7e-01/ 5/115) | ||
| 69 | 4/1.2 | 4 | 22 | 16 (3.8e-03/ 0.1777/ 4/413) | |||||
| 70 | 4/1.2 | 22 | 17 | vesicle coating (3.7e-02/3.8e-02/ 2/ 13) | |||||
| 71 | 4/1.2 | 4 | 19 | brain-derived neurotrophic factor receptor signaling pathway (3.4e-02/5.6e-04/ 1/ 1) | cytoskeletal part (1.7e-02/2.1e-01/ 3/ 418) | brain-derived neurotrophic factor binding (4.2e-02/5.2e-04/ 1/1) | |||
| 72 | 4/1.2 | 4 | 18 | erythropoietin receptor binding (4.2e-02/5.2e-04/ 1/1) | |||||
| 73 | 4/1.2 | 4 | 17 | ||||||
| 74 | 4/1.2 | 4 | 20 | water transport (4.5e-02/8.3e-04/ 1/ 2) | glycerol transmembrane transporter activity (3.5e-02/3.9e-04/ 1/1) | ||||
| 75 | 4/1.2 | 5 | 20 | DNA replication (8.3e-05/1.0e-01/ 4/ 180) | alpha DNA polymerase:primase complex (1.2e-04/2.6e-03/ 2/ 5) | DNA primase activity (2.4e-04/1.6e-03/ 2/3) | DNA replication (2.8e-02/3.7e-02/ 2/33) | ||
| 76 | 4/1 | 5 | 25 | endoplasmic reticulum lumen (1.3e-04/3.1e-02/ 3/ 48) | |||||
| 77 | 4/1 | 8 | 26 | phagocytosis (1.1e-02/1.8e-02/ 2/ 21) | transmembrane receptor activity (1.3e-02/3.0e-01/ 4/324) | ||||
| 78 | 4/1 | 5 | 27 | transmembrane receptor protein tyrosine phosphatase activity (4.6e-03/8.5e-03/ 2/13) | |||||
| 79 | 4/1 | 5 | 29 | rhythmic process (2.9e-02/3.3e-02/ 2/ 48) | Circadian rhythm (2.0e-05/1.3e-02/ 3/12) | ||||
| 80 | 4/1 | 7 | 29 | ||||||
| 81 | 4/1 | 28 | 21 | extracellular region (3.6e-02/2.3e+00/ 8/ 673) | |||||
| 82 | 4/1 | 6 | 21 | ||||||
| 83 | 4/1 | 4 | 25 | regulation of respiratory gaseous exchange by neurological process (2.8e-02/4.2e-04/ 1/ 1) | taurine binding (4.2e-02/5.2e-04/ 1/1) | ||||
| 84 | 4/1 | 4 | 30 | ||||||
| 85 | 4/1 | 6 | 22 | putrescine metabolic process (3.4e-02/5.6e-04/ 1/ 1) | agmatinase activity (4.9e-02/6.6e-04/ 1/1) | ||||
| 86 | 4/1 | 6 | 30 | fascia adherens (3.2e-02/1.3e-03/ 1/ 2) | |||||
| 87 | 4/1 | 4 | 26 | lipoprotein metabolic process (1.9e-02/2.6e-02/ 2/ 47) | |||||
| 88 | 3.8/2 | 16 | 5 | B cell receptor signaling pathway (1.4e-02/1.2e-01/ 3/47) | |||||
| 89 | 3.8/2 | 22 | 4 | B cell receptor signaling pathway (2.0e-02/1.4e-01/ 3/47) | |||||
| 90 | 3.8/2 | 52 | 7 | multicellular organismal process (3.7e-03/9.0e+00/ 21/1611) | extracellular region (1.4e-03/4.1e+00/ 14/ 673) | ||||
| 91 | 3.8/2 | 17 | 4 | ||||||
| 92 | 3.8/2 | 9 | 5 | axonemal dynein complex (4.7e-02/2.0e-03/ 1/ 2) | |||||
| 93 | 3.8/2 | 20 | 3 | blood coagulation (1.4e-02/1.1e-01/ 3/ 50) | extracellular region part (4.0e-02/9.1e-01/ 5/ 376) | ||||
| 94 | 3.8/2 | 13 | 3 | ||||||
| 95 | 3.8/2 | 45 | 6 | response to external stimulus (1.4e-04/2.1e+00/ 12/ 364) | extracellular space (1.8e-07/1.2e+00/ 12/ 237) | growth factor activity (1.4e-04/4.7e-01/ 7/91) | Cytokine-cytokine receptor interaction (2.1e-03/9.0e-01/ 7/115) | ||
| 96 | 3.8/2 | 19 | 4 | antigen processing and presentation of peptide or polysaccharide antigen via MHC class II (2.8e-04/2.4e-02/ 3/ 11) | MHC class II protein complex (2.6e-05/1.6e-02/ 3/ 7) | aldo-keto reductase activity (2.5e-02/2.5e-02/ 2/11) | Asthma (2.9e-03/6.1e-02/ 3/11) | ||
| 97 | 3.8/2 | 4 | 8 | benzoate metabolic process (3.4e-02/5.6e-04/ 1/ 1) | kynureninase activity (4.2e-02/5.2e-04/ 1/1) | ||||
| 98 | 3.8/2 | 6 | 7 | system development (1.0e-03/8.2e-01/ 6/ 987) | |||||
| 99 | 3.8/2 | 16 | 4 | ||||||
| 100 | 3.8/2 | 5 | 6 | regulation of axon diameter (3.4e-02/5.6e-04/ 1/ 1) | neurofilament (4.5e-02/1.9e-03/ 1/ 3) | ||||
| 101 | 3.8/2 | 11 | 4 | ||||||
| 102 | 3.8/2 | 5 | 5 | ||||||
| 103 | 3.8/2 | 15 | 3 | phagocytic vesicle membrane (3.8e-02/1.5e-03/ 1/ 1) | |||||
| 104 | 3.8/2 | 6 | 4 | thiamin diphosphate biosynthetic process (3.4e-02/5.6e-04/ 1/ 1) | thiamin diphosphokinase activity (4.9e-02/6.6e-04/ 1/1) | ||||
| 105 | 3.8/2 | 5 | 5 | ||||||
| 106 | 3.8/2 | 6 | 5 | female meiosis (4.5e-02/8.3e-04/ 1/ 3) | calcium- and calmodulin-responsive adenylate cyclase activity (3.5e-02/3.9e-04/ 1/1) | ||||
| 107 | 3.8/2 | 14 | 4 | angiogenesis (4.1e-02/1.8e-01/ 3/ 102) | extracellular region (7.9e-03/1.0e+00/ 6/ 673) | ||||
| 108 | 3.8/2 | 5 | 5 | cholinesterase activity (4.2e-02/5.2e-04/ 1/1) | |||||
| 109 | 3.8/2 | 40 | 7 | melanosome (1.6e-02/3.8e-01/ 4/ 77) | glycosaminoglycan binding (1.8e-02/2.8e-01/ 4/56) | ||||
| 110 | 3.8/2 | 16 | 4 | platelet activation (1.4e-02/2.0e-02/ 2/ 13) | |||||
| 111 | 3.8/2 | 11 | 4 | extracellular region (3.5e-02/9.5e-01/ 5/ 673) | hormone activity (4.3e-02/3.5e-02/ 2/27) | ||||
| 112 | 3.8/2 | 18 | 3 | phagocytic vesicle membrane (4.5e-02/1.9e-03/ 1/ 1) | |||||
| 113 | 3.8/2 | 30 | 3 | metal ion transport (1.2e-02/5.2e-01/ 5/ 170) | |||||
| 114 | 3.8/2 | 6 | 3 | thyroid hormone generation (4.0e-02/6.9e-04/ 1/ 1) | |||||
| 115 | 3.8/2 | 20 | 3 | dicarboxylic acid transport (6.4e-03/1.3e-02/ 2/ 5) | presynaptic membrane (1.9e-03/1.1e-02/ 2/ 5) | dicarboxylic acid transmembrane transporter activity (7.0e-03/1.1e-02/ 2/5) | |||
| 116 | 3.8/1.8 | 17 | 7 | Fc receptor complex (4.2e-02/1.8e-03/ 1/ 1) | |||||
| 117 | 3.8/1.8 | 8 | 5 | ||||||
| 118 | 3.8/1.8 | 7 | 6 | ||||||
| 119 | 3.8/1.8 | 9 | 4 | integral to plasma membrane (3.1e-02/5.5e-01/ 4/ 535) | |||||
| 120 | 3.8/1.8 | 46 | 7 | cell adhesion (1.3e-02/2.0e+00/ 9/ 368) | melanosome (2.8e-02/4.5e-01/ 4/ 77) | Small cell lung cancer (4.8e-03/4.3e-01/ 5/73) | |||
| 121 | 3.8/1.8 | 6 | 4 | growth hormone receptor complex (1.9e-02/6.4e-04/ 1/ 1) | |||||
| 122 | 3.8/1.8 | 23 | 3 | ||||||
| 123 | 3.8/1.8 | 7 | 6 | nervous system development (1.2e-02/3.4e-01/ 4/ 402) | |||||
| 124 | 3.8/1.8 | 16 | 6 | ||||||
| 125 | 3.8/1.8 | 10 | 6 | ||||||
| 126 | 3.8/1.8 | 14 | 10 | intermediate filament bundle assembly (8.5e-04/4.2e-03/ 2/ 3) | neurofilament (3.0e-04/4.2e-03/ 2/ 3) | Amyotrophic lateral sclerosis (ALS) (3.5e-02/4.2e-02/ 2/38) | |||
| 127 | 3.8/1.8 | 21 | 3 | ||||||
| 128 | 3.8/1.8 | 10 | 6 | ||||||
| 129 | 3.8/1.8 | 19 | 8 | regulation of body fluid levels (2.8e-02/1.5e-01/ 3/ 60) | ATP-dependent RNA helicase activity (4.6e-02/3.7e-02/ 2/15) | ||||
| 130 | 3.8/1.8 | 6 | 9 | detection of virus (4.0e-02/6.9e-04/ 1/ 1) | |||||
| 131 | 3.8/1.8 | 17 | 8 | neurotransmitter secretion (3.2e-02/3.4e-02/ 2/ 19) | endocytic vesicle (2.5e-02/4.6e-02/ 2/ 21) | ||||
| 132 | 3.8/1.8 | 31 | 5 | B cell receptor signaling pathway (2.6e-02/1.6e-01/ 3/47) | |||||
| 133 | 3.8/1.8 | 6 | 5 | growth hormone receptor complex (2.2e-02/7.7e-04/ 1/ 1) | |||||
| 134 | 3.8/1.8 | 18 | 4 | membrane (4.4e-02/6.0e+00/ 12/3116) | transmembrane receptor activity (3.5e-02/6.8e-01/ 5/324) | ||||
| 135 | 3.8/1.8 | 4 | 10 | immune response (1.9e-02/1.6e-01/ 3/ 287) | transmembrane receptor activity (2.8e-02/1.7e-01/ 3/324) | ||||
| 136 | 3.8/1.8 | 4 | 9 | regulation of axon diameter (2.8e-02/4.2e-04/ 1/ 1) | neurofilament (3.8e-02/1.5e-03/ 1/ 3) | ||||
| 137 | 3.8/1.8 | 15 | 9 | monovalent inorganic cation transport (4.4e-02/1.9e-01/ 3/ 127) | |||||
| 138 | 3.8/1.8 | 4 | 8 | taurochenodeoxycholate 6alpha-hydroxylase activity (2.6e-02/2.6e-04/ 1/1) | |||||
| 139 | 3.8/1.6 | 5 | 12 | cell morphogenesis (4.2e-02/2.2e-01/ 3/ 312) | |||||
| 140 | 3.8/1.6 | 43 | 12 | multicellular organismal process (5.9e-06/7.6e+00/ 23/1611) | extracellular region (4.0e-02/3.4e+00/ 10/ 673) | ||||
| 141 | 3.8/1.6 | 15 | 7 | myosin complex (2.2e-02/4.3e-02/ 2/ 24) | |||||
| 142 | 3.8/1.6 | 14 | 8 | ||||||
| 143 | 3.8/1.6 | 5 | 7 | taurochenodeoxycholate 6alpha-hydroxylase activity (3.5e-02/3.9e-04/ 1/1) | |||||
| 144 | 3.8/1.6 | 17 | 4 | extracellular region (3.7e-02/1.4e+00/ 6/ 673) | |||||
| 145 | 3.8/1.6 | 7 | 11 | ||||||
| 146 | 3.8/1.6 | 8 | 6 | growth hormone receptor complex (2.7e-02/1.0e-03/ 1/ 1) | |||||
| 147 | 3.8/1.6 | 8 | 10 | regulation of axon diameter (4.5e-02/8.3e-04/ 1/ 1) | integral to membrane (1.3e-02/2.0e+00/ 7/1983) | ||||
| 148 | 3.8/1.6 | 5 | 11 | monooxygenase activity (3.6e-03/8.9e-03/ 2/34) | |||||
| 149 | 3.8/1.6 | 5 | 12 | ||||||
| 150 | 3.8/1.6 | 5 | 8 | glycine:sodium symporter activity (4.2e-02/5.2e-04/ 1/1) | |||||
| 151 | 3.8/1.6 | 18 | 7 | ||||||
| 152 | 3.8/1.6 | 8 | 7 | angiogenesis (1.3e-02/1.1e-01/ 3/ 102) | |||||
| 153 | 3.8/1.6 | 4 | 12 | ||||||
| 154 | 3.8/1.4 | 20 | 14 | ||||||
| 155 | 3.8/1.4 | 9 | 10 | regulation of aldosterone metabolic process (5.0e-02/9.7e-04/ 1/ 1) | growth hormone receptor complex (3.0e-02/1.2e-03/ 1/ 1) | ||||
| 156 | 3.8/1.4 | 7 | 15 | regulation of ARF protein signal transduction (2.0e-02/2.6e-02/ 2/ 31) | |||||
| 157 | 3.8/1.4 | 11 | 9 | collagen type XIV (3.2e-02/1.3e-03/ 1/ 1) | |||||
| 158 | 3.8/1.4 | 14 | 10 | intermediate filament (3.3e-02/5.5e-02/ 2/ 33) | |||||
| 159 | 3.8/1.4 | 6 | 13 | S phase (6.6e-03/1.3e-02/ 2/ 15) | nucleoplasm (5.6e-04/4.3e-01/ 5/ 565) | ||||
| 160 | 3.8/1.4 | 49 | 13 | nervous system development (4.6e-03/2.2e+00/ 10/ 402) | neuron projection (1.5e-02/3.7e-01/ 4/ 65) | signal transducer activity (2.0e-02/4.3e+00/ 13/780) | |||
| 161 | 3.8/1.4 | 31 | 15 | cell leading edge (2.1e-02/1.8e-01/ 3/ 47) | |||||
| 162 | 3.8/1.4 | 8 | 14 | ||||||
| 163 | 3.8/1.4 | 4 | 13 | ||||||
| 164 | 3.8/1.4 | 15 | 14 | ||||||
| 165 | 3.8/1.4 | 5 | 14 | peptide secretion (7.0e-03/1.3e-02/ 2/ 19) | |||||
| 166 | 3.8/1.4 | 8 | 16 | ||||||
| 167 | 3.8/1.4 | 7 | 17 | induction of programmed cell death in response to chemical stimulus (5.0e-02/9.7e-04/ 1/ 1) | |||||
| 168 | 3.8/1.4 | 6 | 11 | Antigen processing and presentation (4.4e-02/5.0e-02/ 2/45) | |||||
| 169 | 3.8/1.4 | 13 | 14 | ||||||
| 170 | 3.8/1.4 | 16 | 5 | actomyosin, actin part (4.5e-02/1.9e-03/ 1/ 1) | |||||
| 171 | 3.8/1.4 | 6 | 14 | taurochenodeoxycholate 6alpha-hydroxylase activity (4.2e-02/5.2e-04/ 1/1) | |||||
| 172 | 3.8/1.4 | 5 | 13 | ||||||
| 173 | 3.8/1.2 | 5 | 22 | ||||||
| 174 | 3.8/1.2 | 63 | 12 | bone mineralization (8.7e-04/1.2e-01/ 4/ 18) | extracellular region (3.1e-04/5.1e+00/ 17/ 673) | transmembrane receptor activity (3.2e-02/2.3e+00/ 9/324) | |||
| 175 | 3.8/1.2 | 12 | 18 | response to virus (2.4e-04/9.0e-02/ 4/ 65) | |||||
| 176 | 3.8/1.2 | 5 | 18 | antigen processing and presentation of peptide or polysaccharide antigen via MHC class II (1.8e-03/6.1e-03/ 2/ 11) | MHC class II protein complex (3.7e-04/4.5e-03/ 2/ 7) | Systemic lupus erythematosus (3.7e-03/8.0e-02/ 3/54) | |||
| 177 | 3.8/1.2 | 4 | 19 | ||||||
| 178 | 3.8/1.2 | 14 | 17 | ||||||
| 179 | 3.8/1 | 7 | 31 | extracellular matrix organization (1.6e-02/2.3e-02/ 2/ 42) | proteinaceous extracellular matrix (1.3e-03/7.8e-02/ 3/ 153) | ||||
| 180 | 3.8/1 | 54 | 16 | multicellular organismal process (5.7e-04/9.9e+00/ 24/1611) | neuron projection (2.1e-02/4.2e-01/ 4/ 65) | ||||
| 181 | 3.8/1 | 7 | 26 | soft palate development (3.4e-02/5.6e-04/ 1/ 2) | collagen type XI (2.7e-02/1.0e-03/ 1/ 2) | ||||
| 182 | 3.8/1 | 31 | 21 | regulation of peptidyl-serine phosphorylation (5.9e-05/1.7e-02/ 3/ 4) | extracellular space (2.7e-08/8.5e-01/ 11/ 237) | cytokine activity (1.3e-03/2.6e-01/ 5/71) | Jak-STAT signaling pathway (1.4e-03/5.5e-01/ 6/87) | ||
| 183 | 3.8/1 | 9 | 21 | ||||||
| 184 | 3.8/1 | 36 | 19 | regulation of cell proliferation (3.5e-02/1.5e+00/ 7/ 376) | integral to membrane (4.1e-02/8.6e+00/ 17/1983) | ||||
| 185 | 3.8/1 | 12 | 29 | extracellular matrix organization (4.0e-02/4.1e-02/ 2/ 42) | extracellular region part (1.0e-02/3.8e-01/ 4/ 376) | ||||
| 186 | 3.8/1 | 5 | 26 | axoneme (4.5e-02/1.9e-03/ 1/ 5) | |||||
| 187 | 3.8/1 | 16 | 21 | extracellular space (1.7e-03/4.2e-01/ 5/ 237) | receptor binding (9.4e-03/7.9e-01/ 6/400) | ||||
| 188 | 3.8/1 | 10 | 31 | cell morphogenesis (3.8e-03/4.3e-01/ 5/ 312) | |||||
| 189 | 3.8/1 | 6 | 31 | extracellular matrix organization (1.6e-02/2.3e-02/ 2/ 42) | extracellular matrix part (1.2e-02/3.2e-02/ 2/ 63) | ||||
| 190 | 3.8/1 | 13 | 31 | ||||||
| 191 | 3.8/1 | 7 | 31 | heart process (2.1e-02/2.7e-02/ 2/ 32) | |||||
| 192 | 3.8/1 | 36 | 18 | anatomical structure development (5.7e-03/4.7e+00/ 14/1207) | extracellular region (1.6e-02/3.0e+00/ 10/ 673) | ||||
| 193 | 3.8/1 | 8 | 22 | ||||||
| 194 | 3.8/1 | 4 | 30 | axoneme (4.5e-02/1.9e-03/ 1/ 5) | |||||
| 195 | 3.6/2 | 9 | 5 | neurofilament bundle assembly (5.0e-02/9.7e-04/ 1/ 1) | extracellular region (1.3e-02/7.8e-01/ 5/ 673) | ||||
| 196 | 3.6/2 | 50 | 7 | vesicle-mediated transport (3.4e-03/2.1e+00/ 10/ 355) | cytoplasmic vesicle (6.1e-04/1.9e+00/ 10/ 319) | receptor signaling protein serine/threonine kinase activity (1.3e-02/2.5e-01/ 4/40) | |||
| 197 | 3.6/2 | 56 | 4 | cell adhesion (8.9e-04/2.6e+00/ 12/ 368) | extracellular region (1.3e-08/4.6e+00/ 22/ 673) | promoter binding (4.1e-02/3.5e-02/ 2/6) | |||
| 198 | 3.6/2 | 39 | 4 | extracellular matrix organization (3.9e-02/1.8e-01/ 3/ 42) | proteinaceous extracellular matrix (1.6e-03/6.5e-01/ 6/ 153) | ||||
| 199 | 3.6/2 | 13 | 4 | growth hormone receptor complex (3.8e-02/1.5e-03/ 1/ 1) | |||||
| 200 | 3.6/2 | 19 | 5 | ||||||
| 201 | 3.6/2 | 23 | 4 | carbohydrate binding (3.0e-02/3.4e-01/ 4/130) | |||||
| 202 | 3.6/2 | 16 | 6 | ||||||
| 203 | 3.6/2 | 19 | 4 | organ development (7.0e-03/1.6e+00/ 8/ 729) | dendrite (4.2e-02/6.3e-02/ 2/ 29) | ||||
| 204 | 3.6/2 | 8 | 8 | regulation of axon diameter (4.0e-02/6.9e-04/ 1/ 1) | |||||
| 205 | 3.6/2 | 16 | 5 | ||||||
| 206 | 3.6/2 | 58 | 6 | cell adhesion (4.1e-02/2.5e+00/ 9/ 368) | protein-lysine 6-oxidase activity (1.8e-02/2.2e-02/ 2/3) | Small cell lung cancer (1.8e-02/6.0e-01/ 5/73) | |||
| 207 | 3.6/2 | 8 | 4 | B cell tolerance induction (4.0e-02/6.9e-04/ 1/ 1) | |||||
| 208 | 3.6/2 | 12 | 4 | ||||||
| 209 | 3.6/2 | 15 | 4 | extracellular region (1.9e-02/1.2e+00/ 6/ 673) | |||||
| 210 | 3.6/2 | 23 | 6 | ||||||
| 211 | 3.6/2 | 10 | 4 | regulation of aldosterone metabolic process (5.0e-02/9.7e-04/ 1/ 1) | |||||
| 212 | 3.6/1.8 | 35 | 3 | neurotransmitter transport (1.8e-02/1.2e-01/ 3/ 34) | myosin complex (4.1e-03/9.5e-02/ 3/ 24) | transmembrane receptor activity (2.2e-02/1.3e+00/ 7/324) | |||
| 213 | 3.6/1.8 | 54 | 8 | vesicle coating (7.1e-03/8.3e-02/ 3/ 13) | melanosome (4.4e-05/5.1e-01/ 7/ 77) | GTPase activity (1.6e-02/8.0e-01/ 6/125) | ECM-receptor interaction (4.1e-02/4.3e-01/ 4/58) | ||
| 214 | 3.6/1.8 | 20 | 4 | defense response (1.9e-02/6.1e-01/ 5/ 257) | extracellular region (1.5e-03/1.5e+00/ 8/ 673) | ||||
| 215 | 3.6/1.8 | 18 | 5 | extracellular region (1.5e-03/1.5e+00/ 8/ 673) | |||||
| 216 | 3.6/1.8 | 67 | 12 | anatomical structure development (1.2e-05/9.4e+00/ 27/1207) | neuron projection (5.5e-03/5.2e-01/ 5/ 65) | ||||
| 217 | 3.6/1.8 | 12 | 5 | ||||||
| 218 | 3.6/1.8 | 43 | 4 | ||||||
| 219 | 3.6/1.8 | 10 | 4 | G-protein coupled receptor protein signaling pathway (7.0e-03/2.6e-01/ 4/ 231) | extracellular space (4.7e-02/2.7e-01/ 3/ 237) | ||||
| 220 | 3.6/1.8 | 26 | 4 | respiratory gaseous exchange (4.3e-02/4.3e-02/ 2/ 18) | integral to plasma membrane (1.1e-02/1.4e+00/ 7/ 535) | transmembrane receptor activity (2.0e-02/8.9e-01/ 6/324) | |||
| 221 | 3.6/1.8 | 11 | 6 | protein kinase C activity (7.8e-03/1.2e-02/ 2/8) | |||||
| 222 | 3.6/1.8 | 33 | 5 | fibrinolysis (2.6e-02/3.0e-02/ 2/ 8) | |||||
| 223 | 3.6/1.8 | 16 | 8 | plasma membrane part (3.6e-02/1.4e+00/ 6/ 855) | |||||
| 224 | 3.6/1.8 | 14 | 6 | extracellular region (1.6e-03/1.1e+00/ 7/ 673) | |||||
| 225 | 3.6/1.8 | 8 | 6 | antigen processing and presentation of peptide or polysaccharide antigen via MHC class II (5.1e-03/1.1e-02/ 2/ 11) | MHC class II protein complex (7.1e-04/6.3e-03/ 2/ 7) | Systemic lupus erythematosus (1.3e-02/1.2e-01/ 3/54) | |||
| 226 | 3.6/1.8 | 10 | 7 | ||||||
| 227 | 3.6/1.8 | 61 | 9 | vesicle-mediated transport (4.9e-03/2.6e+00/ 11/ 355) | cytoplasmic vesicle (4.5e-06/2.4e+00/ 14/ 319) | receptor signaling protein serine/threonine kinase activity (2.3e-02/3.0e-01/ 4/40) | |||
| 228 | 3.6/1.8 | 8 | 5 | negative regulation of gliogenesis (5.6e-04/3.3e-03/ 2/ 3) | internode region of axon (2.2e-02/7.7e-04/ 1/ 1) | ||||
| 229 | 3.6/1.8 | 12 | 5 | ||||||
| 230 | 3.6/1.8 | 18 | 6 | ||||||
| 231 | 3.6/1.8 | 24 | 7 | ||||||
| 232 | 3.6/1.8 | 10 | 5 | meiosis (2.9e-02/3.3e-02/ 2/ 48) | |||||
| 233 | 3.6/1.8 | 13 | 8 | ||||||
| 234 | 3.6/1.8 | 7 | 8 | nervous system development (1.2e-02/3.4e-01/ 4/ 402) | |||||
| 235 | 3.6/1.6 | 8 | 5 | inflammatory response (3.0e-02/1.7e-01/ 3/ 150) | extracellular space (2.2e-03/2.4e-01/ 4/ 237) | cytokine activity (4.5e-03/6.5e-02/ 3/71) | |||
| 236 | 3.6/1.6 | 14 | 5 | growth hormone receptor complex (4.0e-02/1.7e-03/ 1/ 1) | |||||
| 237 | 3.6/1.6 | 34 | 10 | extracellular matrix organization (2.7e-02/1.5e-01/ 3/ 42) | integral to membrane (1.7e-02/7.4e+00/ 16/1983) | receptor activity (1.4e-02/2.0e+00/ 9/519) | |||
| 238 | 3.6/1.6 | 5 | 10 | angiogenesis (4.4e-05/7.1e-02/ 4/ 102) | collagen type XV (1.9e-02/6.4e-04/ 1/ 1) | interleukin-1, Type II receptor binding (4.9e-02/6.6e-04/ 1/1) | |||
| 239 | 3.6/1.6 | 6 | 10 | regulation of axon diameter (4.0e-02/6.9e-04/ 1/ 1) | |||||
| 240 | 3.6/1.6 | 11 | 11 | collagen type XI (4.7e-02/2.0e-03/ 1/ 2) | |||||
| 241 | 3.6/1.6 | 10 | 11 | organ development (1.4e-02/1.0e+00/ 6/ 729) | |||||
| 242 | 3.6/1.6 | 16 | 10 | ||||||
| 243 | 3.6/1.6 | 13 | 8 | multicellular organismal process (1.4e-04/2.7e+00/ 11/1611) | transcription corepressor activity (3.8e-02/1.6e-01/ 3/92) | TGF-beta signaling pathway (2.7e-02/1.7e-01/ 3/64) | |||
| 244 | 3.6/1.6 | 10 | 6 | ||||||
| 245 | 3.6/1.6 | 5 | 13 | 5 (1.2e-02/ 0.2215/ 4/412) | |||||
| 246 | 3.6/1.6 | 7 | 11 | activation of adenylate cyclase activity by dopamine receptor signaling pathway (4.5e-02/8.3e-04/ 1/ 1) | dopamine receptor coupled via Gs (4.9e-02/6.6e-04/ 1/1) | ||||
| 247 | 3.6/1.6 | 14 | 7 | collagen fibril organization (2.4e-02/2.8e-02/ 2/ 20) | fibrillar collagen (4.3e-03/1.7e-02/ 2/ 10) | ||||
| 248 | 3.6/1.6 | 34 | 11 | fibrinolysis (2.8e-02/3.1e-02/ 2/ 8) | integral to membrane (2.2e-02/6.9e+00/ 15/1983) | receptor activity (8.9e-03/1.9e+00/ 9/519) | |||
| 249 | 3.6/1.6 | 7 | 11 | antibacterial humoral response (3.4e-02/5.6e-04/ 1/ 1) | phagocytic vesicle membrane (1.5e-02/5.1e-04/ 1/ 1) | ||||
| 250 | 3.6/1.6 | 42 | 9 | extracellular matrix organization (3.4e-02/1.6e-01/ 3/ 42) | receptor activity (3.1e-02/2.3e+00/ 9/519) | ||||
| 251 | 3.6/1.6 | 28 | 6 | ||||||
| 252 | 3.6/1.6 | 8 | 9 | immunoglobulin mediated immune response (3.1e-02/3.4e-02/ 2/ 35) | |||||
| 253 | 3.6/1.6 | 10 | 11 | ||||||
| 254 | 3.6/1.6 | 18 | 7 | myosin complex (6.8e-04/4.9e-02/ 3/ 24) | |||||
| 255 | 3.6/1.6 | 29 | 10 | extracellular matrix organization (2.5e-02/1.4e-01/ 3/ 42) | |||||
| 256 | 3.6/1.4 | 9 | 13 | growth hormone receptor complex (3.0e-02/1.2e-03/ 1/ 1) | |||||
| 257 | 3.6/1.4 | 51 | 14 | organ development (6.2e-05/4.8e+00/ 18/ 729) | extracellular region part (3.5e-07/2.3e+00/ 15/ 376) | cytokine activity (7.9e-06/4.3e-01/ 8/71) | Cytokine-cytokine receptor interaction (3.0e-05/9.4e-01/ 9/115) | ||
| 258 | 3.6/1.4 | 7 | 14 | kynurenine metabolic process (2.1e-02/2.8e-04/ 1/ 1) | kynurenine 3-monooxygenase activity (3.5e-02/3.9e-04/ 1/1) | ||||
| 259 | 3.6/1.4 | 15 | 11 | ||||||
| 260 | 3.6/1.4 | 13 | 14 | ||||||
| 261 | 3.6/1.4 | 19 | 15 | ||||||
| 262 | 3.6/1.4 | 18 | 16 | ||||||
| 263 | 3.6/1.4 | 16 | 17 | cell morphogenesis (2.3e-02/6.5e-01/ 5/ 312) | |||||
| 264 | 3.6/1.4 | 46 | 16 | post-Golgi vesicle-mediated transport (7.3e-03/8.4e-02/ 3/ 14) | cytoplasmic vesicle (4.3e-02/1.8e+00/ 7/ 319) | ribonucleotide binding (2.9e-02/5.8e+00/ 15/1002) | |||
| 265 | 3.6/1.4 | 16 | 14 | myelination (3.1e-02/3.3e-02/ 2/ 16) | internode region of axon (4.5e-02/1.9e-03/ 1/ 1) | ||||
| 266 | 3.6/1.4 | 10 | 13 | brush border (3.5e-03/1.5e-02/ 2/ 13) | |||||
| 267 | 3.6/1.4 | 16 | 11 | ||||||
| 268 | 3.6/1.4 | 21 | 13 | extracellular region part (2.6e-02/8.2e-01/ 5/ 376) | |||||
| 269 | 3.6/1.4 | 15 | 11 | eye photoreceptor cell differentiation (4.2e-03/9.7e-03/ 2/ 5) | cell projection part (4.5e-02/6.6e-02/ 2/ 37) | ||||
| 270 | 3.6/1.4 | 10 | 12 | DNA replication (1.9e-08/2.0e-01/ 7/ 180) | replication fork (1.6e-04/3.0e-02/ 3/ 26) | DNA primase activity (8.1e-04/3.1e-03/ 2/3) | DNA replication (3.9e-03/7.4e-02/ 3/33) | ||
| 271 | 3.6/1.4 | 17 | 14 | ||||||
| 272 | 3.6/1.4 | 9 | 14 | DNA strand elongation during DNA replication (4.4e-04/2.9e-03/ 2/ 3) | chromosomal part (1.9e-03/2.3e-01/ 4/ 198) | DNA replication (1.3e-02/2.5e-02/ 2/33) | |||
| 273 | 3.6/1.4 | 9 | 12 | actin cytoskeleton organization (2.9e-02/1.6e-01/ 3/ 147) | platelet dense granule lumen (2.7e-02/1.0e-03/ 1/ 1) | ||||
| 274 | 3.6/1.2 | 75 | 13 | multicellular organismal process (2.6e-05/1.4e+01/ 33/1611) | plasma membrane part (3.9e-03/7.5e+00/ 19/ 855) | ||||
| 275 | 3.6/1.2 | 7 | 16 | regulation of axon diameter (5.0e-02/9.7e-04/ 1/ 1) | |||||
| 276 | 3.6/1.2 | 22 | 18 | innate immune response (3.7e-02/1.7e-01/ 3/ 62) | extracellular region (8.3e-04/1.7e+00/ 9/ 673) | receptor binding (4.4e-02/1.1e+00/ 6/400) | |||
| 277 | 3.6/1.2 | 15 | 18 | ||||||
| 278 | 3.6/1.2 | 29 | 19 | DNA replication (1.3e-13/6.5e-01/ 14/ 180) | nucleoplasm (9.3e-10/2.0e+00/ 16/ 565) | DNA binding (6.3e-04/3.8e+00/ 14/1195) | DNA replication (1.9e-06/1.7e-01/ 6/33) | ||
| 279 | 3.6/1.2 | 11 | 17 | ||||||
| 280 | 3.6/1.2 | 12 | 13 | cilium (3.1e-02/5.3e-02/ 2/ 46) | |||||
| 281 | 3.6/1.2 | 14 | 20 | ||||||
| 282 | 3.6/1.2 | 13 | 19 | myosin complex (1.7e-02/3.7e-02/ 2/ 24) | |||||
| 283 | 3.6/1.2 | 11 | 17 | Dentatorubropallidoluysian atrophy (DRPLA) (3.2e-03/1.0e-02/ 2/14) | |||||
| 284 | 3.6/1.2 | 15 | 15 | ||||||
| 285 | 3.6/1.2 | 14 | 19 | microtubule-based process (5.7e-03/2.2e-01/ 4/ 134) | chromosomal part (7.9e-04/3.5e-01/ 5/ 198) | microtubule motor activity (4.0e-03/5.8e-02/ 3/37) | |||
| 286 | 3.6/1 | 43 | 20 | response to external stimulus (2.0e-05/2.1e+00/ 13/ 364) | extracellular space (1.4e-07/1.2e+00/ 12/ 237) | cytokine activity (4.4e-04/3.6e-01/ 6/71) | Cytokine-cytokine receptor interaction (3.7e-03/9.8e-01/ 7/115) | ||
| 287 | 3.6/1 | 8 | 20 | ||||||
| 288 | 3.6/1 | 8 | 22 | ||||||
| 289 | 3.6/1 | 16 | 22 | ||||||
| 290 | 3.6/1 | 15 | 35 | ||||||
| 291 | 3.6/1 | 10 | 23 | dephosphorylation (2.0e-02/1.3e-01/ 3/ 96) | |||||
| 292 | 3.6/1 | 18 | 29 | cell cycle phase (1.3e-11/6.3e-01/ 12/ 285) | spindle (2.1e-08/1.7e-01/ 7/ 80) | microtubule motor activity (1.9e-04/6.8e-02/ 4/37) | |||
| 293 | 3.6/1 | 12 | 30 | collagen type XV (3.0e-02/1.2e-03/ 1/ 1) | chemokine activity (1.6e-02/1.8e-02/ 2/14) | Y (1.2e-06/ 0.0387/ 5/ 30) | |||
| 294 | 3.6/1 | 6 | 27 | proton-dependent oligopeptide secondary active transmembrane transporter activity (4.9e-02/6.6e-04/ 1/1) | |||||
| 295 | 3.6/1 | 7 | 30 | N-sulfoglucosamine sulfohydrolase activity (4.9e-02/6.6e-04/ 1/1) | |||||
| 296 | 3.4/2 | 94 | 7 | multicellular organismal process (1.0e-06/1.7e+01/ 41/1611) | extracellular region (4.0e-08/7.5e+00/ 28/ 673) | ||||
| 297 | 3.4/2 | 31 | 4 | organic anion transport (2.6e-02/3.0e-02/ 2/ 8) | |||||
| 298 | 3.4/2 | 6 | 6 | ||||||
| 299 | 3.4/2 | 17 | 4 | growth hormone receptor complex (4.5e-02/1.9e-03/ 1/ 1) | |||||
| 300 | 3.4/2 | 82 | 6 | response to wounding (3.4e-06/2.4e+00/ 15/ 226) | extracellular space (1.1e-08/2.3e+00/ 17/ 237) | cytokine activity (1.5e-05/6.8e-01/ 9/71) | Cytokine-cytokine receptor interaction (1.1e-04/1.7e+00/11/115) | ||
| 301 | 3.4/2 | 29 | 5 | ||||||
| 302 | 3.4/2 | 78 | 7 | vesicle-mediated transport (2.5e-03/3.3e+00/ 13/ 355) | cytoplasmic vesicle (3.4e-06/3.1e+00/ 16/ 319) | receptor signaling protein serine/threonine kinase activity (4.9e-03/3.7e-01/ 5/40) | miR-320/320abcd (0.00279/ 4.7945/19/372) | ||
| 303 | 3.4/2 | 18 | 5 | cellular aldehyde metabolic process (2.6e-02/2.9e-02/ 2/ 14) | integral to synaptic vesicle membrane (4.9e-02/2.2e-03/ 1/ 1) | aldo-keto reductase activity (2.1e-02/2.2e-02/ 2/11) | |||
| 304 | 3.4/2 | 48 | 4 | inflammatory response (7.6e-03/7.3e-01/ 6/ 150) | extracellular region (2.2e-02/3.7e+00/ 11/ 673) | calcium-dependent phospholipid binding (9.3e-03/8.2e-02/ 3/16) | |||
| 305 | 3.4/2 | 17 | 3 | growth hormone receptor complex (4.5e-02/1.9e-03/ 1/ 1) | |||||
| 306 | 3.4/2 | 24 | 5 | xenobiotic metabolic process (8.4e-04/3.6e-02/ 3/ 13) | glucuronosyltransferase activity (9.2e-04/3.1e-02/ 3/12) | Pentose and glucuronate interconversions (1.5e-03/4.8e-02/ 3/13) | |||
| 307 | 3.4/2 | 18 | 3 | extracellular region part (5.7e-04/8.7e-01/ 7/ 376) | |||||
| 308 | 3.4/2 | 28 | 9 | intermediate filament bundle assembly (3.1e-03/8.8e-03/ 2/ 3) | neurofilament (1.2e-03/9.2e-03/ 2/ 3) | ||||
| 309 | 3.4/2 | 20 | 5 | defense response (2.4e-02/6.4e-01/ 5/ 257) | extracellular region (2.4e-03/1.6e+00/ 8/ 673) | ||||
| 310 | 3.4/2 | 11 | 4 | B cell tolerance induction (4.5e-02/8.3e-04/ 1/ 1) | |||||
| 311 | 3.4/2 | 67 | 6 | regulation of response to stimulus (4.5e-03/9.4e-01/ 7/ 121) | melanosome (1.3e-03/6.1e-01/ 6/ 77) | receptor signaling protein serine/threonine kinase activity (3.1e-03/3.3e-01/ 5/40) | |||
| 312 | 3.4/2 | 36 | 3 | extracellular region (1.9e-03/2.3e+00/ 10/ 673) | |||||
| 313 | 3.4/2 | 29 | 5 | extracellular region (1.8e-02/2.1e+00/ 8/ 673) | |||||
| 314 | 3.4/2 | 78 | 7 | response to mechanical stimulus (1.7e-03/1.5e-01/ 4/ 16) | cytoplasmic vesicle (3.4e-06/3.1e+00/ 16/ 319) | Small cell lung cancer (4.8e-02/7.9e-01/ 5/73) | |||
| 315 | 3.4/2 | 8 | 8 | aggresome (2.7e-02/1.0e-03/ 1/ 1) | |||||
| 316 | 3.4/2 | 16 | 5 | peptide secretion (2.5e-02/2.9e-02/ 2/ 19) | brush border (5.9e-03/2.0e-02/ 2/ 13) | ||||
| 317 | 3.4/2 | 17 | 4 | ||||||
| 318 | 3.4/2 | 14 | 6 | inflammatory response (5.9e-03/2.3e-01/ 4/ 150) | extracellular space (1.4e-02/3.9e-01/ 4/ 237) | ||||
| 319 | 3.4/2 | 32 | 3 | translational elongation (2.8e-05/2.5e-01/ 6/ 91) | cytosolic part (1.9e-06/3.3e-01/ 7/ 107) | structural constituent of ribosome (4.8e-04/3.8e-01/ 6/121) | Ribosome (2.2e-02/3.5e-01/ 4/68) | ||
| 320 | 3.4/2 | 26 | 4 | embryonic limb morphogenesis (1.5e-02/1.1e-01/ 3/ 37) | extracellular region (9.7e-04/2.2e+00/ 10/ 673) | ||||
| 321 | 3.4/2 | 27 | 3 | ||||||
| 322 | 3.4/1.8 | 18 | 7 | Fc receptor complex (4.5e-02/1.9e-03/ 1/ 1) | |||||
| 323 | 3.4/1.8 | 42 | 7 | translational elongation (1.3e-06/4.0e-01/ 8/ 91) | ribosome (2.5e-05/7.1e-01/ 8/ 149) | structural constituent of ribosome (1.4e-04/4.8e-01/ 7/121) | Ribosome (6.5e-04/2.8e-01/ 5/68) | ||
| 324 | 3.4/1.8 | 65 | 4 | hemoglobin biosynthetic process (1.9e-02/2.6e-02/ 2/ 4) | extracellular region (4.8e-02/4.7e+00/ 12/ 673) | hormone activity (5.7e-03/1.9e-01/ 4/27) | Maturity onset diabetes of the young (3.2e-02/3.7e-02/ 2/5) | ||
| 325 | 3.4/1.8 | 103 | 12 | multicellular organismal process (9.2e-08/1.9e+01/ 45/1611) | extracellular region (1.5e-05/8.1e+00/ 25/ 673) | extracellular matrix structural constituent (1.9e-03/5.0e-01/ 6/42) | |||
| 326 | 3.4/1.8 | 28 | 7 | ||||||
| 327 | 3.4/1.8 | 13 | 6 | ||||||
| 328 | 3.4/1.8 | 24 | 9 | ||||||
| 329 | 3.4/1.8 | 22 | 8 | ||||||
| 330 | 3.4/1.8 | 78 | 9 | organelle localization (5.3e-03/4.0e-01/ 5/ 44) | melanosome (3.8e-05/7.3e-01/ 8/ 77) | ||||
| 331 | 3.4/1.8 | 33 | 7 | ||||||
| 332 | 3.4/1.8 | 9 | 7 | activation of phospholipase C activity by G-protein coupled receptor protein signaling pathway coupled to IP3 second messenger (1.7e-02/2.2e-02/ 2/ 23) | brush border (3.5e-03/1.5e-02/ 2/ 13) | neurotransmitter receptor activity (2.4e-02/2.4e-02/ 2/23) | Neuroactive ligand-receptor interaction (4.5e-02/5.8e-02/ 2/78) | ||
| 333 | 3.4/1.8 | 9 | 9 | regulation of cellular component size (3.6e-02/3.8e-02/ 2/ 39) | |||||
| 334 | 3.4/1.8 | 12 | 7 | regulation of axon diameter (5.0e-02/9.7e-04/ 1/ 1) | |||||
| 335 | 3.4/1.8 | 25 | 7 | ||||||
| 336 | 3.4/1.8 | 40 | 3 | regulation of gonadotropin secretion (7.3e-03/1.5e-02/ 2/ 3) | extracellular region (3.5e-04/3.2e+00/ 13/ 673) | hormone activity (2.4e-02/1.2e-01/ 3/27) | TGF-beta signaling pathway (8.1e-03/2.6e-01/ 4/64) | ||
| 337 | 3.4/1.8 | 18 | 7 | cellular response to reactive oxygen species (5.3e-03/1.1e-02/ 2/ 5) | collagen type XIV (4.9e-02/2.2e-03/ 1/ 1) | thyroid hormone receptor activity (6.4e-03/1.0e-02/ 2/5) | |||
| 338 | 3.4/1.8 | 7 | 6 | extracellular region part (2.9e-03/2.9e-01/ 4/ 376) | |||||
| 339 | 3.4/1.8 | 62 | 3 | extracellular region (3.8e-04/4.7e+00/ 16/ 673) | |||||
| 340 | 3.4/1.8 | 16 | 5 | dendrite (2.7e-02/4.8e-02/ 2/ 29) | |||||
| 341 | 3.4/1.8 | 10 | 7 | brush border (4.3e-03/1.7e-02/ 2/ 13) | |||||
| 342 | 3.4/1.8 | 24 | 5 | ||||||
| 343 | 3.4/1.8 | 54 | 8 | positive regulation of response to stimulus (8.3e-03/4.5e-01/ 5/ 68) | cytoplasmic vesicle (1.2e-03/2.0e+00/ 10/ 319) | receptor signaling protein serine/threonine kinase activity (1.7e-02/2.7e-01/ 4/40) | MAPK signaling pathway (2.8e-02/1.5e+00/ 7/183) | ||
| 344 | 3.4/1.8 | 24 | 5 | neuron differentiation (4.9e-02/4.6e-01/ 4/ 149) | extracellular region (4.4e-04/2.0e+00/ 10/ 673) | ||||
| 345 | 3.4/1.8 | 14 | 4 | G-protein coupled receptor protein signaling pathway (2.1e-02/3.5e-01/ 4/ 231) | |||||
| 346 | 3.4/1.8 | 25 | 8 | ||||||
| 347 | 3.4/1.8 | 32 | 5 | neurotransmitter transport (1.8e-02/1.2e-01/ 3/ 34) | brush border (5.8e-04/4.7e-02/ 3/ 13) | transmembrane receptor activity (2.8e-03/1.2e+00/ 8/324) | |||
| 348 | 3.4/1.8 | 35 | 3 | ion transport (3.4e-02/1.1e+00/ 6/ 286) | extracellular region (4.7e-03/2.6e+00/ 10/ 673) | monovalent cation:proton antiporter activity (1.6e-02/1.8e-02/ 2/5) | |||
| 349 | 3.4/1.6 | 75 | 10 | response to wounding (7.7e-07/2.2e+00/ 15/ 226) | extracellular space (2.4e-09/2.1e+00/ 17/ 237) | cytokine activity (7.8e-07/6.2e-01/ 10/71) | Cytokine-cytokine receptor interaction (2.7e-05/1.5e+00/11/115) | ||
| 350 | 3.4/1.6 | 32 | 6 | eye photoreceptor cell differentiation (1.3e-02/1.9e-02/ 2/ 5) | |||||
| 351 | 3.4/1.6 | 29 | 10 | extracellular region (7.0e-03/2.2e+00/ 9/ 673) | receptor activity (5.3e-03/1.8e+00/ 9/519) | ||||
| 352 | 3.4/1.6 | 17 | 8 | regulation of protein catabolic process (4.9e-02/4.7e-02/ 2/ 21) | |||||
| 353 | 3.4/1.6 | 27 | 12 | homophilic cell adhesion (1.7e-02/1.2e-01/ 3/ 37) | protein kinase binding (4.9e-02/1.7e-01/ 3/58) | Pancreatic cancer (6.3e-03/2.5e-01/ 4/66) | |||
| 354 | 3.4/1.6 | 11 | 14 | extrinsic to external side of plasma membrane (3.2e-02/1.3e-03/ 1/ 1) | |||||
| 355 | 3.4/1.6 | 19 | 8 | ||||||
| 356 | 3.4/1.6 | 26 | 8 | neurotransmitter transport (1.1e-02/9.9e-02/ 3/ 34) | brush border (3.8e-04/4.0e-02/ 3/ 13) | ||||
| 357 | 3.4/1.6 | 15 | 8 | sterol metabolic process (2.2e-05/1.2e-01/ 5/ 64) | intracellular organelle part (4.1e-03/4.8e+00/ 12/2677) | oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen (1.7e-02/1.1e-01/ 3/58) | Biosynthesis of steroids (1.2e-04/7.7e-02/ 4/23) | ||
| 358 | 3.4/1.6 | 25 | 11 | extracellular region part (6.6e-03/9.1e-01/ 6/ 376) | scavenger receptor activity (3.2e-02/2.8e-02/ 2/12) | ||||
| 359 | 3.4/1.6 | 23 | 9 | inflammatory response (2.9e-02/3.8e-01/ 4/ 150) | |||||
| 360 | 3.4/1.6 | 25 | 10 | ||||||
| 361 | 3.4/1.6 | 24 | 13 | anti-apoptosis (3.0e-02/3.8e-01/ 4/ 135) | Chronic myeloid leukemia (3.9e-03/2.1e-01/ 4/64) | ||||
| 362 | 3.4/1.6 | 15 | 8 | sterol metabolic process (8.6e-04/1.2e-01/ 4/ 64) | endoplasmic reticulum membrane (9.6e-03/6.4e-01/ 5/ 335) | oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen (1.7e-02/1.1e-01/ 3/58) | Biosynthesis of steroids (4.8e-03/7.7e-02/ 3/23) | ||
| 363 | 3.4/1.6 | 20 | 9 | extracellular space (3.6e-02/5.2e-01/ 4/ 237) | |||||
| 364 | 3.4/1.6 | 14 | 11 | ||||||
| 365 | 3.4/1.6 | 9 | 11 | ||||||
| 366 | 3.4/1.6 | 30 | 12 | extracellular region part (3.7e-03/1.2e+00/ 7/ 376) | MAP-kinase scaffold activity (2.0e-03/6.3e-03/ 2/2) | ||||
| 367 | 3.4/1.6 | 10 | 10 | ||||||
| 368 | 3.4/1.4 | 78 | 12 | response to external stimulus (8.0e-08/3.6e+00/ 20/ 364) | extracellular region (1.5e-08/6.3e+00/ 26/ 673) | growth factor activity (5.0e-05/8.1e-01/ 9/91) | Cytokine-cytokine receptor interaction (3.6e-04/1.6e+00/10/115) | ||
| 369 | 3.4/1.4 | 19 | 14 | neurotransmitter transport (4.9e-03/7.1e-02/ 3/ 34) | |||||
| 370 | 3.4/1.4 | 12 | 14 | regulation of response to stimulus (4.0e-02/1.8e-01/ 3/ 121) | extracellular region (7.9e-03/1.0e+00/ 6/ 673) | receptor binding (1.7e-03/5.8e-01/ 6/400) | Cytokine-cytokine receptor interaction (2.1e-02/1.7e-01/ 3/115) | ||
| 371 | 3.4/1.4 | 22 | 15 | sensory perception (3.0e-02/3.8e-01/ 4/ 171) | brush border (1.1e-02/2.8e-02/ 2/ 13) | scavenger receptor activity (3.2e-02/2.8e-02/ 2/12) | |||
| 372 | 3.4/1.4 | 14 | 18 | cell morphogenesis (1.7e-02/6.1e-01/ 5/ 312) | |||||
| 373 | 3.4/1.4 | 23 | 19 | cell morphogenesis (3.6e-02/7.4e-01/ 5/ 312) | |||||
| 374 | 3.4/1.4 | 29 | 11 | ||||||
| 375 | 3.4/1.4 | 23 | 16 | brush border (1.3e-02/3.2e-02/ 2/ 13) | |||||
| 376 | 3.4/1.4 | 17 | 13 | embryonic cranial skeleton morphogenesis (5.9e-03/1.2e-02/ 2/ 7) | photoreceptor inner segment (4.5e-02/1.9e-03/ 1/ 1) | ||||
| 377 | 3.4/1.4 | 21 | 18 | cell morphogenesis (3.6e-02/7.4e-01/ 5/ 312) | |||||
| 378 | 3.4/1.4 | 7 | 17 | regulation of axon diameter (4.5e-02/8.3e-04/ 1/ 1) | |||||
| 379 | 3.4/1.4 | 11 | 16 | ||||||
| 380 | 3.4/1.4 | 11 | 16 | ||||||
| 381 | 3.4/1.4 | 21 | 14 | sensory perception (3.0e-02/3.8e-01/ 4/ 171) | brush border (1.1e-02/2.8e-02/ 2/ 13) | ||||
| 382 | 3.4/1.4 | 21 | 12 | neurotransmitter transport (5.8e-03/7.6e-02/ 3/ 34) | membrane (3.1e-02/7.2e+00/ 14/3116) | ||||
| 383 | 3.4/1.4 | 21 | 14 | cell cycle phase (6.8e-12/7.5e-01/ 13/ 285) | spindle (1.4e-09/2.0e-01/ 8/ 80) | microtubule motor activity (4.5e-04/8.7e-02/ 4/37) | |||
| 384 | 3.4/1.4 | 16 | 14 | cell adhesion (2.3e-02/6.6e-01/ 5/ 368) | intrinsic to membrane (1.3e-02/3.6e+00/ 10/2010) | calcium ion binding (1.5e-02/5.6e-01/ 5/390) | |||
| 385 | 3.4/1.4 | 15 | 11 | growth hormone receptor complex (4.2e-02/1.8e-03/ 1/ 1) | |||||
| 386 | 3.4/1.4 | 30 | 14 | ||||||
| 387 | 3.4/1.4 | 20 | 18 | ||||||
| 388 | 3.4/1.4 | 21 | 16 | chromatin silencing (2.7e-02/3.0e-02/ 2/ 12) | Pancreatic cancer (4.3e-03/2.2e-01/ 4/66) | ||||
| 389 | 3.4/1.4 | 12 | 15 | ||||||
| 390 | 3.4/1.4 | 35 | 14 | extracellular region part (3.7e-02/1.3e+00/ 6/ 376) | MAP-kinase scaffold activity (2.5e-03/7.1e-03/ 2/2) | ||||
| 391 | 3.4/1.4 | 8 | 12 | regulation of axon diameter (4.5e-02/8.3e-04/ 1/ 1) | |||||
| 392 | 3.4/1.4 | 22 | 12 | ||||||
| 393 | 3.4/1.4 | 43 | 15 | defense response (4.4e-02/1.1e+00/ 6/ 257) | extracellular region (2.6e-04/3.1e+00/ 13/ 673) | ||||
| 394 | 3.4/1.2 | 69 | 16 | membrane organization (1.1e-02/2.0e+00/ 9/ 234) | cytoplasmic vesicle (8.9e-03/2.7e+00/ 10/ 319) | receptor signaling protein serine/threonine kinase activity (3.1e-02/3.4e-01/ 4/40) | miR-320/320abcd (0.04280/ 4.2034/15/372) | ||
| 395 | 3.4/1.2 | 14 | 17 | inward rectifier potassium channel activity (5.5e-03/9.4e-03/ 2/6) | |||||
| 396 | 3.4/1.2 | 14 | 23 | ||||||
| 397 | 3.4/1.2 | 10 | 14 | regulation of cell projection organization (3.3e-02/3.5e-02/ 2/ 28) | |||||
| 398 | 3.4/1.2 | 45 | 12 | translational elongation (1.6e-06/4.2e-01/ 8/ 91) | ribosome (4.5e-05/7.6e-01/ 8/ 149) | structural constituent of ribosome (2.5e-04/5.2e-01/ 7/121) | Ribosome (2.1e-03/3.5e-01/ 5/68) | ||
| 399 | 3.4/1.2 | 9 | 18 | ||||||
| 400 | 3.4/1.2 | 30 | 20 | brush border (1.8e-02/3.8e-02/ 2/ 13) | |||||
| 401 | 3.4/1.2 | 11 | 21 | tachykinin receptor activity (4.9e-02/6.6e-04/ 1/1) | |||||
| 402 | 3.4/1.2 | 11 | 19 | collagen type XI (4.2e-02/1.8e-03/ 1/ 2) | |||||
| 403 | 3.4/1.2 | 13 | 17 | extrachromosomal circular DNA (3.5e-02/1.4e-03/ 1/ 1) | |||||
| 404 | 3.4/1.2 | 15 | 22 | ||||||
| 405 | 3.4/1.2 | 15 | 20 | brush border (5.9e-03/2.0e-02/ 2/ 13) | |||||
| 406 | 3.4/1.2 | 14 | 19 | ||||||
| 407 | 3.4/1.2 | 15 | 17 | ||||||
| 408 | 3.4/1.2 | 11 | 22 | ||||||
| 409 | 3.4/1.2 | 18 | 25 | cell morphogenesis (2.9e-02/6.9e-01/ 5/ 312) | extrinsic to external side of plasma membrane (4.9e-02/2.2e-03/ 1/ 1) | ||||
| 410 | 3.4/1.2 | 22 | 14 | eye photoreceptor cell differentiation (7.6e-03/1.4e-02/ 2/ 5) | |||||
| 411 | 3.4/1.2 | 8 | 23 | keratinocyte activation (5.0e-02/9.7e-04/ 1/ 1) | |||||
| 412 | 3.4/1 | 18 | 22 | ||||||
| 413 | 3.4/1 | 60 | 21 | organ development (1.6e-07/5.9e+00/ 24/ 729) | extracellular space (8.3e-08/1.7e+00/ 14/ 237) | cytokine activity (2.2e-05/5.1e-01/ 8/71) | Cytokine-cytokine receptor interaction (3.4e-04/1.2e+00/ 9/115) | ||
| 414 | 3.4/1 | 15 | 20 | regulation of ARF protein signal transduction (4.9e-02/4.7e-02/ 2/ 31) | |||||
| 415 | 3.4/1 | 44 | 28 | cell cycle phase (5.7e-27/1.7e+00/ 28/ 285) | chromosomal part (1.0e-19/1.1e+00/ 21/ 198) | microtubule motor activity (1.0e-05/1.6e-01/ 6/37) | Cell cycle (2.9e-03/4.0e-01/ 5/98) | ||
| 416 | 3.4/1 | 13 | 29 | extracellular matrix organization (4.0e-02/4.1e-02/ 2/ 42) | |||||
| 417 | 3.4/1 | 16 | 23 | cilium (4.3e-02/6.5e-02/ 2/ 46) | |||||
| 418 | 3.4/1 | 19 | 26 | eye photoreceptor cell differentiation (6.4e-03/1.3e-02/ 2/ 5) | |||||
| 419 | 3.4/1 | 14 | 29 | ||||||
| 420 | 3.4/1 | 14 | 23 | ||||||
| 421 | 3.4/1 | 28 | 31 | cell morphogenesis (2.9e-02/1.0e+00/ 6/ 312) | |||||
| 422 | 3.4/1 | 17 | 19 | ||||||
| 423 | 3.4/1 | 16 | 21 | ||||||
| 424 | 3.2/2 | 38 | 6 | common-partner SMAD protein phosphorylation (5.1e-03/1.2e-02/ 2/ 3) | |||||
| 425 | 3.2/2 | 56 | 5 | ||||||
| 426 | 3.2/2 | 43 | 5 | xenobiotic metabolic process (2.7e-03/5.6e-02/ 3/ 13) | fibril (1.2e-02/3.0e-02/ 2/ 7) | glucuronosyltransferase activity (3.0e-03/5.2e-02/ 3/12) | Pentose and glucuronate interconversions (3.7e-03/6.8e-02/ 3/13) | ||
| 427 | 3.2/2 | 15 | 7 | cell recognition (4.4e-02/4.3e-02/ 2/ 24) | |||||
| 428 | 3.2/2 | 24 | 3 | extracellular region part (3.7e-04/1.1e+00/ 8/ 376) | |||||
| 429 | 3.2/2 | 66 | 3 | multicellular organismal process (8.5e-03/1.1e+01/ 24/1611) | plasma membrane part (3.6e-04/6.3e+00/ 19/ 855) | signal transducer activity (4.9e-02/5.4e+00/ 14/780) | |||
| 430 | 3.2/2 | 27 | 4 | innate immune response (5.3e-03/2.1e-01/ 4/ 62) | extracellular region (9.8e-05/2.1e+00/ 11/ 673) | ||||
| 431 | 3.2/2 | 57 | 3 | multicellular organismal process (4.4e-02/1.0e+01/ 20/1611) | extracellular region (4.1e-03/4.6e+00/ 14/ 673) | extracellular matrix structural constituent (1.5e-02/2.6e-01/ 4/42) | |||
| 432 | 3.2/2 | 41 | 6 | ||||||
| 433 | 3.2/2 | 27 | 4 | ||||||
| 434 | 3.2/2 | 27 | 6 | ||||||
| 435 | 3.2/2 | 30 | 4 | sterol biosynthetic process (6.6e-07/1.3e-01/ 6/ 34) | Biosynthesis of steroids (7.8e-07/1.5e-01/ 6/23) | ||||
| 436 | 3.2/2 | 55 | 4 | antigen processing and presentation of exogenous peptide antigen (2.0e-02/2.7e-02/ 2/ 4) | IgG binding (1.6e-02/2.0e-02/ 2/3) | ||||
| 437 | 3.2/2 | 57 | 3 | negative regulation of neurological system process (3.6e-02/3.8e-02/ 2/ 7) | |||||
| 438 | 3.2/2 | 13 | 6 | ||||||
| 439 | 3.2/2 | 27 | 4 | MAPKKK cascade (1.5e-02/3.0e-01/ 4/ 112) | |||||
| 440 | 3.2/2 | 53 | 3 | cellular anion homeostasis (1.0e-02/1.8e-02/ 2/ 3) | extracellular region (4.1e-06/4.2e+00/ 18/ 673) | ||||
| 441 | 3.2/2 | 94 | 6 | vesicle-mediated transport (1.1e-02/3.9e+00/ 13/ 355) | cytoplasmic vesicle (2.9e-05/3.6e+00/ 16/ 319) | receptor signaling protein serine/threonine kinase activity (1.1e-02/4.5e-01/ 5/40) | miR-320/320abcd (0.04115/ 5.7140/18/372) | ||
| 442 | 3.2/1.8 | 44 | 10 | ||||||
| 443 | 3.2/1.8 | 45 | 8 | ||||||
| 444 | 3.2/1.8 | 43 | 7 | MAP kinase tyrosine/serine/threonine phosphatase activity (4.2e-02/3.6e-02/ 2/7) | |||||
| 445 | 3.2/1.8 | 78 | 6 | branching morphogenesis of a tube (1.1e-02/2.6e-01/ 4/ 27) | extracellular region (3.0e-02/6.3e+00/ 15/ 673) | Regulation of actin cytoskeleton (2.1e-02/1.8e+00/ 8/147) | |||
| 446 | 3.2/1.8 | 107 | 4 | extracellular region (3.7e-02/7.8e+00/ 17/ 673) | MAP-kinase scaffold activity (1.6e-02/2.3e-02/ 2/2) | ||||
| 447 | 3.2/1.8 | 46 | 7 | ||||||
| 448 | 3.2/1.8 | 24 | 5 | regulation of hormone levels (2.7e-02/1.5e-01/ 3/ 67) | |||||
| 449 | 3.2/1.8 | 106 | 5 | MAP-kinase scaffold activity (1.5e-02/2.3e-02/ 2/2) | |||||
| 450 | 3.2/1.8 | 11 | 6 | insulin receptor complex (2.7e-02/1.0e-03/ 1/ 1) | |||||
| 451 | 3.2/1.8 | 34 | 9 | cell cycle phase (4.3e-17/1.2e+00/ 19/ 285) | chromosomal part (1.5e-16/8.4e-01/ 17/ 198) | ATP binding (5.2e-05/2.8e+00/ 14/801) | DNA replication (4.4e-04/1.1e-01/ 4/33) | ||
| 452 | 3.2/1.8 | 42 | 4 | translational elongation (3.0e-04/3.8e-01/ 6/ 91) | cytosolic part (2.6e-05/4.8e-01/ 7/ 107) | structural constituent of ribosome (3.0e-03/5.6e-01/ 6/121) | Ribosome (4.7e-02/4.6e-01/ 4/68) | ||
| 453 | 3.2/1.8 | 29 | 4 | osteoblast differentiation (8.2e-03/8.6e-02/ 3/ 27) | |||||
| 454 | 3.2/1.8 | 21 | 5 | ||||||
| 455 | 3.2/1.8 | 14 | 6 | anchored to membrane (4.0e-02/6.2e-02/ 2/ 37) | |||||
| 456 | 3.2/1.8 | 47 | 5 | multicellular organismal process (2.6e-02/8.3e+00/ 18/1611) | membrane (1.4e-03/1.7e+01/ 30/3116) | transmembrane receptor activity (1.7e-04/1.7e+00/ 11/324) | |||
| 457 | 3.2/1.8 | 45 | 6 | genetic imprinting (7.3e-03/1.5e-02/ 2/ 3) | extracellular region (1.1e-03/3.5e+00/ 13/ 673) | MAP kinase tyrosine/serine/threonine phosphatase activity (4.4e-02/3.7e-02/ 2/7) | |||
| 458 | 3.2/1.8 | 13 | 9 | angiogenesis (2.4e-03/1.7e-01/ 4/ 102) | extracellular region (1.2e-02/1.1e+00/ 6/ 673) | cytokine activity (1.8e-02/1.1e-01/ 3/71) | |||
| 459 | 3.2/1.8 | 46 | 6 | response to wounding (4.0e-03/1.3e+00/ 8/ 226) | extracellular region part (1.8e-03/2.2e+00/ 10/ 376) | ||||
| 460 | 3.2/1.8 | 83 | 8 | response to mechanical stimulus (2.3e-03/1.6e-01/ 4/ 16) | cytoplasmic vesicle (2.0e-04/3.3e+00/ 14/ 319) | protein binding (2.6e-02/4.4e+01/ 59/4505) | MAPK signaling pathway (3.1e-02/2.0e+00/ 8/183) | ||
| 461 | 3.2/1.8 | 69 | 7 | immune response (3.7e-02/2.0e+00/ 8/ 287) | extracellular region (1.8e-02/4.7e+00/ 13/ 673) | ||||
| 462 | 3.2/1.8 | 16 | 7 | cell surface receptor linked signal transduction (4.0e-02/8.5e-01/ 5/ 683) | |||||
| 463 | 3.2/1.8 | 45 | 3 | female pregnancy (5.0e-04/2.3e-01/ 5/ 45) | extracellular region (5.5e-07/3.4e+00/ 17/ 673) | ||||
| 464 | 3.2/1.8 | 57 | 4 | ||||||
| 465 | 3.2/1.8 | 75 | 5 | extracellular structure organization (4.1e-02/4.1e-01/ 4/ 55) | extracellular region (2.3e-05/5.2e+00/ 19/ 673) | ||||
| 466 | 3.2/1.6 | 16 | 9 | brush border (7.8e-03/2.3e-02/ 2/ 13) | |||||
| 467 | 3.2/1.6 | 58 | 9 | translational elongation (1.8e-03/5.3e-01/ 6/ 91) | cytosolic ribosome (2.7e-04/4.5e-01/ 6/ 70) | structural constituent of ribosome (9.7e-03/7.1e-01/ 6/121) | |||
| 468 | 3.2/1.6 | 34 | 8 | neurotransmitter transport (2.0e-02/1.3e-01/ 3/ 34) | myosin complex (4.1e-03/9.5e-02/ 3/ 24) | inward rectifier potassium channel activity (2.2e-02/2.3e-02/ 2/6) | |||
| 469 | 3.2/1.6 | 39 | 8 | integral to plasma membrane (1.1e-02/2.3e+00/ 9/ 535) | signal transducer activity (3.4e-03/3.1e+00/ 12/780) | B cell receptor signaling pathway (1.1e-02/2.8e-01/ 4/47) | |||
| 470 | 3.2/1.6 | 47 | 10 | osteoblast development (2.0e-02/2.6e-02/ 2/ 5) | extracellular space (2.4e-04/1.3e+00/ 9/ 237) | ||||
| 471 | 3.2/1.6 | 60 | 9 | cell cycle phase (5.1e-15/2.3e+00/ 23/ 285) | chromosomal part (3.5e-14/1.5e+00/ 19/ 198) | microtubule motor activity (7.4e-05/2.5e-01/ 6/37) | Cell cycle (1.2e-03/8.0e-01/ 7/98) | ||
| 472 | 3.2/1.6 | 71 | 8 | response to mechanical stimulus (2.5e-02/1.4e-01/ 3/ 16) | extracellular region (1.2e-02/5.7e+00/ 15/ 673) | Regulation of actin cytoskeleton (4.8e-03/1.4e+00/ 8/147) | |||
| 473 | 3.2/1.6 | 31 | 10 | eye photoreceptor cell differentiation (1.1e-02/1.7e-02/ 2/ 5) | |||||
| 474 | 3.2/1.6 | 10 | 10 | nervous system development (2.2e-02/3.9e-01/ 4/ 402) | |||||
| 475 | 3.2/1.6 | 75 | 11 | extracellular region (4.5e-03/5.2e+00/ 15/ 673) | |||||
| 476 | 3.2/1.6 | 14 | 11 | ||||||
| 477 | 3.2/1.6 | 19 | 11 | regulation of osteoblast differentiation (3.3e-02/3.5e-02/ 2/ 18) | |||||
| 478 | 3.2/1.6 | 68 | 9 | defense response (3.4e-02/1.5e+00/ 7/ 257) | extracellular region (2.2e-03/4.3e+00/ 14/ 673) | ||||
| 479 | 3.2/1.6 | 60 | 10 | defense response (4.1e-02/1.5e+00/ 7/ 257) | plasma membrane (3.0e-02/9.4e+00/ 19/1409) | B cell receptor signaling pathway (4.8e-02/4.5e-01/ 4/47) | |||
| 480 | 3.2/1.6 | 15 | 6 | central element (4.2e-02/1.8e-03/ 1/ 1) | |||||
| 481 | 3.2/1.6 | 39 | 11 | extracellular region (1.5e-02/2.5e+00/ 9/ 673) | |||||
| 482 | 3.2/1.6 | 68 | 10 | integral to membrane (8.7e-03/1.4e+01/ 27/1983) | signal transducer activity (1.1e-02/5.6e+00/ 16/780) | ||||
| 483 | 3.2/1.6 | 22 | 6 | ||||||
| 484 | 3.2/1.6 | 39 | 9 | eye photoreceptor cell differentiation (1.7e-02/2.4e-02/ 2/ 5) | bile acid transmembrane transporter activity (8.3e-03/1.3e-02/ 2/3) | ||||
| 485 | 3.2/1.6 | 13 | 7 | insulin receptor complex (3.0e-02/1.2e-03/ 1/ 1) | |||||
| 486 | 3.2/1.6 | 48 | 11 | multicellular organismal process (1.1e-02/9.0e+00/ 20/1611) | |||||
| 487 | 3.2/1.6 | 24 | 7 | mammary gland development (4.3e-02/4.2e-02/ 2/ 16) | axon (5.0e-02/7.0e-02/ 2/ 25) | ||||
| 488 | 3.2/1.6 | 11 | 9 | generation of a signal involved in cell-cell signaling (4.5e-02/4.5e-02/ 2/ 46) | extrachromosomal circular DNA (3.2e-02/1.3e-03/ 1/ 1) | ||||
| 489 | 3.2/1.6 | 30 | 11 | brush border (2.3e-02/4.3e-02/ 2/ 13) | scavenger receptor activity (4.9e-02/3.9e-02/ 2/12) | ||||
| 490 | 3.2/1.4 | 48 | 13 | cell cycle phase (1.1e-31/1.7e+00/ 31/ 285) | chromosomal part (9.6e-14/1.2e+00/ 17/ 198) | microtubule motor activity (4.0e-04/1.9e-01/ 5/37) | Cell cycle (8.2e-04/5.1e-01/ 6/98) | ||
| 491 | 3.2/1.4 | 28 | 14 | neurotransmitter transport (1.1e-02/9.9e-02/ 3/ 34) | secretory granule membrane (1.6e-02/3.5e-02/ 2/ 11) | inward rectifier potassium channel activity (1.6e-02/1.8e-02/ 2/6) | |||
| 492 | 3.2/1.4 | 29 | 11 | eye photoreceptor cell differentiation (1.0e-02/1.7e-02/ 2/ 5) | |||||
| 493 | 3.2/1.4 | 62 | 13 | cell cycle phase (2.4e-42/2.3e+00/ 41/ 285) | chromosomal part (1.1e-16/1.5e+00/ 21/ 198) | microtubule motor activity (6.1e-06/2.6e-01/ 7/37) | Cell cycle (1.4e-07/7.3e-01/10/98) | ||
| 494 | 3.2/1.4 | 21 | 8 | ||||||
| 495 | 3.2/1.4 | 78 | 12 | cell cycle phase (7.4e-43/2.8e+00/ 45/ 285) | chromosomal part (4.6e-24/1.9e+00/ 29/ 198) | ATP binding (8.1e-07/6.8e+00/ 26/801) | DNA replication (7.4e-10/2.8e-01/ 9/33) | ||
| 496 | 3.2/1.4 | 35 | 16 | aminoglycan metabolic process (1.9e-02/1.3e-01/ 3/ 30) | |||||
| 497 | 3.2/1.4 | 28 | 13 | neurotransmitter transport (1.3e-02/1.0e-01/ 3/ 34) | myosin complex (2.3e-03/7.7e-02/ 3/ 24) | transmembrane receptor activity (3.5e-02/1.0e+00/ 6/324) | |||
| 498 | 3.2/1.4 | 68 | 11 | cell cycle phase (9.2e-37/2.5e+00/ 39/ 285) | chromosome (1.8e-24/2.1e+00/ 30/ 248) | microtubule motor activity (4.3e-07/2.8e-01/ 8/37) | DNA replication (1.5e-05/2.3e-01/ 6/33) | ||
| 499 | 3.2/1.4 | 65 | 12 | cell cycle phase (1.1e-39/2.3e+00/ 40/ 285) | chromosomal part (5.9e-19/1.5e+00/ 23/ 198) | microtubule motor activity (7.3e-06/2.7e-01/ 7/37) | Cell cycle (2.5e-07/7.7e-01/10/98) | ||
| 500 | 3.2/1.4 | 49 | 13 | regulation of cell differentiation (4.1e-03/9.4e-01/ 7/ 178) | |||||
| 501 | 3.2/1.4 | 12 | 14 | ||||||
| 502 | 3.2/1.4 | 30 | 15 | myosin complex (5.0e-02/7.1e-02/ 2/ 24) | |||||
| 503 | 3.2/1.4 | 47 | 16 | proteinaceous extracellular matrix (3.7e-03/7.6e-01/ 6/ 153) | |||||
| 504 | 3.2/1.4 | 37 | 6 | xenobiotic metabolic process (2.2e-03/5.2e-02/ 3/ 13) | microvillus (2.2e-02/4.2e-02/ 2/ 11) | glucuronosyltransferase activity (2.2e-03/4.6e-02/ 3/12) | Pentose and glucuronate interconversions (3.2e-03/6.3e-02/ 3/13) | ||
| 505 | 3.2/1.4 | 34 | 7 | extracellular space (3.9e-02/8.8e-01/ 5/ 237) | |||||
| 506 | 3.2/1.4 | 40 | 14 | positive regulation of tyrosine phosphorylation of Stat3 protein (2.1e-02/2.6e-02/ 2/ 7) | |||||
| 507 | 3.2/1.4 | 37 | 16 | basal plasma membrane (1.7e-02/3.7e-02/ 2/ 11) | scavenger receptor activity (4.9e-02/3.9e-02/ 2/12) | ||||
| 508 | 3.2/1.4 | 46 | 15 | sensory perception (1.0e-02/7.8e-01/ 6/ 171) | basal plasma membrane (2.9e-02/5.1e-02/ 2/ 11) | MAP-kinase scaffold activity (3.7e-03/9.2e-03/ 2/2) | |||
| 509 | 3.2/1.4 | 37 | 11 | intermediate filament bundle assembly (5.7e-03/1.3e-02/ 2/ 3) | neurofilament (2.0e-03/1.2e-02/ 2/ 3) | ||||
| 510 | 3.2/1.4 | 35 | 9 | eye photoreceptor cell differentiation (1.4e-02/2.0e-02/ 2/ 5) | |||||
| 511 | 3.2/1.2 | 22 | 23 | ||||||
| 512 | 3.2/1.2 | 87 | 15 | cell cycle phase (4.4e-52/3.2e+00/ 53/ 285) | chromosomal part (7.7e-28/2.1e+00/ 33/ 198) | microtubule motor activity (1.7e-07/3.6e-01/ 9/37) | DNA replication (8.1e-12/3.8e-01/11/33) | ||
| 513 | 3.2/1.2 | 18 | 21 | osteoclast differentiation (1.4e-02/2.0e-02/ 2/ 11) | |||||
| 514 | 3.2/1.2 | 18 | 17 | digestion (2.5e-03/5.4e-02/ 3/ 26) | trans-1,2-dihydrobenzene-1,2-diol dehydrogenase activity (1.0e-05/7.1e-03/ 3/3) | Metabolism of xenobiotics by cytochrome P450 (1.5e-02/1.2e-01/ 3/37) | |||
| 515 | 3.2/1.2 | 32 | 21 | sensory perception (1.5e-02/5.5e-01/ 5/ 171) | basal plasma membrane (1.6e-02/3.5e-02/ 2/ 11) | olfactory receptor activity (3.5e-02/3.1e-02/ 2/9) | |||
| 516 | 3.2/1.2 | 11 | 21 | fatty acid alpha-oxidation (5.0e-02/9.7e-04/ 1/ 1) | membrane fraction (8.5e-03/3.6e-01/ 4/ 356) | Retinol metabolism (2.3e-02/3.1e-02/ 2/21) | |||
| 517 | 3.2/1.2 | 25 | 21 | ||||||
| 518 | 3.2/1.2 | 34 | 24 | cell morphogenesis (4.6e-02/1.2e+00/ 6/ 312) | |||||
| 519 | 3.2/1.2 | 20 | 19 | ||||||
| 520 | 3.2/1.2 | 10 | 21 | cilium (3.1e-02/5.3e-02/ 2/ 46) | |||||
| 521 | 3.2/1.2 | 34 | 25 | ||||||
| 522 | 3.2/1.2 | 32 | 21 | basal plasma membrane (1.6e-02/3.5e-02/ 2/ 11) | scavenger receptor activity (4.7e-02/3.8e-02/ 2/12) | ||||
| 523 | 3.2/1.2 | 28 | 17 | neurotransmitter transport (1.0e-02/9.4e-02/ 3/ 34) | secretory granule membrane (1.5e-02/3.4e-02/ 2/ 11) | ||||
| 524 | 3.2/1.2 | 23 | 15 | ||||||
| 525 | 3.2/1.2 | 12 | 22 | fatty acid alpha-oxidation (5.0e-02/9.7e-04/ 1/ 1) | membrane fraction (4.9e-03/3.2e-01/ 4/ 356) | Retinol metabolism (2.3e-02/3.1e-02/ 2/21) | |||
| 526 | 3.2/1.2 | 35 | 29 | ||||||
| 527 | 3.2/1 | 38 | 31 | ||||||
| 528 | 3.2/1 | 37 | 22 | ||||||
| 529 | 3.2/1 | 21 | 28 | plasma membrane (3.1e-02/3.1e+00/ 9/1409) | |||||
| 530 | 3.2/1 | 91 | 31 | cell cycle phase (2.8e-49/3.3e+00/ 52/ 285) | chromosome (6.9e-26/2.7e+00/ 34/ 248) | microtubule motor activity (6.4e-10/3.7e-01/ 11/37) | Cell cycle (1.3e-08/9.8e-01/12/98) | ||
| 531 | 3.2/1 | 29 | 26 | chromatin modification (1.6e-02/5.6e-01/ 5/ 162) | |||||
| 532 | 3.2/1 | 34 | 11 | xenobiotic metabolic process (1.9e-03/4.9e-02/ 3/ 13) | glucuronosyltransferase activity (1.7e-03/4.1e-02/ 3/12) | Pentose and glucuronate interconversions (1.5e-03/4.8e-02/ 3/13) | |||
| 533 | 3.2/1 | 12 | 30 | regulation of small GTPase mediated signal transduction (4.1e-02/1.9e-01/ 3/ 137) | |||||
| 534 | 3.2/1 | 37 | 28 | defense response (7.3e-03/1.1e+00/ 7/ 257) | |||||
| 535 | 3.2/1 | 29 | 23 | Retinol metabolism (4.6e-02/4.7e-02/ 2/21) | |||||
| 536 | 3.2/1 | 38 | 30 | transcription regulator activity (2.1e-02/3.3e+00/ 11/806) | |||||
| 537 | 3.2/1 | 15 | 36 | negative regulation of immune response (6.5e-03/1.2e-02/ 2/ 8) | |||||
| 538 | 3.2/1 | 21 | 25 | cell adhesion (4.8e-02/8.2e-01/ 5/ 368) | membrane (3.1e-02/7.2e+00/ 14/3116) | ||||
| 539 | 3.2/1 | 21 | 30 | ||||||
| 540 | 3.2/1 | 20 | 30 | ||||||
| 541 | 3.2/1 | 27 | 25 | eye photoreceptor cell differentiation (9.6e-03/1.6e-02/ 2/ 5) | |||||
| 542 | 3.2/1 | 17 | 25 | ||||||
| 543 | 3/2 | 137 | 7 | protein transport (3.1e-03/8.4e+00/ 22/ 526) | melanosome (2.9e-06/1.2e+00/ 11/ 77) | protein binding (1.9e-02/7.1e+01/ 90/4505) | MAPK signaling pathway (4.3e-02/3.7e+00/11/183) | miR-320/320abcd (0.00386/ 8.0127/25/372) | |
| 544 | 3/2 | 52 | 3 | genetic imprinting (7.9e-03/1.5e-02/ 2/ 3) | extracellular region (2.2e-02/3.7e+00/ 11/ 673) | ||||
| 545 | 3/2 | 73 | 6 | transition metal ion binding (6.0e-03/9.4e+00/ 22/1404) | miR-138 (0.04029/ 1.4740/ 9/253) | ||||
| 546 | 3/2 | 53 | 4 | sterol metabolic process (4.6e-09/4.4e-01/ 10/ 64) | endoplasmic reticulum membrane (1.9e-04/2.0e+00/ 11/ 335) | Biosynthesis of steroids (2.4e-09/2.1e-01/ 8/23) | |||
| 547 | 3/2 | 46 | 4 | activation of MAPK activity (3.7e-02/1.7e-01/ 3/ 37) | |||||
| 548 | 3/2 | 61 | 5 | xenobiotic metabolic process (5.4e-03/7.4e-02/ 3/ 13) | fibril (2.3e-02/4.5e-02/ 2/ 7) | glucuronosyltransferase activity (6.7e-03/7.2e-02/ 3/12) | Pentose and glucuronate interconversions (5.1e-03/7.7e-02/ 3/13) | ||
| 549 | 3/2 | 58 | 3 | immune system process (1.2e-02/3.0e+00/ 11/ 466) | phosphatidate phosphatase activity (3.5e-02/3.2e-02/ 2/5) | ||||
| 550 | 3/2 | 125 | 3 | response to reactive oxygen species (4.0e-03/3.8e-01/ 5/ 26) | extracellular region (3.0e-03/9.7e+00/ 23/ 673) | transmembrane receptor activity (9.1e-03/4.7e+00/ 15/324) | Small cell lung cancer (3.8e-02/1.5e+00/ 7/73) | ||
| 551 | 3/2 | 71 | 6 | ||||||
| 552 | 3/2 | 67 | 3 | ||||||
| 553 | 3/2 | 45 | 4 | MAPKKK cascade (5.0e-02/4.5e-01/ 4/ 112) | |||||
| 554 | 3/2 | 88 | 4 | DNA binding (4.9e-02/9.6e+00/ 20/1195) | |||||
| 555 | 3/2 | 91 | 4 | cell communication (1.8e-02/1.9e+01/ 33/1908) | plasma membrane part (7.6e-05/8.4e+00/ 24/ 855) | transmembrane receptor activity (8.3e-03/3.1e+00/ 12/324) | |||
| 556 | 3/2 | 44 | 5 | sterol metabolic process (5.7e-10/3.6e-01/ 10/ 64) | extracellular matrix (7.6e-04/8.3e-01/ 7/ 163) | Biosynthesis of steroids (7.4e-10/1.8e-01/ 8/23) | |||
| 557 | 3/2 | 38 | 5 | cell junction (4.5e-02/9.1e-01/ 5/ 216) | |||||
| 558 | 3/2 | 54 | 3 | ||||||
| 559 | 3/2 | 61 | 5 | ||||||
| 560 | 3/2 | 68 | 3 | ||||||
| 561 | 3/2 | 64 | 4 | embryonic limb morphogenesis (1.2e-03/2.8e-01/ 5/ 37) | extracellular region (7.1e-03/4.8e+00/ 14/ 673) | sequence-specific DNA binding (3.5e-02/1.8e+00/ 8/257) | |||
| 562 | 3/2 | 70 | 4 | multicellular organismal development (1.4e-02/1.0e+01/ 22/1257) | extracellular region (3.2e-06/5.5e+00/ 21/ 673) | ||||
| 563 | 3/2 | 59 | 5 | sterol metabolic process (3.0e-10/4.6e-01/ 11/ 64) | extracellular matrix (4.4e-03/1.1e+00/ 7/ 163) | Biosynthesis of steroids (2.7e-07/2.2e-01/ 7/23) | |||
| 564 | 3/2 | 85 | 4 | extracellular matrix organization (2.8e-03/3.4e-01/ 5/ 42) | integral to plasma membrane (8.8e-03/4.9e+00/ 14/ 535) | transmembrane receptor activity (1.3e-02/2.8e+00/ 11/324) | |||
| 565 | 3/2 | 51 | 4 | extracellular region (2.2e-02/3.7e+00/ 11/ 673) | |||||
| 566 | 3/1.8 | 48 | 5 | activation of MAPK activity (3.7e-02/1.7e-01/ 3/ 37) | |||||
| 567 | 3/1.8 | 117 | 3 | glycoprotein catabolic process (4.9e-02/2.0e-01/ 3/ 17) | alkali metal ion binding (2.5e-02/8.9e-01/ 6/74) | ||||
| 568 | 3/1.8 | 174 | 12 | multicellular organismal process (1.7e-10/3.1e+01/ 70/1611) | extracellular region (9.8e-09/1.4e+01/ 41/ 673) | extracellular matrix structural constituent (4.5e-05/8.2e-01/ 9/42) | ECM-receptor interaction (1.3e-02/1.2e+00/ 7/58) | ||
| 569 | 3/1.8 | 72 | 5 | extracellular region (9.9e-03/5.0e+00/ 14/ 673) | B cell receptor signaling pathway (3.9e-02/4.2e-01/ 4/47) | ||||
| 570 | 3/1.8 | 173 | 10 | multicellular organismal process (1.1e-07/3.2e+01/ 65/1611) | extracellular region (2.9e-08/1.4e+01/ 40/ 673) | extracellular matrix structural constituent (2.4e-03/8.0e-01/ 7/42) | |||
| 571 | 3/1.8 | 44 | 5 | osteoblast development (1.7e-02/2.4e-02/ 2/ 5) | |||||
| 572 | 3/1.8 | 20 | 6 | nascent polypeptide-associated complex (4.0e-02/1.7e-03/ 1/ 1) | |||||
| 573 | 3/1.8 | 54 | 6 | cell surface receptor linked signal transduction (3.5e-02/3.6e+00/ 11/ 683) | plasma membrane part (3.4e-03/5.1e+00/ 15/ 855) | B cell receptor signaling pathway (3.4e-02/4.0e-01/ 4/47) | |||
| 574 | 3/1.8 | 26 | 7 | salivary gland morphogenesis (3.1e-03/8.8e-03/ 2/ 3) | aldo-keto reductase activity (3.7e-02/3.2e-02/ 2/11) | ||||
| 575 | 3/1.8 | 78 | 7 | multicellular organismal process (1.5e-05/1.5e+01/ 36/1611) | integral to plasma membrane (6.7e-03/4.7e+00/ 14/ 535) | ||||
| 576 | 3/1.8 | 41 | 5 | osteoblast development (1.4e-02/2.0e-02/ 2/ 5) | |||||
| 577 | 3/1.8 | 30 | 7 | cell adhesion (1.6e-03/1.2e+00/ 8/ 368) | rough endoplasmic reticulum membrane (1.7e-02/3.7e-02/ 2/ 10) | actin filament binding (1.3e-02/9.2e-02/ 3/27) | |||
| 578 | 3/1.8 | 46 | 7 | multicellular organismal process (2.0e-02/8.7e+00/ 19/1611) | extracellular region (8.2e-04/3.4e+00/ 13/ 673) | ||||
| 579 | 3/1.8 | 35 | 5 | MAPKKK cascade (2.4e-02/3.4e-01/ 4/ 112) | plasma membrane part (1.9e-02/3.2e+00/ 10/ 855) | receptor signaling protein activity (3.0e-02/3.4e-01/ 4/108) | |||
| 580 | 3/1.8 | 61 | 6 | cell surface receptor linked signal transduction (4.1e-02/4.3e+00/ 12/ 683) | plasma membrane part (2.7e-04/5.7e+00/ 18/ 855) | signal transducer activity (2.2e-02/4.9e+00/ 14/780) | B cell receptor signaling pathway (3.4e-02/4.0e-01/ 4/47) | ||
| 581 | 3/1.8 | 19 | 9 | angiogenesis (8.1e-03/2.4e-01/ 4/ 102) | extracellular region (9.9e-03/1.5e+00/ 7/ 673) | cytokine activity (4.0e-02/1.6e-01/ 3/71) | |||
| 582 | 3/1.8 | 64 | 5 | cholesterol catabolic process (1.2e-02/2.0e-02/ 2/ 3) | membrane (3.2e-04/2.2e+01/ 39/3116) | transmembrane receptor activity (4.2e-04/2.2e+00/ 12/324) | |||
| 583 | 3/1.8 | 46 | 7 | Dentatorubropallidoluysian atrophy (DRPLA) (4.7e-02/4.7e-02/ 2/14) | |||||
| 584 | 3/1.8 | 62 | 5 | genetic imprinting (1.2e-02/2.0e-02/ 2/ 3) | extracellular region (8.4e-03/4.9e+00/ 14/ 673) | serine-type endopeptidase activity (3.4e-02/3.5e-01/ 4/51) | |||
| 585 | 3/1.6 | 76 | 8 | extracellular region (3.9e-05/5.3e+00/ 19/ 673) | B cell receptor signaling pathway (4.8e-02/4.5e-01/ 4/47) | ||||
| 586 | 3/1.6 | 77 | 9 | extracellular region (8.1e-05/5.6e+00/ 19/ 673) | |||||
| 587 | 3/1.6 | 69 | 10 | ||||||
| 588 | 3/1.6 | 92 | 7 | positive regulation of exocytosis (4.7e-02/4.8e-02/ 2/ 5) | extracellular region (2.0e-03/6.5e+00/ 18/ 673) | transmembrane receptor activity (2.0e-02/3.0e+00/ 11/324) | |||
| 589 | 3/1.6 | 31 | 8 | inflammatory response (1.8e-04/5.6e-01/ 7/ 150) | extracellular space (5.7e-04/8.2e-01/ 7/ 237) | cytokine activity (1.3e-02/2.5e-01/ 4/71) | Cytokine-cytokine receptor interaction (1.1e-02/5.6e-01/ 5/115) | ||
| 590 | 3/1.6 | 105 | 9 | cell cycle phase (3.2e-30/3.7e+00/ 41/ 285) | chromosomal part (6.3e-22/2.5e+00/ 30/ 198) | adenyl nucleotide binding (1.3e-05/9.5e+00/ 29/855) | DNA replication (1.2e-10/4.8e-01/11/33) | ||
| 591 | 3/1.6 | 49 | 7 | eye photoreceptor cell differentiation (2.2e-02/2.8e-02/ 2/ 5) | bile acid transmembrane transporter activity (1.1e-02/1.6e-02/ 2/3) | ||||
| 592 | 3/1.6 | 49 | 9 | neurotransmitter transport (2.9e-03/1.7e-01/ 4/ 34) | myosin complex (8.9e-03/1.3e-01/ 3/ 24) | inward rectifier potassium channel activity (3.4e-02/3.1e-02/ 2/6) | |||
| 593 | 3/1.6 | 32 | 12 | ||||||
| 594 | 3/1.6 | 42 | 8 | nuclear division (2.0e-16/8.2e-01/ 17/ 173) | chromosome (8.4e-10/1.2e+00/ 14/ 248) | microtubule motor activity (3.3e-03/1.6e-01/ 4/37) | Cell cycle (6.1e-03/4.7e-01/ 5/98) | ||
| 595 | 3/1.6 | 76 | 7 | cell cycle phase (2.4e-16/2.8e+00/ 26/ 285) | chromosomal part (1.2e-14/1.8e+00/ 21/ 198) | microtubule motor activity (1.9e-04/3.1e-01/ 6/37) | Biosynthesis of steroids (1.5e-05/2.3e-01/ 6/23) | ||
| 596 | 3/1.6 | 15 | 9 | peptidyl-prolyl cis-trans isomerase activity (4.9e-02/3.9e-02/ 2/25) | |||||
| 597 | 3/1.6 | 54 | 10 | monovalent inorganic cation transport (8.4e-04/7.1e-01/ 7/ 127) | extracellular region part (4.4e-02/2.3e+00/ 8/ 376) | voltage-gated potassium channel activity (3.1e-02/1.4e-01/ 3/24) | |||
| 598 | 3/1.6 | 99 | 9 | cell cycle phase (8.5e-50/3.6e+00/ 54/ 285) | chromosome (2.9e-29/3.0e+00/ 38/ 248) | microtubule motor activity (3.5e-07/4.1e-01/ 9/37) | DNA replication (5.1e-10/3.9e-01/10/33) | ||
| 599 | 3/1.6 | 13 | 9 | neuropeptide signaling pathway (4.7e-02/4.6e-02/ 2/ 33) | |||||
| 600 | 3/1.6 | 23 | 10 | activation of adenylate cyclase activity (2.3e-02/2.7e-02/ 2/ 13) | membrane (2.2e-02/8.4e+00/ 16/3116) | transmembrane receptor activity (3.7e-03/6.4e-01/ 6/324) | |||
| 601 | 3/1.6 | 55 | 8 | common-partner SMAD protein phosphorylation (8.7e-03/1.6e-02/ 2/ 3) | plasma membrane part (2.1e-03/5.5e+00/ 16/ 855) | ||||
| 602 | 3/1.6 | 96 | 10 | extracellular region (4.9e-04/6.9e+00/ 20/ 673) | |||||
| 603 | 3/1.6 | 71 | 8 | extracellular region (5.9e-03/4.7e+00/ 14/ 673) | lipid transporter activity (2.4e-02/3.1e-01/ 4/43) | ||||
| 604 | 3/1.6 | 35 | 8 | ||||||
| 605 | 3/1.6 | 66 | 11 | system process (5.4e-03/3.2e+00/ 12/ 445) | extracellular region (4.1e-03/4.6e+00/ 14/ 673) | receptor activity (8.5e-05/3.5e+00/ 16/519) | Neuroactive ligand-receptor interaction (7.0e-03/7.5e-01/ 6/78) | ||
| 606 | 3/1.6 | 38 | 10 | protein kinase C activity (3.8e-02/3.3e-02/ 2/8) | |||||
| 607 | 3/1.4 | 39 | 11 | eye photoreceptor cell differentiation (1.6e-02/2.2e-02/ 2/ 5) | plasma membrane (2.2e-02/6.5e+00/ 15/1409) | Neuroactive ligand-receptor interaction (1.5e-02/3.2e-01/ 4/78) | |||
| 608 | 3/1.4 | 41 | 14 | neurotransmitter transport (1.4e-03/1.4e-01/ 4/ 34) | myosin complex (5.6e-03/1.1e-01/ 3/ 24) | inward rectifier potassium channel activity (2.4e-02/2.4e-02/ 2/6) | |||
| 609 | 3/1.4 | 41 | 16 | neurite morphogenesis (1.9e-02/3.1e-01/ 4/ 80) | Dentatorubropallidoluysian atrophy (DRPLA) (4.0e-02/4.2e-02/ 2/14) | 19 (1.5e-02/ 2.5132/11/570) | |||
| 610 | 3/1.4 | 126 | 12 | cell cycle phase (2.0e-58/4.6e+00/ 66/ 285) | chromosomal part (1.1e-29/3.0e+00/ 39/ 198) | ATP binding (3.4e-08/1.1e+01/ 38/801) | DNA replication (1.7e-14/5.5e-01/14/33) | ||
| 611 | 3/1.4 | 31 | 14 | scavenger receptor activity (4.9e-02/3.9e-02/ 2/12) | |||||
| 612 | 3/1.4 | 44 | 16 | ||||||
| 613 | 3/1.4 | 74 | 14 | extracellular region (1.1e-03/5.1e+00/ 16/ 673) | |||||
| 614 | 3/1.4 | 28 | 11 | endomembrane system (1.4e-02/2.0e+00/ 8/ 753) | |||||
| 615 | 3/1.4 | 34 | 12 | osteoblast differentiation (1.0e-02/9.4e-02/ 3/ 27) | |||||
| 616 | 3/1.4 | 39 | 13 | neurite morphogenesis (1.7e-02/3.0e-01/ 4/ 80) | |||||
| 617 | 3/1.4 | 35 | 17 | anatomical structure morphogenesis (3.4e-02/2.5e+00/ 9/ 679) | neuron projection (4.1e-02/2.4e-01/ 3/ 65) | ||||
| 618 | 3/1.4 | 66 | 13 | extracellular region (2.4e-04/4.5e+00/ 16/ 673) | |||||
| 619 | 3/1.2 | 25 | 18 | sarcomere (4.6e-02/6.8e-02/ 2/ 24) | |||||
| 620 | 3/1.2 | 57 | 8 | xenobiotic metabolic process (5.4e-03/7.4e-02/ 3/ 13) | proteinaceous extracellular matrix (8.4e-03/9.0e-01/ 6/ 153) | glucuronosyltransferase activity (6.4e-03/7.1e-02/ 3/12) | Pentose and glucuronate interconversions (5.1e-03/7.7e-02/ 3/13) | ||
| 621 | 3/1.2 | 56 | 24 | activation of JUN kinase activity (6.9e-03/8.2e-02/ 3/ 14) | |||||
| 622 | 3/1.2 | 50 | 23 | activation of JUN kinase activity (4.8e-03/7.0e-02/ 3/ 14) | |||||
| 623 | 3/1.2 | 27 | 22 | ||||||
| 624 | 3/1.2 | 18 | 22 | digestion (3.9e-02/4.0e-02/ 2/ 26) | cation transmembrane transporter activity (1.9e-02/3.1e-01/ 4/213) | ||||
| 625 | 3/1.2 | 40 | 16 | homophilic cell adhesion (1.4e-03/1.4e-01/ 4/ 37) | |||||
| 626 | 3/1.2 | 53 | 8 | xenobiotic metabolic process (5.7e-03/7.6e-02/ 3/ 13) | melanosome membrane (1.3e-03/1.1e-02/ 2/ 2) | glucuronosyltransferase activity (4.8e-03/6.3e-02/ 3/12) | Pentose and glucuronate interconversions (6.0e-03/8.2e-02/ 3/13) | ||
| 627 | 3/1.2 | 56 | 24 | ||||||
| 628 | 3/1.2 | 72 | 15 | collagen catabolic process (8.1e-03/8.8e-02/ 3/ 12) | extracellular space (1.9e-04/2.0e+00/ 11/ 237) | prostaglandin-endoperoxide synthase activity (8.2e-03/1.5e-02/ 2/2) | Neuroactive ligand-receptor interaction (1.2e-03/7.8e-01/ 7/78) | ||
| 629 | 3/1.2 | 59 | 23 | MAPK signaling pathway (2.2e-02/1.4e+00/ 7/183) | |||||
| 630 | 3/1.2 | 35 | 15 | osteoblast differentiation (1.2e-02/1.0e-01/ 3/ 27) | cell projection (1.1e-02/9.7e-01/ 6/ 236) | ||||
| 631 | 3/1 | 52 | 24 | oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen (2.5e-02/2.5e-02/ 2/6) | Retinol metabolism (6.6e-03/8.6e-02/ 3/21) | ||||
| 632 | 3/1 | 154 | 16 | multicellular organismal process (7.6e-11/2.8e+01/ 66/1611) | extracellular region (3.9e-07/1.2e+01/ 35/ 673) | extracellular matrix structural constituent (1.8e-03/7.5e-01/ 7/42) | ECM-receptor interaction (1.3e-02/1.2e+00/ 7/58) | ||
| 633 | 3/1 | 137 | 27 | cell cycle phase (8.1e-57/4.9e+00/ 66/ 285) | chromosome (9.4e-30/3.9e+00/ 43/ 248) | microtubule motor activity (1.6e-09/5.6e-01/ 12/37) | Cell cycle (1.2e-14/1.7e+00/20/98) | ||
| 634 | 3/1 | 54 | 33 | 19 (3.6e-02/ 3.3100/12/570) | |||||
| 635 | 3/1 | 38 | 27 | eye photoreceptor cell differentiation (1.4e-02/2.1e-02/ 2/ 5) | cell projection part (1.6e-02/1.6e-01/ 3/ 37) | ||||
| 636 | 3/1 | 56 | 34 | disaccharide metabolic process (1.2e-02/2.0e-02/ 2/ 3) | |||||
| 637 | 3/1 | 19 | 29 | nucleobase, nucleoside and nucleotide biosynthetic process (1.4e-02/2.0e-02/ 2/ 11) | |||||
| 638 | 3/1 | 37 | 31 | ||||||
| 639 | 3/1 | 49 | 31 | negative regulation of developmental process (3.8e-03/1.3e+00/ 8/ 283) | transcription factor activity (2.7e-02/2.3e+00/ 9/477) | Chronic myeloid leukemia (1.6e-03/3.3e-01/ 5/64) | |||
| 640 | 3/1 | 42 | 14 | xenobiotic metabolic process (3.4e-03/6.1e-02/ 3/ 13) | melanosome membrane (9.6e-04/9.2e-03/ 2/ 2) | glucuronosyltransferase activity (7.1e-05/5.2e-02/ 4/12) | Pentose and glucuronate interconversions (1.1e-04/7.3e-02/ 4/13) | ||
| 641 | 3/1 | 33 | 33 | ||||||
| 642 | 3/1 | 15 | 32 | microtubule cytoskeleton (4.7e-02/5.8e-01/ 4/ 321) | |||||
| 643 | 3/1 | 37 | 30 | ||||||
| 644 | 3/1 | 65 | 33 | 19 (5.7e-03/ 3.9843/15/570) | |||||
| 645 | 2.8/2 | 125 | 6 | DNA binding (1.3e-02/1.4e+01/ 29/1195) | |||||
| 646 | 2.8/2 | 86 | 4 | sterol metabolic process (2.4e-12/7.0e-01/ 14/ 64) | endoplasmic reticulum membrane (9.4e-04/3.3e+00/ 13/ 335) | oxidoreductase activity (4.6e-02/4.0e+00/ 12/400) | Biosynthesis of steroids (1.3e-09/3.0e-01/ 9/23) | ||
| 647 | 2.8/2 | 82 | 4 | xenobiotic metabolic process (1.5e-02/1.2e-01/ 3/ 13) | extracellular matrix part (7.5e-03/5.6e-01/ 5/ 63) | glucuronosyltransferase activity (1.6e-02/1.1e-01/ 3/12) | Pentose and glucuronate interconversions (1.4e-02/1.2e-01/ 3/13) | ||
| 648 | 2.8/2 | 142 | 3 | immune system process (5.9e-03/7.6e+00/ 20/ 466) | extracellular region (5.2e-06/1.1e+01/ 31/ 673) | ||||
| 649 | 2.8/2 | 119 | 3 | prostanoid metabolic process (5.2e-04/1.2e-01/ 4/ 9) | extracellular region (3.8e-02/9.1e+00/ 19/ 673) | receptor activity (1.5e-02/6.8e+00/ 18/519) | |||
| 650 | 2.8/2 | 107 | 5 | cell cycle phase (3.6e-16/3.6e+00/ 29/ 285) | chromosomal part (8.9e-14/2.6e+00/ 23/ 198) | microtubule motor activity (1.1e-02/4.5e-01/ 5/37) | DNA replication (4.7e-06/5.0e-01/ 8/33) | ||
| 651 | 2.8/2 | 123 | 6 | cell cycle phase (2.1e-19/4.2e+00/ 34/ 285) | chromosome, centromeric region (1.4e-16/9.1e-01/ 18/ 63) | microtubule motor activity (1.6e-05/4.9e-01/ 8/37) | Biosynthesis of steroids (4.0e-07/3.8e-01/ 8/23) | ||
| 652 | 2.8/2 | 64 | 5 | intrinsic to membrane (4.7e-02/1.3e+01/ 23/2010) | |||||
| 653 | 2.8/2 | 56 | 5 | response to UV-C (2.5e-02/3.0e-02/ 2/ 5) | |||||
| 654 | 2.8/2 | 103 | 6 | genetic imprinting (2.7e-02/3.5e-02/ 2/ 3) | extracellular region (3.7e-03/8.0e+00/ 20/ 673) | carbohydrate binding (4.5e-02/1.4e+00/ 7/130) | |||
| 655 | 2.8/2 | 60 | 7 | ||||||
| 656 | 2.8/2 | 197 | 4 | cell adhesion (2.5e-04/8.6e+00/ 25/ 368) | plasma membrane (7.1e-03/3.2e+01/ 52/1409) | transmembrane receptor activity (2.0e-02/7.6e+00/ 19/324) | Small cell lung cancer (2.7e-03/2.0e+00/10/73) | ||
| 657 | 2.8/2 | 74 | 4 | intrinsic to membrane (3.9e-02/1.5e+01/ 26/2010) | |||||
| 658 | 2.8/2 | 126 | 3 | integral to Golgi membrane (1.1e-02/3.4e-01/ 4/ 25) | MAP-kinase scaffold activity (2.0e-02/2.8e-02/ 2/2) | ||||
| 659 | 2.8/2 | 44 | 5 | cell adhesion (2.5e-03/2.0e+00/ 10/ 368) | extracellular region (3.3e-05/3.4e+00/ 15/ 673) | extracellular matrix binding (3.4e-02/3.1e-02/ 2/6) | |||
| 660 | 2.8/2 | 109 | 3 | DNA replication (1.6e-05/2.3e+00/ 14/ 180) | extracellular space (1.1e-04/3.1e+00/ 14/ 237) | growth factor activity (4.5e-04/1.1e+00/ 9/91) | DNA replication (2.4e-03/5.9e-01/ 6/33) | ||
| 661 | 2.8/2 | 116 | 3 | mammary gland development (4.3e-02/1.9e-01/ 3/ 16) | extracellular region (5.0e-02/8.0e+00/ 17/ 673) | ||||
| 662 | 2.8/2 | 53 | 6 | ||||||
| 663 | 2.8/2 | 94 | 6 | cell cycle phase (8.7e-34/3.2e+00/ 41/ 285) | chromosome (1.4e-17/2.7e+00/ 27/ 248) | microtubule motor activity (5.7e-04/3.8e-01/ 6/37) | Cell cycle (2.7e-06/1.2e+00/11/98) | ||
| 664 | 2.8/2 | 112 | 3 | multicellular organismal process (2.4e-02/2.1e+01/ 36/1611) | plasma membrane (1.0e-02/1.8e+01/ 32/1409) | ||||
| 665 | 2.8/2 | 93 | 5 | genetic imprinting (2.2e-02/3.0e-02/ 2/ 3) | extracellular region (5.0e-07/7.3e+00/ 26/ 673) | endopeptidase activity (2.7e-03/1.8e+00/ 10/176) | |||
| 666 | 2.8/2 | 185 | 3 | cell adhesion (1.0e-02/7.9e+00/ 20/ 368) | extracellular region (5.9e-04/1.4e+01/ 32/ 673) | transmembrane receptor activity (3.0e-03/6.9e+00/ 20/324) | Chronic myeloid leukemia (2.2e-02/1.8e+00/ 8/64) | ||
| 667 | 2.8/2 | 98 | 3 | multicellular organismal development (6.1e-04/1.4e+01/ 31/1257) | extracellular region (1.1e-06/7.6e+00/ 26/ 673) | growth factor activity (5.1e-03/9.1e-01/ 7/91) | |||
| 668 | 2.8/2 | 120 | 4 | DNA replication (1.5e-06/2.6e+00/ 16/ 180) | chromosomal part (6.7e-09/2.9e+00/ 19/ 198) | growth factor activity (2.7e-02/1.3e+00/ 7/91) | DNA replication (1.8e-04/5.6e-01/ 7/33) | ||
| 669 | 2.8/2 | 115 | 6 | system development (6.1e-04/1.3e+01/ 31/ 987) | extracellular region part (1.0e-03/4.9e+00/ 16/ 376) | calcium ion binding (5.3e-03/5.0e+00/ 16/390) | |||
| 670 | 2.8/2 | 59 | 4 | ||||||
| 671 | 2.8/2 | 174 | 4 | developmental process (1.6e-06/3.8e+01/ 70/1870) | extracellular region (2.4e-14/1.3e+01/ 49/ 673) | cytokine binding (6.6e-03/9.6e-01/ 7/50) | Cytokine-cytokine receptor interaction (4.2e-03/2.6e+00/11/115) | ||
| 672 | 2.8/2 | 138 | 4 | response to hexose stimulus (4.2e-03/7.7e-02/ 3/ 5) | cell fraction (1.2e-02/7.4e+00/ 18/ 468) | MAPK signaling pathway (2.9e-02/3.5e+00/11/183) | 19 (1.7e-02/ 8.4590/22/570) | ||
| 673 | 2.8/2 | 145 | 3 | MAPKKK cascade (7.1e-04/1.6e+00/ 10/ 112) | extracellular region (1.7e-02/9.7e+00/ 21/ 673) | ||||
| 674 | 2.8/1.8 | 115 | 5 | cell cycle phase (8.5e-11/4.1e+00/ 25/ 285) | chromosomal part (4.7e-14/2.8e+00/ 24/ 198) | growth factor activity (4.8e-03/1.2e+00/ 8/91) | DNA replication (7.9e-08/6.4e-01/10/33) | ||
| 675 | 2.8/1.8 | 124 | 3 | nucleic acid binding (4.2e-02/2.1e+01/ 35/1782) | |||||
| 676 | 2.8/1.8 | 82 | 6 | platelet alpha granule membrane (2.1e-02/4.4e-02/ 2/ 5) | |||||
| 677 | 2.8/1.8 | 36 | 7 | multicellular organismal process (1.4e-03/6.7e+00/ 18/1611) | aldo-keto reductase activity (2.1e-03/4.5e-02/ 3/11) | ||||
| 678 | 2.8/1.8 | 55 | 6 | multicellular organismal process (9.9e-04/1.1e+01/ 25/1611) | extracellular region (1.4e-04/4.3e+00/ 16/ 673) | calcium ion binding (2.5e-02/2.7e+00/ 10/390) | |||
| 679 | 2.8/1.8 | 58 | 6 | multicellular organismal process (2.9e-04/9.0e+00/ 23/1611) | intrinsic to membrane (2.8e-02/1.3e+01/ 23/2010) | bile acid:sodium symporter activity (4.8e-03/1.1e-02/ 2/2) | |||
| 680 | 2.8/1.8 | 98 | 5 | extracellular structure organization (1.9e-02/5.7e-01/ 5/ 55) | proteinaceous extracellular matrix (2.8e-02/1.6e+00/ 7/ 153) | signal transducer activity (3.7e-02/7.7e+00/ 18/780) | |||
| 681 | 2.8/1.8 | 146 | 7 | cell cycle phase (5.0e-37/5.1e+00/ 52/ 285) | chromosomal part (4.0e-23/3.4e+00/ 35/ 198) | ATP binding (1.7e-07/1.3e+01/ 39/801) | DNA replication (2.3e-10/6.8e-01/12/33) | ||
| 682 | 2.8/1.8 | 73 | 9 | regulation of multicellular organismal process (7.0e-03/2.3e+00/ 10/ 313) | transmembrane receptor activity (5.1e-03/2.5e+00/ 11/324) | ||||
| 683 | 2.8/1.8 | 90 | 5 | sterol metabolic process (3.5e-12/7.2e-01/ 14/ 64) | endomembrane system (1.0e-03/7.9e+00/ 21/ 753) | DNA primase activity (2.9e-02/3.1e-02/ 2/3) | Biosynthesis of steroids (5.5e-09/3.5e-01/ 9/23) | ||
| 684 | 2.8/1.8 | 21 | 8 | nervous system development (6.6e-04/7.8e-01/ 7/ 402) | cytokine activity (4.4e-02/1.7e-01/ 3/71) | ||||
| 685 | 2.8/1.8 | 111 | 8 | nucleic acid binding (3.2e-02/1.9e+01/ 33/1782) | |||||
| 686 | 2.8/1.8 | 125 | 5 | cell fate determination (4.5e-02/1.9e-01/ 3/ 15) | extracellular region (2.4e-03/9.0e+00/ 22/ 673) | gamma-glutamyltransferase activity (1.9e-02/2.6e-02/ 2/2) | |||
| 687 | 2.8/1.8 | 65 | 4 | receptor signaling protein activity (3.3e-02/6.2e-01/ 5/108) | |||||
| 688 | 2.8/1.8 | 61 | 7 | ||||||
| 689 | 2.8/1.8 | 124 | 8 | cell cycle phase (1.6e-48/4.5e+00/ 58/ 285) | chromosome (8.7e-28/3.7e+00/ 40/ 248) | microtubule motor activity (1.7e-07/5.2e-01/ 10/37) | DNA replication (1.6e-07/4.9e-01/ 9/33) | ||
| 690 | 2.8/1.8 | 63 | 8 | regulation of bone resorption (1.9e-02/2.6e-02/ 2/ 4) | axon (1.8e-02/1.7e-01/ 3/ 25) | ||||
| 691 | 2.8/1.8 | 48 | 4 | ER overload response (2.1e-02/2.7e-02/ 2/ 6) | endoplasmic reticulum lumen (2.0e-04/2.4e-01/ 5/ 48) | low-density lipoprotein receptor binding (4.6e-02/3.9e-02/ 2/7) | |||
| 692 | 2.8/1.8 | 82 | 5 | plasma membrane part (1.6e-03/7.7e+00/ 20/ 855) | signal transducer activity (4.9e-02/6.0e+00/ 15/780) | B cell receptor signaling pathway (4.3e-02/4.4e-01/ 4/47) | |||
| 693 | 2.8/1.8 | 104 | 5 | signal transduction (3.5e-02/1.8e+01/ 31/1768) | plasma membrane part (8.4e-04/9.1e+00/ 23/ 855) | receptor binding (1.5e-02/3.9e+00/ 13/400) | |||
| 694 | 2.8/1.8 | 48 | 7 | sensory perception (1.3e-02/8.3e-01/ 6/ 171) | plasma membrane (4.1e-03/7.4e+00/ 18/1409) | bile acid:sodium symporter activity (3.9e-03/9.4e-03/ 2/2) | |||
| 695 | 2.8/1.6 | 53 | 8 | homophilic cell adhesion (2.8e-02/1.5e-01/ 3/ 37) | |||||
| 696 | 2.8/1.6 | 68 | 5 | positive regulation of MAP kinase activity (1.5e-02/2.9e-01/ 4/ 47) | extracellular space (3.8e-02/1.7e+00/ 7/ 237) | Neuroactive ligand-receptor interaction (4.8e-02/4.6e-01/ 4/78) | |||
| 697 | 2.8/1.6 | 71 | 9 | system process (5.4e-03/3.6e+00/ 13/ 445) | axoneme (1.9e-02/4.1e-02/ 2/ 5) | bile acid transmembrane transporter activity (2.0e-02/2.4e-02/ 2/3) | |||
| 698 | 2.8/1.6 | 101 | 11 | extracellular region (7.7e-03/7.2e+00/ 18/ 673) | gamma-glutamyltransferase activity (1.4e-02/2.1e-02/ 2/2) | 19 (4.6e-02/ 6.1297/17/570) | |||
| 699 | 2.8/1.6 | 39 | 11 | multicellular organismal process (4.2e-04/6.3e+00/ 18/1611) | anchored to membrane (9.4e-04/1.7e-01/ 4/ 37) | ||||
| 700 | 2.8/1.6 | 100 | 7 | cell cycle phase (2.4e-36/3.4e+00/ 44/ 285) | chromosome (5.8e-19/2.9e+00/ 29/ 248) | microtubule motor activity (6.0e-06/4.1e-01/ 8/37) | DNA replication (1.3e-06/4.3e-01/ 8/33) | ||
| 701 | 2.8/1.6 | 46 | 10 | multicellular organismal process (6.2e-03/7.4e+00/ 18/1611) | anchored to membrane (1.6e-03/1.9e-01/ 4/ 37) | G-protein coupled receptor activity (2.6e-02/5.8e-01/ 5/131) | |||
| 702 | 2.8/1.6 | 62 | 7 | ||||||
| 703 | 2.8/1.6 | 100 | 12 | multicellular organismal process (9.1e-04/1.6e+01/ 33/1611) | extracellular region (5.0e-03/7.0e+00/ 18/ 673) | receptor activity (4.0e-04/5.0e+00/ 18/519) | Neuroactive ligand-receptor interaction (7.0e-03/7.5e-01/ 6/78) | ||
| 704 | 2.8/1.6 | 143 | 9 | cell cycle phase (6.9e-55/5.1e+00/ 66/ 285) | chromosome (1.2e-29/4.2e+00/ 44/ 248) | ATP binding (4.3e-08/1.3e+01/ 41/801) | Cell cycle (2.0e-12/1.9e+00/19/98) | ||
| 705 | 2.8/1.6 | 120 | 11 | extracellular region (2.5e-04/8.3e+00/ 23/ 673) | lipid transporter activity (2.0e-02/5.4e-01/ 5/43) | ||||
| 706 | 2.8/1.6 | 51 | 13 | protein import into nucleus (4.5e-02/4.3e-01/ 4/ 77) | |||||
| 707 | 2.8/1.6 | 110 | 9 | plasma membrane (6.0e-03/1.6e+01/ 31/1409) | |||||
| 708 | 2.8/1.6 | 106 | 8 | response to wounding (3.3e-02/2.4e+00/ 9/ 226) | extracellular region (2.4e-04/7.7e+00/ 22/ 673) | ||||
| 709 | 2.8/1.6 | 83 | 8 | ||||||
| 710 | 2.8/1.6 | 57 | 10 | multicellular organismal process (1.8e-03/9.2e+00/ 22/1611) | anchored to membrane (3.1e-03/2.3e-01/ 4/ 37) | ||||
| 711 | 2.8/1.4 | 168 | 12 | cell cycle phase (7.7e-60/6.0e+00/ 74/ 285) | chromosome (1.5e-30/5.0e+00/ 48/ 248) | ATP binding (7.8e-09/1.6e+01/ 47/801) | Cell cycle (2.8e-17/2.3e+00/25/98) | ||
| 712 | 2.8/1.4 | 55 | 13 | multicellular organismal process (1.1e-02/9.0e+00/ 20/1611) | extracellular region part (1.6e-02/2.4e+00/ 9/ 376) | ||||
| 713 | 2.8/1.4 | 94 | 11 | plasma membrane (4.5e-02/1.4e+01/ 25/1409) | very-low-density lipoprotein receptor activity (1.3e-02/2.1e-02/ 2/2) | ||||
| 714 | 2.8/1.4 | 57 | 14 | establishment of localization in cell (2.4e-02/3.4e+00/ 11/ 592) | |||||
| 715 | 2.8/1.4 | 51 | 14 | ||||||
| 716 | 2.8/1.4 | 93 | 12 | cell surface receptor linked signal transduction (3.5e-02/6.5e+00/ 16/ 683) | extracellular region (4.4e-03/6.9e+00/ 18/ 673) | ||||
| 717 | 2.8/1.4 | 47 | 12 | multicellular organismal process (2.6e-02/7.6e+00/ 17/1611) | anchored to membrane (1.8e-03/2.0e-01/ 4/ 37) | transmembrane receptor activity (1.1e-02/1.5e+00/ 8/324) | |||
| 718 | 2.8/1.4 | 110 | 14 | extracellular region (6.2e-04/7.6e+00/ 21/ 673) | |||||
| 719 | 2.8/1.4 | 67 | 14 | osteoblast development (3.1e-02/3.5e-02/ 2/ 5) | cell projection (3.7e-02/1.7e+00/ 7/ 236) | ||||
| 720 | 2.8/1.4 | 83 | 12 | calcium ion binding (3.9e-02/3.4e+00/ 11/390) | |||||
| 721 | 2.8/1.4 | 83 | 13 | collagen catabolic process (9.7e-03/9.5e-02/ 3/ 12) | neurofilament (7.6e-03/2.6e-02/ 2/ 3) | calcium ion binding (1.4e-02/3.4e+00/ 12/390) | Amyotrophic lateral sclerosis (ALS) (2.1e-02/3.4e-01/ 4/38) | ||
| 722 | 2.8/1.4 | 61 | 14 | positive regulation of specific transcription from RNA polymerase II promoter (1.1e-02/1.0e-01/ 3/ 15) | calcium ion binding (2.5e-02/2.7e+00/ 10/390) | ||||
| 723 | 2.8/1.4 | 96 | 13 | regulation of multicellular organismal process (1.8e-02/3.1e+00/ 11/ 313) | plasma membrane (3.8e-02/1.4e+01/ 25/1409) | transmembrane receptor activity (3.0e-03/3.2e+00/ 13/324) | |||
| 724 | 2.8/1.4 | 60 | 14 | cell morphogenesis (3.3e-02/1.9e+00/ 8/ 312) | |||||
| 725 | 2.8/1.4 | 90 | 15 | neurological system process (2.6e-02/2.8e+00/ 10/ 317) | extracellular region (3.1e-03/6.1e+00/ 17/ 673) | MAP-kinase scaffold activity (9.9e-03/1.7e-02/ 2/2) | Neuroactive ligand-receptor interaction (3.6e-02/7.3e-01/ 5/78) | ||
| 726 | 2.8/1.4 | 103 | 17 | multicellular organismal process (3.7e-02/1.6e+01/ 29/1611) | extracellular region (1.1e-03/7.3e+00/ 20/ 673) | MAP-kinase scaffold activity (1.3e-02/2.0e-02/ 2/2) | |||
| 727 | 2.8/1.4 | 106 | 13 | regulation of multicellular organismal process (4.0e-02/3.5e+00/ 11/ 313) | plasma membrane (1.5e-02/1.6e+01/ 29/1409) | transmembrane receptor activity (7.9e-03/3.6e+00/ 13/324) | |||
| 728 | 2.8/1.4 | 84 | 19 | 19 (2.0e-02/ 5.0876/16/570) | |||||
| 729 | 2.8/1.2 | 97 | 18 | insoluble fraction (3.5e-03/3.3e+00/ 12/ 369) | oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen (2.4e-03/5.1e-02/ 3/6) | Retinol metabolism (2.5e-03/1.7e-01/ 4/21) | |||
| 730 | 2.8/1.2 | 87 | 26 | activation of JUN kinase activity (1.7e-02/1.2e-01/ 3/ 14) | 19 (2.8e-02/ 5.2715/16/570) | ||||
| 731 | 2.8/1.2 | 63 | 22 | cell morphogenesis (4.4e-02/2.0e+00/ 8/ 312) | |||||
| 732 | 2.8/1.2 | 71 | 21 | positive regulation of JUN kinase activity (1.6e-02/1.2e-01/ 3/ 16) | |||||
| 733 | 2.8/1.2 | 65 | 16 | osteoclast differentiation (4.4e-03/6.9e-02/ 3/ 11) | transmembrane receptor activity (7.9e-03/2.2e+00/ 10/324) | ||||
| 734 | 2.8/1.2 | 47 | 18 | multicellular organismal process (1.9e-02/8.1e+00/ 18/1611) | extracellular region (3.1e-02/3.9e+00/ 11/ 673) | transmembrane receptor activity (4.0e-03/1.6e+00/ 9/324) | |||
| 735 | 2.8/1 | 98 | 33 | negative regulation of calcium ion transport (4.0e-02/4.4e-02/ 2/ 4) | 19 (4.2e-04/ 5.9458/21/570) | ||||
| 736 | 2.8/1 | 82 | 28 | activation of JUN kinase activity (1.5e-02/1.1e-01/ 3/ 14) | 19 (4.4e-02/ 4.9651/15/570) | ||||
| 737 | 2.8/1 | 93 | 32 | MAPK signaling pathway (2.5e-02/1.9e+00/ 8/183) | 19 (5.5e-05/ 5.7006/22/570) | ||||
| 738 | 2.8/1 | 103 | 21 | regulation of multicellular organismal process (3.5e-02/3.4e+00/ 11/ 313) | |||||
| 739 | 2.8/1 | 81 | 26 | activation of JUN kinase activity (1.6e-02/1.2e-01/ 3/ 14) | |||||
| 740 | 2.8/1 | 40 | 22 | regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolic process (9.4e-03/5.6e+00/ 15/1396) | |||||
| 741 | 2.8/1 | 85 | 26 | response to external stimulus (4.7e-04/3.2e+00/ 14/ 364) | extracellular region (2.6e-05/6.7e+00/ 22/ 673) | prostaglandin-endoperoxide synthase activity (1.1e-02/1.9e-02/ 2/2) | Neuroactive ligand-receptor interaction (1.4e-02/8.7e-01/ 6/78) | ||
| 742 | 2.6/2 | 162 | 6 | cell cycle phase (4.2e-42/5.5e+00/ 58/ 285) | chromosome (1.4e-25/4.7e+00/ 42/ 248) | microtubule motor activity (1.1e-06/6.7e-01/ 10/37) | DNA replication (1.4e-07/6.8e-01/10/33) | ||
| 743 | 2.6/2 | 195 | 6 | transcription (9.8e-03/2.5e+01/ 43/1413) | DNA binding (1.1e-03/2.2e+01/ 43/1195) | ||||
| 744 | 2.6/2 | 93 | 6 | multicellular organismal process (5.2e-05/1.6e+01/ 36/1611) | plasma membrane (3.9e-05/1.5e+01/ 34/1409) | neuropeptide receptor activity (1.0e-03/4.0e-02/ 3/4) | |||
| 745 | 2.6/2 | 129 | 5 | positive regulation of defense response to virus by host (1.5e-02/2.7e-02/ 2/ 2) | proteinaceous extracellular matrix (8.4e-03/2.1e+00/ 9/ 153) | glucuronosyltransferase activity (4.3e-02/1.7e-01/ 3/12) | Pentose and glucuronate interconversions (3.1e-02/1.6e-01/ 3/13) | ||
| 746 | 2.6/2 | 174 | 5 | cell cycle phase (9.4e-11/6.1e+00/ 30/ 285) | chromosome, centromeric region (8.1e-13/1.3e+00/ 17/ 63) | microtubule motor activity (1.3e-03/7.1e-01/ 7/37) | Biosynthesis of steroids (3.7e-07/5.6e-01/ 9/23) | ||
| 747 | 2.6/2 | 151 | 3 | inflammatory response (7.6e-06/2.5e+00/ 15/ 150) | extracellular region part (1.2e-06/6.4e+00/ 24/ 376) | cytokine activity (7.6e-04/1.2e+00/ 9/71) | Cytokine-cytokine receptor interaction (2.5e-03/2.4e+00/11/115) | ||
| 748 | 2.6/2 | 113 | 4 | extracellular space (1.4e-02/2.8e+00/ 10/ 237) | |||||
| 749 | 2.6/2 | 180 | 4 | multicellular organismal process (1.8e-08/3.2e+01/ 68/1611) | extracellular region (2.1e-06/1.4e+01/ 37/ 673) | extracellular matrix structural constituent (4.3e-03/8.9e-01/ 7/42) | |||
| 750 | 2.6/2 | 50 | 7 | multicellular organismal process (2.7e-03/9.4e+00/ 22/1611) | trans-1,2-dihydrobenzene-1,2-diol dehydrogenase activity (8.2e-05/1.7e-02/ 3/3) | Metabolism of xenobiotics by cytochrome P450 (2.0e-02/3.3e-01/ 4/37) | |||
| 751 | 2.6/2 | 186 | 7 | response to wounding (4.0e-05/4.7e+00/ 19/ 226) | extracellular region (3.8e-08/1.4e+01/ 41/ 673) | calcium ion binding (1.2e-03/8.1e+00/ 23/390) | |||
| 752 | 2.6/2 | 225 | 6 | Ras protein signal transduction (2.6e-03/4.7e+00/ 16/ 178) | cytoplasmic vesicle (4.5e-05/8.3e+00/ 25/ 319) | protein binding (1.5e-02/1.2e+02/142/4505) | MAPK signaling pathway (4.3e-02/5.4e+00/14/183) | miR-320/320abcd (0.00164/12.9386/35/372) | |
| 753 | 2.6/2 | 121 | 5 | MAPKKK cascade (1.0e-03/1.3e+00/ 9/ 112) | plasma membrane part (2.1e-02/1.1e+01/ 22/ 855) | receptor signaling protein activity (6.7e-03/1.3e+00/ 8/108) | MAPK signaling pathway (3.6e-02/2.5e+00/ 9/183) | ||
| 754 | 2.6/2 | 75 | 4 | regulation of the force of heart contraction (3.6e-02/3.9e-02/ 2/ 5) | intrinsic to membrane (2.0e-02/1.6e+01/ 28/2010) | bile acid:sodium symporter activity (8.0e-03/1.5e-02/ 2/2) | |||
| 755 | 2.6/2 | 153 | 3 | genetic imprinting (4.3e-02/4.9e-02/ 2/ 3) | extracellular region (8.6e-03/1.1e+01/ 24/ 673) | ||||
| 756 | 2.6/2 | 203 | 4 | cell cycle phase (2.7e-15/7.0e+00/ 38/ 285) | chromosomal part (4.3e-12/4.8e+00/ 28/ 198) | DNA binding (1.0e-04/2.7e+01/ 54/1195) | DNA replication (7.2e-07/1.1e+00/11/33) | ||
| 757 | 2.6/2 | 270 | 4 | cell adhesion (1.4e-03/1.1e+01/ 28/ 368) | plasma membrane (1.6e-03/4.4e+01/ 69/1409) | cytokine binding (7.5e-04/1.6e+00/ 10/50) | Small cell lung cancer (2.0e-02/2.7e+00/10/73) | ||
| 758 | 2.6/2 | 202 | 3 | phospholipid homeostasis (2.8e-02/4.0e-02/ 2/ 2) | nucleic acid binding (7.2e-04/3.6e+01/ 61/1782) | ||||
| 759 | 2.6/2 | 109 | 5 | osteoblast development (4.8e-02/4.9e-02/ 2/ 5) | intrinsic to membrane (3.9e-02/2.2e+01/ 35/2010) | ||||
| 760 | 2.6/2 | 120 | 6 | ||||||
| 761 | 2.6/2 | 42 | 8 | extracellular matrix organization (4.8e-03/2.0e-01/ 4/ 42) | fibrillar collagen (2.9e-02/5.1e-02/ 2/ 10) | platelet-derived growth factor binding (1.5e-02/1.8e-02/ 2/4) | Colorectal cancer (4.8e-02/4.6e-01/ 4/73) | ||
| 762 | 2.6/2 | 144 | 5 | nuclear division (1.3e-12/2.8e+00/ 23/ 173) | chromosome (6.0e-08/4.1e+00/ 21/ 248) | ||||
| 763 | 2.6/2 | 119 | 5 | response to external stimulus (1.9e-02/4.2e+00/ 13/ 364) | neurofilament (1.4e-02/3.7e-02/ 2/ 3) | calcium ion binding (4.6e-02/4.6e+00/ 13/390) | Amyotrophic lateral sclerosis (ALS) (4.8e-02/4.5e-01/ 4/38) | ||
| 764 | 2.6/2 | 167 | 3 | 19 (1.6e-02/10.2366/25/570) | |||||
| 765 | 2.6/2 | 121 | 5 | multicellular organismal process (4.3e-05/2.0e+01/ 42/1611) | intrinsic to membrane (7.0e-07/2.6e+01/ 53/2010) | transmembrane receptor activity (2.6e-06/4.0e+00/ 20/324) | Neuroactive ligand-receptor interaction (2.3e-02/9.9e-01/ 6/78) | ||
| 766 | 2.6/2 | 84 | 5 | multicellular organismal process (2.8e-04/1.3e+01/ 30/1611) | intrinsic to membrane (6.9e-04/1.7e+01/ 34/2010) | neuropeptide receptor activity (6.4e-04/3.3e-02/ 3/4) | |||
| 767 | 2.6/2 | 121 | 5 | common-partner SMAD protein phosphorylation (3.1e-02/3.8e-02/ 2/ 3) | plasma membrane part (1.2e-02/1.2e+01/ 24/ 855) | ||||
| 768 | 2.6/1.8 | 103 | 5 | multicellular organismal process (1.1e-06/1.8e+01/ 42/1611) | intrinsic to membrane (1.5e-04/2.3e+01/ 44/2010) | receptor activity (5.2e-04/5.6e+00/ 19/519) | Neuroactive ligand-receptor interaction (1.9e-02/9.3e-01/ 6/78) | ||
| 769 | 2.6/1.8 | 127 | 8 | neurological system process (1.8e-05/4.5e+00/ 19/ 317) | intrinsic to membrane (5.1e-04/3.0e+01/ 51/2010) | transmembrane receptor activity (1.5e-04/4.5e+00/ 18/324) | Neuroactive ligand-receptor interaction (4.3e-03/9.9e-01/ 7/78) | ||
| 770 | 2.6/1.8 | 171 | 6 | cell cycle phase (2.3e-45/6.1e+00/ 63/ 285) | chromosome (1.9e-25/5.0e+00/ 43/ 248) | microtubule motor activity (2.2e-07/7.4e-01/ 11/37) | DNA replication (7.3e-12/8.6e-01/14/33) | ||
| 771 | 2.6/1.8 | 133 | 8 | chromatin-mediated maintenance of transcription (3.3e-02/4.0e-02/ 2/ 3) | 19 (1.2e-02/ 8.1525/22/570) | ||||
| 772 | 2.6/1.8 | 227 | 9 | vesicle-mediated transport (1.1e-03/9.5e+00/ 25/ 355) | cytoplasmic vesicle (3.0e-05/8.7e+00/ 26/ 319) | protein binding (4.1e-03/1.2e+02/146/4505) | MAPK signaling pathway (3.5e-02/5.3e+00/14/183) | miR-320/320abcd (0.00937/12.8072/32/372) | |
| 773 | 2.6/1.8 | 75 | 7 | multicellular organismal process (4.5e-04/1.5e+01/ 32/1611) | extracellular region (2.0e-04/5.9e+00/ 19/ 673) | signal transducer activity (4.2e-02/7.2e+00/ 17/780) | |||
| 774 | 2.6/1.8 | 175 | 8 | cell cycle phase (1.8e-56/6.2e+00/ 72/ 285) | chromosome (3.0e-30/5.0e+00/ 48/ 248) | ATP binding (4.3e-08/1.6e+01/ 46/801) | DNA replication (6.5e-15/8.2e-01/16/33) | ||
| 775 | 2.6/1.8 | 118 | 5 | intrinsic to membrane (5.5e-03/2.5e+01/ 42/2010) | sodium:bicarbonate symporter activity (1.5e-02/2.3e-02/ 2/2) | ||||
| 776 | 2.6/1.8 | 139 | 6 | xenobiotic metabolic process (4.3e-02/1.9e-01/ 3/ 13) | extracellular region (4.8e-06/1.0e+01/ 30/ 673) | glucuronosyltransferase activity (5.0e-02/1.8e-01/ 3/12) | Pentose and glucuronate interconversions (4.8e-02/2.0e-01/ 3/13) | miR-23ab (0.01474/ 9.2417/25/551) | |
| 777 | 2.6/1.8 | 66 | 5 | multicellular organismal process (5.5e-04/1.2e+01/ 28/1611) | MHC class II protein complex (7.5e-04/5.5e-02/ 3/ 7) | trans-1,2-dihydrobenzene-1,2-diol dehydrogenase activity (1.6e-04/2.2e-02/ 3/3) | Antigen processing and presentation (1.4e-02/5.5e-01/ 5/45) | ||
| 778 | 2.6/1.8 | 193 | 4 | neurological system process (1.6e-02/6.4e+00/ 17/ 317) | integral to plasma membrane (3.4e-03/1.1e+01/ 25/ 535) | transmembrane receptor activity (2.0e-02/6.3e+00/ 17/324) | |||
| 779 | 2.6/1.8 | 211 | 6 | cell cycle phase (1.4e-33/7.2e+00/ 57/ 285) | chromosomal part (6.3e-24/4.9e+00/ 41/ 198) | adenyl nucleotide binding (1.6e-06/2.0e+01/ 49/855) | DNA replication (1.5e-13/1.0e+00/16/33) | ||
| 780 | 2.6/1.8 | 120 | 8 | positive regulation of JUN kinase activity (4.8e-03/2.0e-01/ 4/ 16) | |||||
| 781 | 2.6/1.8 | 139 | 5 | epidermis development (2.5e-02/9.6e-01/ 6/ 62) | extracellular region (3.7e-07/1.1e+01/ 33/ 673) | endopeptidase activity (2.5e-03/2.7e+00/ 12/176) | |||
| 782 | 2.6/1.8 | 132 | 8 | intermediate filament bundle assembly (3.7e-02/4.3e-02/ 2/ 3) | extracellular region (4.9e-04/9.8e+00/ 25/ 673) | extracellular matrix structural constituent (2.7e-02/5.9e-01/ 5/42) | Pentose and glucuronate interconversions (3.4e-02/1.7e-01/ 3/13) | miR-23ab (0.04118/ 8.1716/22/551) | |
| 783 | 2.6/1.8 | 169 | 4 | multicellular organismal process (4.1e-03/2.8e+01/ 48/1611) | plasma membrane part (3.7e-04/1.5e+01/ 33/ 855) | signal transducer activity (1.3e-03/1.4e+01/ 32/780) | Renin-angiotensin system (4.0e-02/1.9e-01/ 3/9) | ||
| 784 | 2.6/1.8 | 198 | 8 | cell cycle phase (3.7e-56/6.9e+00/ 75/ 285) | chromosome (1.3e-30/5.7e+00/ 51/ 248) | ATP binding (1.1e-08/1.8e+01/ 51/801) | Cell cycle (1.8e-17/2.7e+00/27/98) | ||
| 785 | 2.6/1.8 | 215 | 5 | cell cycle phase (1.6e-28/7.5e+00/ 53/ 285) | chromosomal part (2.5e-21/5.1e+00/ 39/ 198) | DNA binding (5.7e-05/2.9e+01/ 57/1195) | DNA replication (1.0e-05/1.1e+00/10/33) | ||
| 786 | 2.6/1.8 | 118 | 6 | platelet alpha granule membrane (3.8e-02/6.4e-02/ 2/ 5) | |||||
| 787 | 2.6/1.8 | 206 | 3 | immune response (1.5e-04/6.2e+00/ 21/ 287) | plasma membrane (2.5e-06/3.1e+01/ 61/1409) | receptor activity (1.6e-05/1.1e+01/ 33/519) | Type I diabetes mellitus (2.4e-02/6.5e-01/ 5/26) | ||
| 788 | 2.6/1.6 | 120 | 10 | platelet alpha granule membrane (3.9e-02/6.5e-02/ 2/ 5) | 19 (4.8e-02/ 7.3556/19/570) | ||||
| 789 | 2.6/1.6 | 94 | 11 | multicellular organismal process (2.0e-06/1.6e+01/ 39/1611) | plasma membrane (4.5e-05/1.6e+01/ 35/1409) | transmembrane receptor activity (1.8e-04/3.2e+00/ 15/324) | Neuroactive ligand-receptor interaction (4.1e-02/7.5e-01/ 5/78) | ||
| 790 | 2.6/1.6 | 158 | 9 | DNA binding (6.9e-03/1.7e+01/ 33/1195) | Retinol metabolism (6.6e-03/2.3e-01/ 4/21) | ||||
| 791 | 2.6/1.6 | 118 | 12 | translational elongation (3.5e-02/1.0e+00/ 6/ 91) | cytosolic ribosome (7.4e-03/8.7e-01/ 6/ 70) | ||||
| 792 | 2.6/1.6 | 130 | 8 | genetic imprinting (3.2e-02/3.9e-02/ 2/ 3) | extracellular region (5.1e-03/9.5e+00/ 22/ 673) | hormone activity (3.4e-02/3.5e-01/ 4/27) | |||
| 793 | 2.6/1.6 | 148 | 11 | regulation of cyclase activity (3.2e-02/3.8e-01/ 4/ 25) | extracellular space (1.3e-03/3.9e+00/ 14/ 237) | prostaglandin-endoperoxide synthase activity (2.4e-02/3.1e-02/ 2/2) | Neuroactive ligand-receptor interaction (1.7e-04/1.4e+00/10/78) | ||
| 794 | 2.6/1.6 | 119 | 11 | system process (3.3e-04/5.6e+00/ 19/ 445) | extracellular region (2.6e-04/8.9e+00/ 24/ 673) | transmembrane receptor activity (1.3e-04/4.0e+00/ 17/324) | |||
| 795 | 2.6/1.6 | 153 | 10 | cell cycle phase (3.4e-24/5.3e+00/ 42/ 285) | chromosome (2.1e-14/4.6e+00/ 30/ 248) | growth factor activity (1.8e-04/1.6e+00/ 11/91) | DNA replication (1.2e-04/7.7e-01/ 8/33) | ||
| 796 | 2.6/1.6 | 144 | 9 | regulation of multicellular organismal process (1.8e-02/4.7e+00/ 14/ 313) | plasma membrane (6.9e-03/2.1e+01/ 37/1409) | very-low-density lipoprotein receptor activity (2.3e-02/3.0e-02/ 2/2) | Neuroactive ligand-receptor interaction (3.7e-02/1.1e+00/ 6/78) | ||
| 797 | 2.6/1.6 | 113 | 10 | system process (1.2e-04/5.2e+00/ 19/ 445) | plasma membrane (1.2e-03/1.7e+01/ 34/1409) | neurotransmitter receptor activity (1.2e-03/2.6e-01/ 5/23) | |||
| 798 | 2.6/1.6 | 94 | 9 | multicellular organismal process (3.2e-06/1.7e+01/ 39/1611) | plasma membrane (7.2e-05/1.5e+01/ 34/1409) | G-protein coupled receptor activity (2.5e-04/1.3e+00/ 10/131) | |||
| 799 | 2.6/1.6 | 109 | 7 | ||||||
| 800 | 2.6/1.6 | 110 | 14 | positive regulation of JUN kinase activity (3.8e-03/1.9e-01/ 4/ 16) | |||||
| 801 | 2.6/1.6 | 136 | 9 | extracellular region (3.8e-03/9.9e+00/ 23/ 673) | transmembrane receptor activity (5.0e-02/4.6e+00/ 13/324) | ||||
| 802 | 2.6/1.6 | 119 | 10 | sensory perception (4.8e-03/2.1e+00/ 10/ 171) | extracellular region (4.1e-04/8.5e+00/ 23/ 673) | neurotransmitter receptor activity (1.8e-03/2.9e-01/ 5/23) | |||
| 803 | 2.6/1.6 | 97 | 9 | multicellular organismal process (6.2e-07/1.7e+01/ 41/1611) | plasma membrane (6.7e-06/1.6e+01/ 37/1409) | transmembrane receptor activity (6.4e-05/3.3e+00/ 16/324) | Neuroactive ligand-receptor interaction (1.2e-02/8.4e-01/ 6/78) | ||
| 804 | 2.6/1.6 | 113 | 14 | regulation of transcription factor import into nucleus (2.7e-02/1.5e-01/ 3/ 13) | neurofilament (1.4e-02/3.7e-02/ 2/ 3) | ||||
| 805 | 2.6/1.6 | 185 | 6 | multicellular organismal process (3.5e-06/3.5e+01/ 66/1611) | extracellular region part (2.3e-08/7.9e+00/ 30/ 376) | calcium ion binding (2.1e-02/8.2e+00/ 20/390) | |||
| 806 | 2.6/1.4 | 145 | 15 | insoluble fraction (1.3e-02/5.0e+00/ 14/ 369) | oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen (6.0e-03/7.6e-02/ 3/6) | Retinol metabolism (6.4e-04/2.6e-01/ 5/21) | |||
| 807 | 2.6/1.4 | 147 | 11 | cell cycle phase (1.9e-37/5.0e+00/ 52/ 285) | chromosome (3.8e-18/4.3e+00/ 33/ 248) | microtubule motor activity (3.9e-07/5.9e-01/ 10/37) | Cell cycle (2.4e-05/1.8e+00/12/98) | ||
| 808 | 2.6/1.4 | 127 | 8 | xenobiotic metabolic process (3.5e-02/1.7e-01/ 3/ 13) | melanosome membrane (6.4e-03/2.7e-02/ 2/ 2) | glucuronosyltransferase activity (3.8e-02/1.6e-01/ 3/12) | Androgen and estrogen metabolism (1.3e-02/2.9e-01/ 4/21) | ||
| 809 | 2.6/1.4 | 96 | 13 | system process (1.3e-03/4.6e+00/ 16/ 445) | anchored to membrane (2.1e-03/4.1e-01/ 5/ 37) | bile acid transmembrane transporter activity (3.2e-04/3.0e-02/ 3/3) | |||
| 810 | 2.6/1.4 | 101 | 17 | activation of JUN kinase activity (2.9e-02/1.6e-01/ 3/ 14) | |||||
| 811 | 2.6/1.4 | 106 | 17 | cell morphogenesis (2.2e-02/3.7e+00/ 12/ 312) | sequence-specific DNA binding (4.8e-02/2.9e+00/ 10/257) | ||||
| 812 | 2.6/1.4 | 112 | 18 | Chondroitin sulfate biosynthesis (4.8e-02/2.0e-01/ 3/16) | 19 (2.4e-05/ 6.8040/25/570) | ||||
| 813 | 2.6/1.4 | 120 | 16 | multicellular organismal process (5.9e-04/2.0e+01/ 40/1611) | extracellular region (1.0e-04/9.0e+00/ 25/ 673) | transmembrane receptor activity (4.3e-04/3.9e+00/ 16/324) | |||
| 814 | 2.6/1.4 | 105 | 13 | mRNA transport (3.4e-02/6.8e-01/ 5/ 65) | |||||
| 815 | 2.6/1.4 | 103 | 14 | cell adhesion (7.3e-03/3.7e+00/ 13/ 368) | lipoprotein binding (4.9e-02/1.8e-01/ 3/17) | ||||
| 816 | 2.6/1.4 | 138 | 15 | multicellular organismal process (5.7e-03/2.2e+01/ 40/1611) | extracellular region (9.3e-05/1.0e+01/ 27/ 673) | transmembrane receptor activity (4.5e-03/4.4e+00/ 15/324) | |||
| 817 | 2.6/1.4 | 127 | 17 | Ras protein signal transduction (3.0e-02/2.3e+00/ 9/ 178) | protein binding (5.7e-03/6.0e+01/ 79/4505) | MAPK signaling pathway (1.0e-02/2.5e+00/10/183) | 19 (3.5e-02/ 7.7234/20/570) | ||
| 818 | 2.6/1.4 | 106 | 15 | regulation of transcription factor import into nucleus (2.2e-02/1.4e-01/ 3/ 13) | plasma membrane part (2.5e-02/9.5e+00/ 20/ 855) | ||||
| 819 | 2.6/1.4 | 116 | 14 | regulation of multicellular organismal process (4.6e-04/3.7e+00/ 15/ 313) | calcium ion binding (2.3e-02/4.7e+00/ 14/390) | ||||
| 820 | 2.6/1.4 | 123 | 20 | regulation of dephosphorylation (8.2e-03/9.4e-02/ 3/ 7) | Chondroitin sulfate biosynthesis (4.3e-02/1.9e-01/ 3/16) | 19 (1.2e-04/ 7.4782/25/570) | |||
| 821 | 2.6/1.2 | 226 | 14 | cell cycle phase (7.0e-62/7.7e+00/ 83/ 285) | chromosome (3.5e-30/6.5e+00/ 53/ 248) | ATP binding (5.0e-10/2.0e+01/ 58/801) | Cell cycle (1.5e-18/2.9e+00/29/98) | ||
| 822 | 2.6/1.2 | 112 | 10 | response to steroid hormone stimulus (6.4e-03/4.3e-01/ 5/ 37) | proteinaceous extracellular matrix (1.4e-02/1.8e+00/ 8/ 153) | glucuronosyltransferase activity (2.9e-02/1.4e-01/ 3/12) | Pentose and glucuronate interconversions (1.8e-02/1.3e-01/ 3/13) | ||
| 823 | 2.6/1.2 | 99 | 20 | positive regulation of JUN kinase activity (3.8e-02/1.8e-01/ 3/ 16) | |||||
| 824 | 2.6/1.2 | 124 | 21 | neurite morphogenesis (2.7e-02/9.7e-01/ 6/ 80) | |||||
| 825 | 2.6/1.2 | 122 | 21 | positive regulation of gene expression, epigenetic (4.1e-03/7.3e-02/ 3/ 6) | Dentatorubropallidoluysian atrophy (DRPLA) (1.8e-02/1.3e-01/ 3/14) | 19 (2.2e-02/ 7.4169/20/570) | |||
| 826 | 2.6/1.2 | 112 | 20 | positive regulation of JUN kinase activity (3.0e-03/1.8e-01/ 4/ 16) | Dentatorubropallidoluysian atrophy (DRPLA) (2.3e-02/1.5e-01/ 3/14) | ||||
| 827 | 2.6/1.2 | 150 | 18 | regulation of cell proliferation (2.3e-03/5.9e+00/ 18/ 376) | extracellular region (2.8e-05/1.1e+01/ 30/ 673) | purinergic nucleotide receptor activity (1.5e-03/1.4e-01/ 4/9) | Neuroactive ligand-receptor interaction (7.8e-03/1.5e+00/ 8/78) | 13 (4.3e-02/ 2.7584/11/171) | |
| 828 | 2.6/1.2 | 124 | 22 | positive regulation of gene expression, epigenetic (5.2e-03/8.0e-02/ 3/ 6) | intracellular organelle (3.0e-02/6.6e+01/ 80/5196) | 19 (1.2e-02/ 7.5395/21/570) | |||
| 829 | 2.6/1.2 | 104 | 19 | positive regulation of JUN kinase activity (3.9e-02/1.8e-01/ 3/ 16) | platelet alpha granule lumen (2.1e-02/1.8e-01/ 3/ 17) | ||||
| 830 | 2.6/1 | 106 | 31 | activation of JUN kinase activity (3.1e-02/1.6e-01/ 3/ 14) | extracellular region (3.8e-03/7.4e+00/ 19/ 673) | ||||
| 831 | 2.6/1 | 94 | 19 | xenobiotic metabolic process (7.6e-04/1.2e-01/ 4/ 13) | proteinaceous extracellular matrix (5.2e-03/1.5e+00/ 8/ 153) | glucuronosyltransferase activity (1.9e-02/1.1e-01/ 3/12) | Drug metabolism - other enzymes (1.4e-02/2.9e-01/ 4/29) | ||
| 832 | 2.6/1 | 124 | 31 | activation of JUN kinase activity (4.3e-02/1.9e-01/ 3/ 14) | 19 (1.5e-03/ 7.5395/23/570) | ||||
| 833 | 2.6/1 | 127 | 31 | activation of JUN kinase activity (3.5e-03/1.9e-01/ 4/ 14) | 19 (6.1e-06/ 7.7234/28/570) | ||||
| 834 | 2.6/1 | 128 | 28 | activation of JUN kinase activity (3.9e-03/1.9e-01/ 4/ 14) | 19 (6.5e-03/ 7.7847/22/570) | ||||
| 835 | 2.4/2 | 226 | 3 | cell activation (2.0e-02/3.6e+00/ 12/ 152) | cytoplasmic vesicle part (3.9e-02/2.2e+00/ 8/ 90) | signal transducer activity (3.2e-04/1.8e+01/ 40/780) | |||
| 836 | 2.4/2 | 315 | 4 | cell cycle phase (1.9e-35/1.1e+01/ 69/ 285) | chromosome (2.3e-20/9.0e+00/ 49/ 248) | DNA binding (1.6e-05/4.2e+01/ 77/1195) | DNA replication (8.1e-09/1.4e+00/14/33) | ||
| 837 | 2.4/2 | 280 | 4 | regulation of gene expression (2.7e-04/3.9e+01/ 67/1464) | nucleus (4.6e-03/8.3e+01/109/3059) | nucleic acid binding (2.5e-05/4.9e+01/ 84/1782) | miR-138 (0.01963/ 8.0403/23/253) | ||
| 838 | 2.4/2 | 193 | 4 | positive regulation of defense response to virus by host (2.7e-02/3.9e-02/ 2/ 2) | proteinaceous extracellular matrix (7.2e-04/3.2e+00/ 13/ 153) | ||||
| 839 | 2.4/2 | 289 | 5 | cell cycle phase (1.5e-25/1.0e+01/ 57/ 285) | chromosomal part (6.3e-18/6.7e+00/ 40/ 198) | microtubule motor activity (8.3e-05/1.2e+00/ 10/37) | DNA replication (1.1e-11/1.4e+00/16/33) | ||
| 840 | 2.4/2 | 218 | 5 | epidermis development (3.3e-02/1.4e+00/ 7/ 62) | extracellular region (9.7e-06/1.7e+01/ 40/ 673) | endopeptidase activity (2.1e-03/4.0e+00/ 15/176) | |||
| 841 | 2.4/2 | 274 | 6 | multicellular organismal process (1.6e-07/4.9e+01/ 90/1611) | extracellular region part (8.3e-09/1.2e+01/ 38/ 376) | calcium ion binding (1.5e-03/1.2e+01/ 29/390) | Cell junctions (1.8e-02/2.2e+00/ 9/59) | ||
| 842 | 2.4/2 | 310 | 4 | cell cycle phase (2.6e-31/1.1e+01/ 65/ 285) | chromosomal part (2.4e-19/7.2e+00/ 43/ 198) | DNA binding (1.0e-05/4.2e+01/ 78/1195) | Cell cycle (7.7e-10/4.4e+00/24/98) | ||
| 843 | 2.4/2 | 184 | 5 | multicellular organismal process (3.3e-06/3.0e+01/ 60/1611) | plasma membrane (5.1e-09/2.7e+01/ 61/1409) | transmembrane receptor activity (2.2e-09/6.1e+00/ 30/324) | Neuroactive ligand-receptor interaction (1.4e-02/1.6e+00/ 8/78) | ||
| 844 | 2.4/2 | 170 | 6 | intracellular mRNA localization (4.7e-02/5.3e-02/ 2/ 3) | cytoskeletal part (3.2e-02/7.5e+00/ 17/ 418) | ||||
| 845 | 2.4/2 | 264 | 6 | MAPKKK cascade (4.2e-03/3.4e+00/ 13/ 112) | cytoplasmic vesicle (3.0e-06/9.8e+00/ 30/ 319) | mannose binding (4.0e-02/1.8e-01/ 3/6) | miR-320/320abcd (0.00250/14.5805/37/372) | ||
| 846 | 2.4/2 | 253 | 6 | 19 (8.3e-03/15.4468/34/570) | |||||
| 847 | 2.4/2 | 195 | 5 | response to external stimulus (6.5e-03/7.0e+00/ 19/ 364) | intrinsic to membrane (3.6e-03/4.0e+01/ 62/2010) | sodium:bicarbonate symporter activity (3.4e-02/3.9e-02/ 2/2) | Neuroactive ligand-receptor interaction (3.3e-02/1.5e+00/ 7/78) | ||
| 848 | 2.4/2 | 309 | 3 | extracellular region (9.9e-03/2.1e+01/ 38/ 673) | receptor activity (1.8e-03/1.7e+01/ 36/519) | 19 (1.6e-02/18.9407/38/570) | |||
| 849 | 2.4/2 | 262 | 3 | defense response (1.3e-04/7.7e+00/ 24/ 257) | extracellular region (2.3e-06/2.0e+01/ 47/ 673) | ||||
| 850 | 2.4/2 | 116 | 4 | cell adhesion (3.1e-02/5.1e+00/ 14/ 368) | extracellular region (1.0e-04/9.0e+00/ 25/ 673) | ||||
| 851 | 2.4/2 | 202 | 8 | response to external stimulus (1.0e-11/9.1e+00/ 38/ 364) | extracellular region (1.7e-18/1.6e+01/ 61/ 673) | cytokine activity (2.9e-08/1.7e+00/ 16/71) | Cytokine-cytokine receptor interaction (7.5e-05/3.6e+00/16/115) | ||
| 852 | 2.4/2 | 260 | 3 | signal transduction (2.8e-02/5.2e+01/ 74/1768) | plasma membrane (7.0e-05/4.2e+01/ 72/1409) | receptor activity (1.2e-02/1.6e+01/ 32/519) | Cytokine-cytokine receptor interaction (1.6e-02/4.2e+00/13/115) | ||
| 853 | 2.4/2 | 305 | 5 | cell cycle phase (1.6e-37/1.0e+01/ 70/ 285) | chromosome (4.2e-22/8.6e+00/ 50/ 248) | microtubule motor activity (1.8e-05/1.3e+00/ 11/37) | DNA replication (9.8e-07/1.4e+00/12/33) | ||
| 854 | 2.4/2 | 262 | 5 | cell cycle phase (3.6e-08/9.1e+00/ 33/ 285) | chromosome, centromeric region (3.0e-05/2.0e+00/ 12/ 63) | cytokine activity (3.9e-07/2.1e+00/ 16/71) | Cytokine-cytokine receptor interaction (9.8e-05/4.7e+00/18/115) | ||
| 855 | 2.4/2 | 193 | 4 | MAPKKK cascade (2.4e-02/2.2e+00/ 9/ 112) | integral to plasma membrane (1.5e-03/1.1e+01/ 26/ 535) | ||||
| 856 | 2.4/2 | 259 | 4 | neurotransmitter secretion (1.1e-02/5.1e-01/ 5/ 19) | plasma membrane part (7.4e-03/2.3e+01/ 40/ 855) | transmembrane receptor activity (2.4e-02/8.3e+00/ 20/324) | |||
| 857 | 2.4/2 | 202 | 5 | positive regulation of defense response to virus by host (3.0e-02/4.3e-02/ 2/ 2) | extracellular matrix part (2.4e-03/1.4e+00/ 8/ 63) | ||||
| 858 | 2.4/1.8 | 171 | 5 | aging (5.0e-02/7.8e-01/ 5/ 45) | |||||
| 859 | 2.4/1.8 | 315 | 6 | cell cycle phase (9.2e-43/1.1e+01/ 76/ 285) | chromosomal part (6.4e-25/7.1e+00/ 49/ 198) | ATP binding (1.3e-05/2.8e+01/ 59/801) | DNA replication (1.4e-13/1.5e+00/18/33) | ||
| 860 | 2.4/1.8 | 246 | 3 | regulation of biosynthetic process (1.3e-02/3.6e+01/ 57/1478) | nucleic acid binding (3.2e-03/4.2e+01/ 67/1782) | Retinol metabolism (4.7e-02/4.5e-01/ 4/21) | |||
| 861 | 2.4/1.8 | 188 | 8 | ||||||
| 862 | 2.4/1.8 | 231 | 8 | positive regulation of protein kinase activity (7.0e-03/2.7e+00/ 11/ 97) | cytoplasmic vesicle (5.0e-07/8.5e+00/ 29/ 319) | protein kinase activity (3.3e-02/9.3e+00/ 21/355) | miR-320/320abcd (0.00511/12.8729/33/372) | ||
| 863 | 2.4/1.8 | 201 | 7 | extracellular region (5.1e-06/1.5e+01/ 38/ 673) | UDP-glycosyltransferase activity (6.2e-03/1.3e+00/ 8/61) | ||||
| 864 | 2.4/1.8 | 186 | 6 | nervous system development (4.0e-02/7.8e+00/ 18/ 402) | plasma membrane part (1.7e-03/1.8e+01/ 35/ 855) | ||||
| 865 | 2.4/1.8 | 226 | 7 | multicellular organismal process (7.7e-06/3.9e+01/ 71/1611) | plasma membrane (6.7e-08/3.6e+01/ 72/1409) | transmembrane receptor activity (1.0e-07/7.8e+00/ 31/324) | Neuroactive ligand-receptor interaction (3.6e-03/2.1e+00/10/78) | ||
| 866 | 2.4/1.8 | 121 | 6 | positive regulation of transforming growth factor beta receptor signaling pathway (1.3e-02/1.1e-01/ 3/ 9) | extracellular region (2.2e-02/8.6e+00/ 19/ 673) | ||||
| 867 | 2.4/1.8 | 242 | 6 | cell cycle phase (1.2e-48/8.0e+00/ 73/ 285) | chromosome (1.4e-25/6.9e+00/ 49/ 248) | microtubule motor activity (2.5e-06/9.9e-01/ 11/37) | Cell cycle (8.2e-11/2.9e+00/21/98) | ||
| 868 | 2.4/1.8 | 258 | 3 | plasma membrane (2.4e-02/3.8e+01/ 57/1409) | |||||
| 869 | 2.4/1.8 | 224 | 6 | multicellular organismal process (2.8e-03/3.7e+01/ 60/1611) | plasma membrane (4.6e-05/3.4e+01/ 61/1409) | very-low-density lipoprotein receptor activity (4.4e-02/4.7e-02/ 2/2) | Neuroactive ligand-receptor interaction (3.2e-02/1.9e+00/ 8/78) | ||
| 870 | 2.4/1.8 | 198 | 5 | regulation of growth (1.6e-02/3.0e+00/ 11/ 151) | extracellular region (2.3e-02/1.4e+01/ 27/ 673) | gamma-glutamyltransferase activity (3.6e-02/4.1e-02/ 2/2) | |||
| 871 | 2.4/1.8 | 318 | 5 | cell cycle phase (1.0e-39/1.1e+01/ 74/ 285) | chromosomal part (3.1e-19/7.3e+00/ 43/ 198) | DNA binding (1.1e-05/4.3e+01/ 79/1195) | DNA replication (3.8e-11/1.5e+00/16/33) | ||
| 872 | 2.4/1.8 | 204 | 6 | system process (4.1e-10/9.8e+00/ 37/ 445) | intrinsic to membrane (6.5e-07/4.7e+01/ 82/2010) | transmembrane receptor activity (7.6e-07/7.2e+00/ 28/324) | Neuroactive ligand-receptor interaction (1.9e-03/1.9e+00/10/78) | ||
| 873 | 2.4/1.8 | 109 | 6 | anatomical structure morphogenesis (1.3e-02/8.3e+00/ 20/ 679) | secretory granule (1.1e-02/6.2e-01/ 5/ 56) | ||||
| 874 | 2.4/1.8 | 134 | 9 | response to external stimulus (7.7e-05/5.5e+00/ 20/ 364) | extracellular region (7.7e-06/1.0e+01/ 29/ 673) | MHC class I receptor activity (1.2e-03/1.3e-01/ 4/9) | Graft-versus-host disease (2.3e-03/3.5e-01/ 5/21) | ||
| 875 | 2.4/1.8 | 91 | 9 | antigen processing and presentation of peptide antigen (5.3e-03/2.1e-01/ 4/ 21) | MHC class I protein complex (1.4e-02/1.6e-01/ 3/ 15) | MHC class I receptor activity (9.2e-03/8.5e-02/ 3/9) | |||
| 876 | 2.4/1.8 | 212 | 6 | extracellular matrix organization (2.2e-02/9.3e-01/ 6/ 42) | neurofilament (3.6e-02/6.7e-02/ 2/ 3) | ||||
| 877 | 2.4/1.6 | 183 | 7 | xenobiotic metabolic process (9.2e-03/2.6e-01/ 4/ 13) | proteinaceous extracellular matrix (5.6e-04/3.1e+00/ 13/ 153) | glucuronosyltransferase activity (8.2e-03/2.3e-01/ 4/12) | Androgen and estrogen metabolism (6.7e-03/4.6e-01/ 5/21) | ||
| 878 | 2.4/1.6 | 227 | 11 | cell cycle phase (3.7e-16/7.8e+00/ 41/ 285) | chromosome (7.5e-09/6.6e+00/ 28/ 248) | growth factor activity (8.4e-04/2.3e+00/ 12/91) | DNA replication (2.0e-04/1.1e+00/ 9/33) | ||
| 879 | 2.4/1.6 | 203 | 8 | bile acid biosynthetic process (2.8e-02/4.1e-02/ 2/ 2) | |||||
| 880 | 2.4/1.6 | 186 | 8 | regulation of transcription factor import into nucleus (7.9e-03/2.5e-01/ 4/ 13) | neurofilament (2.8e-02/5.6e-02/ 2/ 3) | calcium ion binding (2.0e-02/7.6e+00/ 19/390) | |||
| 881 | 2.4/1.6 | 174 | 6 | positive regulation of JUN kinase activity (1.4e-02/2.9e-01/ 4/ 16) | plasma membrane (4.9e-04/2.7e+01/ 49/1409) | ABC transporters - General (4.8e-02/4.5e-01/ 4/23) | |||
| 882 | 2.4/1.6 | 170 | 8 | multicellular organismal process (1.2e-05/2.9e+01/ 57/1611) | plasma membrane (4.9e-06/2.7e+01/ 54/1409) | transmembrane receptor activity (1.5e-05/5.9e+00/ 23/324) | Neuroactive ligand-receptor interaction (1.4e-02/1.6e+00/ 8/78) | ||
| 883 | 2.4/1.6 | 236 | 8 | transcription (1.5e-03/3.1e+01/ 54/1413) | DNA binding (3.2e-04/2.6e+01/ 50/1195) | Retinol metabolism (2.4e-02/3.6e-01/ 4/21) | |||
| 884 | 2.4/1.6 | 121 | 11 | regulation of epithelial to mesenchymal transition (3.4e-02/4.1e-02/ 2/ 3) | membrane (3.2e-02/4.3e+01/ 59/3116) | 19 (3.2e-04/ 7.3556/24/570) | |||
| 885 | 2.4/1.6 | 245 | 7 | cell cycle phase (4.0e-50/8.5e+00/ 76/ 285) | chromosome (6.8e-27/7.0e+00/ 51/ 248) | microtubule motor activity (3.7e-07/1.0e+00/ 12/37) | DNA replication (8.4e-13/1.1e+00/16/33) | ||
| 886 | 2.4/1.6 | 169 | 11 | multicellular organismal process (3.7e-08/3.0e+01/ 63/1611) | plasma membrane (2.8e-07/2.7e+01/ 57/1409) | transmembrane receptor activity (1.3e-05/5.9e+00/ 23/324) | Neuroactive ligand-receptor interaction (3.3e-02/1.5e+00/ 7/78) | ||
| 887 | 2.4/1.6 | 167 | 12 | mRNA transport (3.6e-02/1.0e+00/ 6/ 65) | |||||
| 888 | 2.4/1.6 | 200 | 9 | system process (2.8e-08/9.7e+00/ 34/ 445) | plasma membrane (2.6e-06/3.2e+01/ 63/1409) | transmembrane receptor activity (2.2e-09/7.0e+00/ 32/324) | Neuroactive ligand-receptor interaction (2.7e-04/1.9e+00/11/78) | ||
| 889 | 2.4/1.6 | 204 | 9 | system process (1.1e-06/9.0e+00/ 30/ 445) | extracellular region (1.1e-05/1.5e+01/ 37/ 673) | transmembrane receptor activity (1.1e-05/6.8e+00/ 25/324) | Neuroactive ligand-receptor interaction (1.8e-02/1.7e+00/ 8/78) | ||
| 890 | 2.4/1.6 | 139 | 11 | extracellular region (5.1e-03/9.5e+00/ 22/ 673) | protein kinase C activity (1.8e-02/1.2e-01/ 3/8) | ||||
| 891 | 2.4/1.6 | 230 | 10 | digestion (2.4e-02/6.3e-01/ 5/ 26) | plasma membrane (3.0e-05/3.5e+01/ 64/1409) | transmembrane receptor activity (6.4e-03/7.9e+00/ 21/324) | Neuroactive ligand-receptor interaction (1.3e-03/2.2e+00/11/78) | ||
| 892 | 2.4/1.6 | 264 | 8 | cell cycle phase (1.6e-55/8.9e+00/ 82/ 285) | chromosome (4.2e-28/7.6e+00/ 54/ 248) | ATP binding (5.9e-08/2.4e+01/ 59/801) | Cell cycle (3.0e-15/3.7e+00/28/98) | ||
| 893 | 2.4/1.6 | 178 | 8 | glucuronosyltransferase activity (8.6e-03/2.3e-01/ 4/12) | Starch and sucrose metabolism (4.4e-03/4.1e-01/ 5/24) | ||||
| 894 | 2.4/1.6 | 187 | 9 | activation of JUN kinase activity (1.0e-02/2.7e-01/ 4/ 14) | 19 (3.3e-02/11.4625/26/570) | ||||
| 895 | 2.4/1.6 | 84 | 10 | response to stimulus (2.9e-02/1.3e+01/ 25/1325) | secretory granule (4.9e-03/5.0e-01/ 5/ 56) | Cell adhesion molecules (CAMs) (4.7e-02/7.8e-01/ 5/70) | |||
| 896 | 2.4/1.6 | 283 | 9 | cell cycle phase (1.8e-22/9.7e+00/ 53/ 285) | chromosomal part (1.1e-14/6.7e+00/ 36/ 198) | microtubule motor activity (4.7e-04/1.2e+00/ 9/37) | DNA replication (4.1e-10/1.4e+00/15/33) | ||
| 897 | 2.4/1.6 | 227 | 14 | MAPKKK cascade (2.3e-02/2.7e+00/ 10/ 112) | 19 (2.5e-03/13.7918/33/570) | ||||
| 898 | 2.4/1.6 | 64 | 9 | multicellular organismal process (2.8e-05/1.2e+01/ 30/1611) | 3-alpha-hydroxysteroid dehydrogenase (A-specific) activity (7.6e-03/1.4e-02/ 2/2) | Bile acid biosynthesis (2.6e-02/1.5e-01/ 3/17) | |||
| 899 | 2.4/1.4 | 218 | 16 | axoneme (3.6e-03/1.1e-01/ 3/ 5) | oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen (1.8e-02/1.2e-01/ 3/6) | Retinol metabolism (3.6e-03/3.9e-01/ 5/21) | |||
| 900 | 2.4/1.4 | 185 | 7 | transmembrane receptor protein tyrosine kinase signaling pathway (4.0e-02/2.9e+00/ 10/ 147) | extracellular region (2.3e-02/1.4e+01/ 26/ 673) | Starch and sucrose metabolism (3.4e-02/4.0e-01/ 4/24) | |||
| 901 | 2.4/1.4 | 312 | 10 | cell cycle phase (1.3e-54/1.0e+01/ 86/ 285) | chromosome (9.3e-27/8.8e+00/ 56/ 248) | ATP binding (2.7e-08/2.8e+01/ 66/801) | DNA replication (1.3e-15/1.3e+00/19/33) | ||
| 902 | 2.4/1.4 | 177 | 14 | intermediate filament bundle assembly (5.0e-02/5.5e-02/ 2/ 3) | neurofilament (2.6e-02/5.5e-02/ 2/ 3) | ||||
| 903 | 2.4/1.4 | 187 | 10 | positive regulation of JUN kinase activity (1.5e-03/3.1e-01/ 5/ 16) | plasma membrane part (1.5e-03/1.7e+01/ 35/ 855) | ||||
| 904 | 2.4/1.4 | 237 | 12 | cell cycle phase (1.6e-45/8.0e+00/ 70/ 285) | chromosome (4.6e-24/6.7e+00/ 47/ 248) | microtubule motor activity (2.4e-07/9.8e-01/ 12/37) | DNA replication (8.0e-06/1.0e+00/10/33) | ||
| 905 | 2.4/1.4 | 270 | 9 | cell cycle phase (7.1e-55/9.0e+00/ 82/ 285) | chromosome (7.2e-28/7.7e+00/ 54/ 248) | ATP binding (1.6e-07/2.4e+01/ 59/801) | Cell cycle (1.1e-16/3.6e+00/29/98) | ||
| 906 | 2.4/1.4 | 193 | 16 | positive regulation of JUN kinase activity (2.0e-02/3.3e-01/ 4/ 16) | |||||
| 907 | 2.4/1.4 | 184 | 18 | activation of JUN kinase activity (1.2e-02/2.8e-01/ 4/ 14) | neuron projection (3.5e-02/1.2e+00/ 6/ 65) | 19 (1.2e-02/11.1560/27/570) | |||
| 908 | 2.4/1.4 | 188 | 15 | regulation of multicellular organismal process (3.4e-03/6.0e+00/ 18/ 313) | platelet alpha granule lumen (9.9e-03/3.4e-01/ 4/ 17) | calcium ion binding (4.0e-03/7.7e+00/ 21/390) | |||
| 909 | 2.4/1.4 | 239 | 10 | cell cycle phase (6.1e-36/8.4e+00/ 63/ 285) | chromosome (1.5e-20/7.0e+00/ 44/ 248) | microtubule motor activity (1.9e-04/1.0e+00/ 9/37) | DNA replication (5.5e-09/1.1e+00/13/33) | ||
| 910 | 2.4/1.4 | 109 | 12 | bile acid biosynthetic process (1.0e-02/2.1e-02/ 2/ 2) | |||||
| 911 | 2.4/1.4 | 295 | 13 | cell cycle phase (1.2e-37/9.5e+00/ 68/ 285) | chromosomal part (3.2e-22/6.7e+00/ 45/ 198) | ATP binding (1.5e-05/2.6e+01/ 56/801) | DNA replication (1.9e-15/1.1e+00/18/33) | ||
| 912 | 2.4/1.4 | 197 | 16 | multicellular organismal process (7.5e-07/3.4e+01/ 67/1611) | extracellular region (4.1e-08/1.5e+01/ 42/ 673) | transmembrane receptor activity (8.3e-07/6.8e+00/ 27/324) | Drug metabolism - cytochrome P450 (1.2e-02/8.3e-01/ 6/36) | ||
| 913 | 2.4/1.4 | 178 | 13 | regulation of transcription factor import into nucleus (6.9e-03/2.3e-01/ 4/ 13) | plasma membrane (2.6e-02/2.6e+01/ 41/1409) | calcium ion binding (2.8e-02/7.2e+00/ 18/390) | |||
| 914 | 2.4/1.4 | 189 | 20 | activation of JUN kinase activity (1.2e-02/2.8e-01/ 4/ 14) | 19 (7.5e-06/11.5238/35/570) | ||||
| 915 | 2.4/1.2 | 191 | 16 | regulation of multicellular organismal process (2.7e-02/6.1e+00/ 16/ 313) | plasma membrane part (2.3e-03/1.7e+01/ 34/ 855) | ||||
| 916 | 2.4/1.2 | 207 | 25 | activation of JUN kinase activity (1.6e-02/3.1e-01/ 4/ 14) | enzyme binding (4.3e-02/5.1e+00/ 14/225) | 19 (1.1e-03/12.6272/32/570) | |||
| 917 | 2.4/1.2 | 186 | 18 | positive regulation of JUN kinase activity (1.6e-02/3.0e-01/ 4/ 16) | neurofilament (3.0e-02/6.0e-02/ 2/ 3) | calcium ion binding (3.7e-02/7.5e+00/ 18/390) | |||
| 918 | 2.4/1.2 | 176 | 11 | xenobiotic metabolic process (7.9e-03/2.5e-01/ 4/ 13) | proteinaceous extracellular matrix (6.7e-03/3.0e+00/ 11/ 153) | Androgen and estrogen metabolism (2.4e-02/3.6e-01/ 4/21) | |||
| 919 | 2.4/1.2 | 311 | 18 | cell cycle phase (2.3e-48/1.0e+01/ 80/ 285) | chromosomal part (5.3e-26/7.0e+00/ 50/ 198) | ATP binding (1.1e-05/2.8e+01/ 59/801) | DNA replication (1.7e-14/1.3e+00/18/33) | ||
| 920 | 2.4/1.2 | 178 | 10 | positive regulation of defense response to virus by host (2.4e-02/3.7e-02/ 2/ 2) | apolipoprotein B mRNA editing enzyme complex (2.9e-02/5.8e-02/ 2/ 3) | Starch and sucrose metabolism (3.2e-02/3.9e-01/ 4/24) | |||
| 921 | 2.4/1.2 | 177 | 22 | activation of JUN kinase activity (1.2e-02/2.8e-01/ 4/ 14) | neuron projection (2.7e-02/1.2e+00/ 6/ 65) | 19 (6.3e-03/10.7270/27/570) | |||
| 922 | 2.4/1 | 213 | 34 | protein kinase cascade (8.4e-03/6.5e+00/ 18/ 286) | MAPK signaling pathway (1.8e-02/3.7e+00/12/183) | 19 (4.6e-07/12.9949/41/570) | |||
| 923 | 2.4/1 | 285 | 30 | cell cycle phase (7.7e-60/9.2e+00/ 87/ 285) | chromosome (5.9e-30/8.2e+00/ 58/ 248) | ATP binding (2.8e-09/2.5e+01/ 65/801) | Cell cycle (7.1e-17/3.5e+00/29/98) | ||
| 924 | 2.4/1 | 241 | 26 | DNA replication (1.4e-14/5.1e+00/ 32/ 180) | chromosomal part (4.5e-07/5.5e+00/ 23/ 198) | DNA-directed DNA polymerase activity (1.1e-02/4.8e-01/ 5/18) | DNA replication (2.9e-13/1.1e+00/16/33) | ||
| 925 | 2.4/1 | 153 | 31 | cell adhesion (3.4e-03/6.0e+00/ 18/ 368) | plasma membrane (3.3e-02/2.1e+01/ 35/1409) | ||||
| 926 | 2.2/2 | 368 | 6 | protein modification process (2.9e-03/3.8e+01/ 63/ 887) | cytoplasmic vesicle (6.2e-05/1.3e+01/ 33/ 319) | protein binding (1.9e-02/1.9e+02/218/4505) | miR-320/320abcd (0.01474/19.3750/41/372) | ||
| 927 | 2.2/2 | 336 | 6 | intermediate filament cytoskeleton organization (2.2e-02/3.6e-01/ 4/ 10) | extracellular region (6.3e-05/2.5e+01/ 50/ 673) | endopeptidase activity (2.0e-02/6.3e+00/ 17/176) | |||
| 928 | 2.2/2 | 299 | 4 | transmembrane receptor protein tyrosine kinase signaling pathway (4.4e-02/4.7e+00/ 13/ 147) | extracellular region (4.7e-03/2.2e+01/ 40/ 673) | ||||
| 929 | 2.2/2 | 354 | 5 | activation of MAPK activity (9.9e-03/1.5e+00/ 8/ 37) | melanosome (2.1e-03/3.1e+00/ 12/ 77) | protein binding (1.9e-02/1.8e+02/211/4505) | miR-320/320abcd (0.00056/18.7839/46/372) | ||
| 930 | 2.2/2 | 278 | 7 | immune system process (7.6e-08/1.6e+01/ 44/ 466) | extracellular region (6.9e-16/2.2e+01/ 68/ 673) | signal transducer activity (9.8e-05/2.5e+01/ 52/780) | Cytokine-cytokine receptor interaction (1.2e-03/4.6e+00/16/115) | ||
| 931 | 2.2/2 | 300 | 4 | response to external stimulus (4.6e-03/1.1e+01/ 26/ 364) | intrinsic to membrane (7.3e-04/6.3e+01/ 93/2010) | calcium ion binding (3.6e-03/1.2e+01/ 28/390) | |||
| 932 | 2.2/2 | 432 | 5 | cell cycle phase (5.5e-38/1.5e+01/ 82/ 285) | chromosomal part (2.6e-18/9.8e+00/ 48/ 198) | microtubule motor activity (4.4e-05/1.8e+00/ 12/37) | DNA replication (9.7e-12/1.9e+00/18/33) | ||
| 933 | 2.2/2 | 431 | 4 | cell cycle phase (4.1e-36/1.5e+01/ 80/ 285) | chromosomal part (1.7e-17/9.8e+00/ 47/ 198) | DNA binding (1.7e-05/5.8e+01/ 99/1195) | DNA replication (1.9e-10/2.0e+00/17/33) | ||
| 934 | 2.2/2 | 317 | 5 | multicellular organismal process (7.6e-03/5.3e+01/ 78/1611) | intrinsic to membrane (1.2e-04/6.7e+01/101/2010) | calcium ion binding (2.7e-03/1.3e+01/ 30/390) | Neuroactive ligand-receptor interaction (1.8e-02/2.6e+00/10/78) | ||
| 935 | 2.2/2 | 376 | 5 | multicellular organismal process (9.2e-09/6.9e+01/120/1611) | extracellular region (1.7e-21/2.8e+01/ 90/ 673) | cytokine activity (3.3e-04/2.9e+00/ 14/71) | Cytokine-cytokine receptor interaction (1.5e-03/5.2e+00/17/115) | ||
| 936 | 2.2/2 | 274 | 5 | immune system process (3.0e-09/1.6e+01/ 47/ 466) | extracellular region (9.5e-15/2.2e+01/ 66/ 673) | growth factor activity (1.8e-05/2.9e+00/ 16/91) | Cytokine-cytokine receptor interaction (1.4e-04/4.8e+00/18/115) | ||
| 937 | 2.2/2 | 220 | 6 | response to wounding (2.5e-08/6.2e+00/ 27/ 226) | extracellular region (8.4e-12/1.7e+01/ 53/ 673) | cytokine activity (9.6e-05/1.8e+00/ 12/71) | Cytokine-cytokine receptor interaction (1.4e-03/3.6e+00/14/115) | ||
| 938 | 2.2/2 | 304 | 4 | anatomical structure morphogenesis (2.6e-02/2.1e+01/ 37/ 679) | plasma membrane (3.8e-04/4.6e+01/ 74/1409) | ||||
| 939 | 2.2/2 | 284 | 7 | positive regulation of defense response to virus by host (4.8e-02/6.1e-02/ 2/ 2) | extracellular matrix (5.0e-03/5.0e+00/ 15/ 163) | cadmium ion binding (4.4e-02/1.9e-01/ 3/6) | Starch and sucrose metabolism (3.1e-02/7.0e-01/ 5/24) | ||
| 940 | 2.2/2 | 454 | 4 | cell cycle phase (6.1e-40/1.5e+01/ 85/ 285) | chromosome (3.3e-25/1.3e+01/ 64/ 248) | DNA binding (8.3e-07/6.0e+01/106/1195) | DNA replication (1.1e-11/2.0e+00/18/33) | miR-17-5p/20/93.mr/106/519.d (0.01474/31.8512/58/633) | |
| 941 | 2.2/2 | 300 | 5 | neurological system process (2.4e-08/1.0e+01/ 35/ 317) | plasma membrane (1.0e-08/4.6e+01/ 89/1409) | transmembrane receptor activity (1.1e-10/1.0e+01/ 41/324) | Neuroactive ligand-receptor interaction (3.1e-04/2.7e+00/13/78) | ||
| 942 | 2.2/2 | 350 | 3 | cell-cell recognition (3.0e-03/2.2e-01/ 4/ 6) | extracellular region (1.2e-03/2.6e+01/ 47/ 673) | endopeptidase activity (4.6e-02/6.4e+00/ 16/176) | |||
| 943 | 2.2/2 | 232 | 5 | poly(A)+ mRNA export from nucleus (3.7e-02/5.0e-02/ 2/ 2) | |||||
| 944 | 2.2/2 | 279 | 5 | response to wounding (1.5e-09/7.6e+00/ 32/ 226) | extracellular region (7.6e-18/2.2e+01/ 72/ 673) | growth factor activity (1.7e-05/2.9e+00/ 16/91) | Cytokine-cytokine receptor interaction (9.8e-05/4.7e+00/18/115) | ||
| 945 | 2.2/2 | 332 | 6 | system process (4.1e-10/1.5e+01/ 48/ 445) | extracellular region (2.8e-09/2.4e+01/ 60/ 673) | transmembrane receptor activity (2.5e-11/1.1e+01/ 45/324) | Neuroactive ligand-receptor interaction (1.6e-04/3.0e+00/14/78) | ||
| 946 | 2.2/2 | 202 | 4 | cholesterol metabolic process (4.2e-03/1.3e+00/ 8/ 56) | extracellular space (2.1e-06/5.5e+00/ 22/ 237) | cytokine activity (9.5e-04/1.6e+00/ 10/71) | |||
| 947 | 2.2/2 | 368 | 5 | cell cycle phase (9.3e-49/1.2e+01/ 86/ 285) | chromosome (7.1e-25/1.0e+01/ 58/ 248) | ATP binding (1.9e-06/3.2e+01/ 68/801) | Cell cycle (1.5e-13/4.7e+00/29/98) | ||
| 948 | 2.2/2 | 188 | 4 | anatomical structure development (3.8e-03/2.7e+01/ 47/1207) | extracellular region (8.2e-06/1.4e+01/ 36/ 673) | receptor binding (2.2e-02/8.3e+00/ 20/400) | |||
| 949 | 2.2/2 | 323 | 7 | protein modification process (3.7e-02/3.4e+01/ 53/ 887) | cytoplasmic vesicle (1.2e-07/1.2e+01/ 36/ 319) | oxidoreductase activity, acting on the CH-NH2 group of donors (1.3e-02/2.9e-01/ 4/8) | miR-320/320abcd (0.01963/17.6017/38/372) | ||
| 950 | 2.2/2 | 301 | 6 | melanosome membrane (2.7e-02/6.4e-02/ 2/ 2) | |||||
| 951 | 2.2/2 | 238 | 6 | deacetylase activity (3.8e-02/3.8e-01/ 4/16) | 17 (5.0e-03/13.6608/32/536) | ||||
| 952 | 2.2/2 | 339 | 4 | peripheral nervous system development (1.9e-02/6.1e-01/ 5/ 17) | extracellular region (3.2e-03/2.4e+01/ 44/ 673) | ||||
| 953 | 2.2/1.8 | 311 | 7 | negative regulation of transcription factor import into nucleus (1.9e-03/1.9e-01/ 4/ 6) | caveola (3.5e-02/5.2e-01/ 4/ 16) | ||||
| 954 | 2.2/1.8 | 431 | 6 | cell cycle phase (1.0e-46/1.4e+01/ 91/ 285) | chromosomal part (1.7e-21/9.8e+00/ 52/ 198) | microtubule motor activity (8.8e-06/1.8e+00/ 13/37) | DNA replication (1.5e-12/2.0e+00/19/33) | ||
| 955 | 2.2/1.8 | 273 | 7 | signal transduction (1.7e-02/4.9e+01/ 71/1768) | plasma membrane part (1.2e-03/2.5e+01/ 46/ 855) | transmembrane receptor activity (4.9e-02/9.0e+00/ 20/324) | |||
| 956 | 2.2/1.8 | 345 | 7 | negative regulation of hormone secretion (1.7e-02/3.4e-01/ 4/ 9) | extracellular region (4.8e-04/2.5e+01/ 48/ 673) | receptor binding (5.5e-03/1.5e+01/ 32/400) | |||
| 957 | 2.2/1.8 | 323 | 6 | response to heat (4.3e-02/7.6e-01/ 5/ 22) | proteinaceous extracellular matrix (7.6e-06/5.5e+00/ 21/ 153) | UDP-glycosyltransferase activity (2.6e-02/2.2e+00/ 9/61) | |||
| 958 | 2.2/1.8 | 294 | 7 | extracellular region (3.2e-07/2.2e+01/ 52/ 673) | UDP-glycosyltransferase activity (3.7e-03/2.0e+00/ 10/61) | Starch and sucrose metabolism (4.8e-02/7.9e-01/ 5/24) | miR-23ab (0.02048/19.2617/40/551) | ||
| 959 | 2.2/1.8 | 302 | 6 | MAPKKK cascade (2.1e-03/3.7e+00/ 14/ 112) | plasma membrane (1.3e-04/4.6e+01/ 76/1409) | receptor signaling protein serine/threonine kinase activity (2.3e-02/1.3e+00/ 7/40) | MAPK signaling pathway (3.1e-02/7.1e+00/17/183) | ||
| 960 | 2.2/1.8 | 294 | 5 | cell communication (1.0e-02/5.6e+01/ 81/1908) | plasma membrane part (1.4e-04/2.6e+01/ 51/ 855) | ||||
| 961 | 2.2/1.8 | 418 | 5 | cell cycle phase (7.2e-27/1.4e+01/ 69/ 285) | chromosomal part (5.1e-14/9.7e+00/ 42/ 198) | DNA binding (7.2e-06/5.6e+01/ 98/1195) | DNA replication (4.4e-09/2.0e+00/16/33) | ||
| 962 | 2.2/1.8 | 287 | 6 | wound healing (3.1e-02/2.3e+00/ 9/ 79) | plasma membrane (1.8e-03/4.4e+01/ 69/1409) | ||||
| 963 | 2.2/1.8 | 255 | 4 | protein processing (1.6e-02/8.7e-01/ 6/ 30) | membrane (1.1e-04/9.1e+01/126/3116) | Small cell lung cancer (3.5e-02/2.4e+00/ 9/73) | 19 (5.5e-05/15.6307/40/570) | ||
| 964 | 2.2/1.8 | 244 | 9 | immune system process (3.4e-10/1.4e+01/ 45/ 466) | extracellular region (1.6e-11/1.9e+01/ 55/ 673) | signal transducer activity (6.6e-06/2.2e+01/ 51/780) | Cytokine-cytokine receptor interaction (1.3e-03/4.1e+00/15/115) | ||
| 965 | 2.2/1.8 | 338 | 4 | epidermis development (2.9e-02/2.3e+00/ 9/ 62) | extracellular region (1.1e-04/2.5e+01/ 50/ 673) | endopeptidase activity (1.4e-03/6.4e+00/ 20/176) | |||
| 966 | 2.2/1.8 | 285 | 5 | epidermis development (1.6e-03/1.8e+00/ 10/ 62) | extracellular region (6.9e-07/2.1e+01/ 50/ 673) | ||||
| 967 | 2.2/1.8 | 305 | 9 | skeletal system development (6.6e-03/5.8e+00/ 17/ 156) | cytoplasmic vesicle (2.1e-07/1.1e+01/ 35/ 319) | receptor activity (4.7e-03/1.8e+01/ 37/519) | Cytokine-cytokine receptor interaction (3.3e-02/4.6e+00/13/115) | miR-320/320abcd (0.01179/16.8792/38/372) | |
| 968 | 2.2/1.8 | 334 | 5 | binding of sperm to zona pellucida (2.7e-02/1.7e-01/ 3/ 5) | extracellular region part (2.0e-02/1.4e+01/ 27/ 376) | hormone activity (2.8e-02/9.5e-01/ 6/27) | |||
| 969 | 2.2/1.8 | 264 | 4 | oxidation reduction (4.5e-02/1.1e+01/ 22/ 366) | MHC class II protein complex (2.2e-02/2.0e-01/ 3/ 7) | oxidoreductase activity, acting on the aldehyde or oxo group of donors (1.8e-02/5.4e-01/ 5/20) | Valine, leucine and isoleucine degradation (3.2e-03/1.3e+00/ 8/42) | ||
| 970 | 2.2/1.6 | 281 | 11 | multicellular organismal process (5.3e-07/5.4e+01/ 94/1611) | extracellular region (2.4e-15/2.2e+01/ 68/ 673) | sequence-specific DNA binding (1.4e-04/8.0e+00/ 25/257) | Complement and coagulation cascades (3.5e-02/1.1e+00/ 6/33) | ||
| 971 | 2.2/1.6 | 293 | 11 | regulation of transcription factor import into nucleus (3.2e-02/4.0e-01/ 4/ 13) | platelet alpha granule lumen (4.0e-02/5.4e-01/ 4/ 17) | calcium ion binding (4.3e-03/1.2e+01/ 28/390) | |||
| 972 | 2.2/1.6 | 316 | 10 | multicellular organismal process (2.6e-04/5.0e+01/ 81/1611) | integral to plasma membrane (5.1e-05/1.7e+01/ 39/ 535) | G-protein coupled receptor activity (1.5e-04/4.0e+00/ 17/131) | Neuroactive ligand-receptor interaction (2.7e-03/2.4e+00/11/78) | ||
| 973 | 2.2/1.6 | 387 | 7 | cell cycle phase (7.3e-45/1.3e+01/ 85/ 285) | chromosome (7.0e-22/1.1e+01/ 56/ 248) | ATP binding (6.8e-07/3.4e+01/ 72/801) | DNA replication (2.9e-12/1.8e+00/18/33) | ||
| 974 | 2.2/1.6 | 422 | 8 | cell cycle phase (1.8e-50/1.4e+01/ 93/ 285) | chromosome (1.0e-23/1.2e+01/ 60/ 248) | microtubule motor activity (6.2e-06/1.7e+00/ 13/37) | DNA replication (2.1e-13/1.8e+00/19/33) | ||
| 975 | 2.2/1.6 | 305 | 12 | cell adhesion (1.0e-02/1.2e+01/ 26/ 368) | intrinsic to membrane (2.7e-02/6.5e+01/ 87/2010) | calcium ion binding (1.3e-03/1.2e+01/ 30/390) | |||
| 976 | 2.2/1.6 | 270 | 8 | intra-Golgi vesicle-mediated transport (3.0e-02/3.9e-01/ 4/ 14) | glucuronosyltransferase activity (2.7e-02/3.5e-01/ 4/12) | Starch and sucrose metabolism (2.3e-02/6.4e-01/ 5/24) | |||
| 977 | 2.2/1.6 | 349 | 10 | cell cycle phase (4.1e-40/1.2e+01/ 77/ 285) | chromosome (1.1e-20/1.0e+01/ 52/ 248) | ATP binding (1.1e-05/3.1e+01/ 64/801) | DNA replication (8.9e-11/1.6e+00/16/33) | ||
| 978 | 2.2/1.6 | 136 | 9 | iron ion transport (3.6e-02/1.8e-01/ 3/ 12) | |||||
| 979 | 2.2/1.6 | 370 | 7 | defense response (1.5e-03/1.0e+01/ 26/ 257) | intrinsic to membrane (4.2e-02/8.0e+01/103/2010) | G-protein coupled receptor activity (8.5e-03/5.2e+00/ 16/131) | Neuroactive ligand-receptor interaction (1.4e-02/3.6e+00/12/78) | ||
| 980 | 2.2/1.6 | 158 | 10 | antigen processing and presentation of peptide antigen via MHC class I (9.6e-04/2.8e-01/ 5/ 17) | extracellular region (6.2e-06/1.1e+01/ 31/ 673) | MHC class I receptor activity (1.9e-03/1.5e-01/ 4/9) | Cell adhesion molecules (CAMs) (6.5e-03/1.4e+00/ 8/70) | ||
| 981 | 2.2/1.6 | 288 | 10 | multicellular organismal development (3.1e-02/3.9e+01/ 59/1257) | extracellular region (3.2e-04/2.1e+01/ 43/ 673) | UDP-glycosyltransferase activity (1.3e-02/1.9e+00/ 9/61) | Porphyrin and chlorophyll metabolism (3.4e-02/7.1e-01/ 5/24) | ||
| 982 | 2.2/1.6 | 311 | 10 | cell cycle phase (1.1e-15/1.1e+01/ 47/ 285) | chromosomal part (1.2e-06/7.3e+00/ 26/ 198) | cytokine activity (2.6e-04/2.4e+00/ 13/71) | DNA replication (2.3e-05/1.5e+00/11/33) | ||
| 983 | 2.2/1.6 | 400 | 8 | cell cycle phase (1.4e-32/1.4e+01/ 74/ 285) | chromosomal part (3.9e-16/9.2e+00/ 44/ 198) | cytokine activity (3.2e-05/3.1e+00/ 16/71) | DNA replication (2.3e-09/1.9e+00/16/33) | ||
| 984 | 2.2/1.4 | 381 | 12 | cell cycle phase (5.8e-47/1.3e+01/ 86/ 285) | chromosome (1.9e-22/1.1e+01/ 56/ 248) | ATP binding (1.3e-05/3.4e+01/ 68/801) | Cell cycle (1.8e-12/5.2e+00/29/98) | ||
| 985 | 2.2/1.4 | 319 | 15 | G-protein coupled receptor protein signaling pathway (1.1e-03/7.1e+00/ 21/ 231) | integral to plasma membrane (2.0e-05/1.7e+01/ 40/ 535) | G-protein coupled receptor activity (6.5e-04/4.0e+00/ 16/131) | Neuroactive ligand-receptor interaction (3.2e-03/2.5e+00/11/78) | ||
| 986 | 2.2/1.4 | 281 | 18 | activation of JUN kinase activity (4.5e-03/4.2e-01/ 5/ 14) | membrane (2.4e-02/9.4e+01/118/3116) | protein binding (2.4e-02/1.4e+02/161/4505) | MAPK signaling pathway (3.8e-02/4.8e+00/13/183) | 19 (4.6e-07/17.1631/48/570) | |
| 987 | 2.2/1.4 | 384 | 9 | cell cycle phase (1.1e-47/1.2e+01/ 86/ 285) | chromosome (1.2e-25/1.1e+01/ 60/ 248) | ATP binding (5.4e-07/3.4e+01/ 72/801) | DNA replication (4.7e-14/1.7e+00/19/33) | ||
| 988 | 2.2/1.4 | 298 | 15 | protein kinase cascade (3.1e-02/8.8e+00/ 20/ 286) | neuron projection (2.1e-02/2.0e+00/ 8/ 65) | ||||
| 989 | 2.2/1.4 | 444 | 9 | cell cycle phase (2.9e-52/1.5e+01/ 97/ 285) | chromosome (2.9e-25/1.3e+01/ 64/ 248) | microtubule motor activity (1.0e-05/1.8e+00/ 13/37) | Cell cycle (6.8e-15/6.1e+00/34/98) | ||
| 990 | 2.2/1.4 | 291 | 13 | positive regulation of MAP kinase activity (6.4e-03/1.4e+00/ 8/ 47) | intrinsic to membrane (9.1e-03/6.2e+01/ 86/2010) | calcium ion binding (5.7e-03/1.2e+01/ 27/390) | |||
| 991 | 2.2/1.4 | 317 | 15 | protein kinase cascade (1.5e-02/9.5e+00/ 22/ 286) | plasma membrane (5.0e-03/4.6e+01/ 70/1409) | calcium ion binding (2.6e-03/1.3e+01/ 30/390) | |||
| 992 | 2.2/1.4 | 419 | 12 | cell cycle phase (1.5e-52/1.3e+01/ 94/ 285) | chromosome (2.0e-28/1.2e+01/ 66/ 248) | ATP binding (4.4e-06/3.7e+01/ 74/801) | Cell cycle (8.7e-16/4.9e+00/32/98) | ||
| 993 | 2.2/1.4 | 221 | 17 | activation of JUN kinase activity (1.7e-03/3.3e-01/ 5/ 14) | extracellular region (1.0e-03/1.6e+01/ 33/ 673) | Cell adhesion molecules (CAMs) (6.1e-03/1.8e+00/ 9/70) | |||
| 994 | 2.2/1.4 | 303 | 12 | potassium channel activity (2.9e-02/9.6e-01/ 6/30) | |||||
| 995 | 2.2/1.4 | 343 | 13 | endocytosis (6.1e-03/5.2e+00/ 16/ 143) | membrane part (6.1e-04/9.0e+01/124/2382) | calcium ion binding (6.1e-03/1.4e+01/ 31/390) | Neuroactive ligand-receptor interaction (2.0e-03/3.3e+00/13/78) | ||
| 996 | 2.2/1.4 | 184 | 9 | UDP-glucose metabolic process (2.9e-02/4.1e-02/ 2/ 2) | integral to plasma membrane (4.1e-03/1.1e+01/ 25/ 535) | malate dehydrogenase (oxaloacetate-decarboxylating) (NADP+) activity (3.6e-02/4.0e-02/ 2/2) | |||
| 997 | 2.2/1.4 | 154 | 14 | multicellular organismal process (3.4e-05/2.8e+01/ 54/1611) | plasma membrane (2.3e-04/2.5e+01/ 47/1409) | MHC class I receptor activity (1.8e-03/1.5e-01/ 4/9) | Allograft rejection (3.9e-03/4.0e-01/ 5/21) | 1 (3.3e-02/15.7737/32/965) | |
| 998 | 2.2/1.4 | 305 | 15 | positive regulation of JUN kinase activity (9.7e-04/5.1e-01/ 6/ 16) | protein binding (3.6e-02/1.4e+02/167/4505) | ||||
| 999 | 2.2/1.2 | 342 | 17 | cell cycle phase (2.0e-58/1.1e+01/ 91/ 285) | chromosome (5.0e-28/9.7e+00/ 60/ 248) | ATP binding (1.2e-07/3.0e+01/ 68/801) | Cell cycle (7.0e-18/4.0e+00/32/98) | ||
| 1000 | 2.2/1.2 | 389 | 18 | cell cycle phase (6.2e-51/1.2e+01/ 89/ 285) | chromosome (1.6e-29/1.1e+01/ 65/ 248) | ATP binding (6.8e-07/3.4e+01/ 72/801) | DNA replication (1.3e-14/1.5e+00/19/33) | ||
| 1001 | 2.2/1.2 | 350 | 17 | cell cycle phase (1.3e-45/1.2e+01/ 82/ 285) | chromosome (4.3e-23/1.0e+01/ 55/ 248) | ATP binding (7.6e-07/3.2e+01/ 68/801) | DNA replication (3.4e-13/1.6e+00/18/33) | ||
| 1002 | 2.2/1.2 | 278 | 21 | regulation of cellular process (1.7e-02/9.9e+01/125/3404) | |||||
| 1003 | 2.2/1.2 | 300 | 10 | extracellular matrix (3.2e-03/5.3e+00/ 16/ 163) | |||||
| 1004 | 2.2/1.2 | 291 | 22 | anatomical structure morphogenesis (2.2e-03/2.1e+01/ 41/ 679) | neuron projection (5.5e-03/2.0e+00/ 9/ 65) | MAPK signaling pathway (9.2e-03/5.7e+00/16/183) | 19 (5.0e-04/17.7761/41/570) | ||
| 1005 | 2.2/1 | 338 | 28 | multicellular organismal process (4.1e-04/5.1e+01/ 82/1611) | integral to plasma membrane (2.2e-05/1.8e+01/ 41/ 535) | heme binding (5.1e-05/1.4e+00/ 11/44) | Retinol metabolism (4.4e-05/7.0e-01/ 8/21) | ||
| 1006 | 2.2/1 | 390 | 33 | cell cycle phase (9.0e-53/1.2e+01/ 91/ 285) | chromosome (1.8e-27/1.1e+01/ 63/ 248) | ATP binding (9.6e-09/3.4e+01/ 77/801) | DNA replication (6.9e-17/1.6e+00/21/33) | ||
| 1007 | 2.2/1 | 303 | 21 | regulation of transcription (6.4e-04/4.1e+01/ 69/1314) | extracellular space (7.1e-04/7.4e+00/ 21/ 237) | DNA binding (1.9e-04/3.7e+01/ 67/1195) | Cytokine-cytokine receptor interaction (9.9e-03/3.4e+00/12/115) | miR-17-5p/20/93.mr/106/519.d (0.01401/24.2516/48/633) | |
| 1008 | 2.2/1 | 307 | 32 | protein kinase cascade (1.9e-02/9.0e+00/ 21/ 286) | neuron projection (6.7e-03/2.1e+00/ 9/ 65) | protein binding (4.5e-02/1.5e+02/172/4505) | 19 (2.4e-05/18.7569/46/570) | ||
| 1009 | 2/2 | 387 | 5 | immune system process (1.3e-09/2.2e+01/ 58/ 466) | extracellular region (1.7e-15/3.0e+01/ 82/ 673) | signal transducer activity (2.1e-05/3.5e+01/ 68/780) | Complement and coagulation cascades (1.6e-05/1.8e+00/12/33) | ||
| 1010 | 2/2 | 411 | 4 | organ development (1.6e-12/3.7e+01/ 87/ 729) | extracellular region (1.3e-30/3.2e+01/113/ 673) | receptor binding (2.7e-11/1.9e+01/ 59/400) | Cytokine-cytokine receptor interaction (6.6e-06/6.3e+00/23/115) | ||
| 1011 | 2/2 | 446 | 4 | extracellular region (8.4e-06/3.3e+01/ 64/ 673) | RNA helicase activity (4.9e-02/1.1e+00/ 6/23) | ||||
| 1012 | 2/2 | 546 | 4 | regulation of transcription (2.3e-05/7.0e+01/111/1314) | DNA binding (2.2e-05/6.5e+01/107/1195) | ||||
| 1013 | 2/2 | 503 | 6 | cell cycle phase (1.2e-44/1.6e+01/ 92/ 285) | chromosome (3.4e-21/1.4e+01/ 61/ 248) | ATP binding (6.6e-06/4.4e+01/ 83/801) | Cell cycle (1.0e-11/6.0e+00/30/98) | ||
| 1014 | 2/2 | 453 | 5 | regulation of biological process (3.1e-02/1.7e+02/198/3518) | |||||
| 1015 | 2/2 | 446 | 4 | multicellular organismal process (1.5e-09/7.5e+01/130/1611) | extracellular region (9.3e-11/3.2e+01/ 76/ 673) | transmembrane receptor activity (3.7e-15/1.5e+01/ 59/324) | Neuroactive ligand-receptor interaction (1.8e-04/3.9e+00/16/78) | ||
| 1016 | 2/2 | 466 | 7 | epidermis development (6.0e-03/3.2e+00/ 12/ 62) | extracellular region (7.5e-03/3.5e+01/ 56/ 673) | UDP-glycosyltransferase activity (2.2e-02/3.1e+00/ 11/61) | |||
| 1017 | 2/2 | 457 | 6 | negative regulation of foam cell differentiation (1.3e-02/3.3e-01/ 4/ 7) | |||||
| 1018 | 2/2 | 401 | 6 | transcription factor complex (2.9e-02/4.3e+00/ 12/ 106) | deacetylase activity (2.8e-02/6.4e-01/ 5/16) | ||||
| 1019 | 2/2 | 488 | 3 | nuclear division (9.0e-07/8.9e+00/ 30/ 173) | microtubule cytoskeleton (6.2e-04/1.7e+01/ 36/ 321) | calcium ion binding (3.1e-03/2.0e+01/ 40/390) | |||
| 1020 | 2/2 | 480 | 5 | nuclear division (8.8e-05/8.7e+00/ 26/ 173) | intrinsic to membrane (3.9e-02/1.0e+02/129/2010) | calcium ion transmembrane transporter activity (4.8e-02/4.5e-01/ 4/9) | |||
| 1021 | 2/2 | 493 | 3 | cell-cell recognition (9.2e-03/3.1e-01/ 4/ 6) | extracellular region (8.7e-04/3.6e+01/ 61/ 673) | endopeptidase activity (2.6e-02/9.1e+00/ 21/176) | |||
| 1022 | 2/2 | 390 | 7 | immune system process (1.5e-11/2.2e+01/ 62/ 466) | extracellular region (1.6e-16/3.1e+01/ 85/ 673) | cytokine activity (1.9e-09/3.1e+00/ 22/71) | Cytokine-cytokine receptor interaction (3.6e-08/6.7e+00/27/115) | ||
| 1023 | 2/2 | 517 | 5 | cell-cell recognition (1.0e-02/3.2e-01/ 4/ 6) | extracellular region (8.7e-04/3.7e+01/ 63/ 673) | endopeptidase inhibitor activity (1.6e-02/3.0e+00/ 11/56) | |||
| 1024 | 2/2 | 538 | 3 | G-protein signaling, coupled to cyclic nucleotide second messenger (4.0e-03/1.7e+00/ 9/ 30) | secretory granule membrane (7.7e-03/6.4e-01/ 5/ 11) | receptor activity (1.8e-04/3.0e+01/ 58/519) | Neuroactive ligand-receptor interaction (4.2e-02/4.8e+00/13/78) | ||
| 1025 | 2/2 | 386 | 7 | multicellular organismal process (8.0e-10/7.4e+01/129/1611) | extracellular region (1.6e-18/3.0e+01/ 87/ 673) | signal transducer activity (4.3e-07/3.4e+01/ 73/780) | Complement and coagulation cascades (1.3e-04/1.8e+00/11/33) | ||
| 1026 | 2/2 | 381 | 7 | response to external stimulus (1.1e-11/1.7e+01/ 53/ 364) | extracellular region (3.1e-11/3.0e+01/ 73/ 673) | signal transducer activity (1.1e-06/3.3e+01/ 70/780) | Cytokine-cytokine receptor interaction (1.6e-04/6.4e+00/21/115) | ||
| 1027 | 2/2 | 476 | 3 | cell activation (3.9e-03/7.2e+00/ 20/ 152) | |||||
| 1028 | 2/2 | 588 | 5 | cell cycle phase (1.0e-35/1.9e+01/ 91/ 285) | chromosomal part (5.3e-18/1.3e+01/ 55/ 198) | microtubule motor activity (1.3e-04/2.4e+00/ 13/37) | DNA replication (5.4e-11/2.5e+00/19/33) | ||
| 1029 | 2/2 | 535 | 3 | regulation of CD4-positive, alpha beta T cell differentiation (3.9e-02/2.2e-01/ 3/ 4) | plasma membrane (8.5e-03/7.8e+01/107/1409) | signal transducer activity (5.8e-03/4.3e+01/ 69/780) | |||
| 1030 | 2/2 | 335 | 6 | response to wounding (1.4e-10/9.3e+00/ 37/ 226) | extracellular region (3.9e-13/2.6e+01/ 71/ 673) | MHC class I receptor activity (1.1e-04/3.5e-01/ 6/9) | Complement and coagulation cascades (3.5e-04/1.6e+00/10/33) | ||
| 1031 | 2/2 | 475 | 6 | regulation of cellular process (1.6e-04/1.6e+02/205/3404) | |||||
| 1032 | 2/2 | 486 | 5 | multicellular organismal process (3.2e-02/8.1e+01/108/1611) | extracellular region (5.2e-05/3.5e+01/ 64/ 673) | endopeptidase activity (9.7e-03/8.9e+00/ 22/176) | |||
| 1033 | 2/2 | 455 | 4 | ||||||
| 1034 | 2/2 | 458 | 4 | response to wounding (2.3e-02/1.1e+01/ 23/ 226) | plasma membrane (4.4e-05/6.7e+01/105/1409) | Rap GTPase activator activity (1.3e-02/1.4e-01/ 3/3) | |||
| 1035 | 2/2 | 476 | 7 | ||||||
| 1036 | 2/2 | 501 | 4 | complement activation, classical pathway (5.1e-03/7.4e-01/ 6/ 14) | extracellular region (4.5e-04/3.6e+01/ 63/ 673) | endopeptidase inhibitor activity (1.6e-02/3.0e+00/ 11/56) | |||
| 1037 | 2/2 | 343 | 5 | multicellular organismal process (1.0e-04/5.8e+01/ 93/1611) | MHC protein complex (4.1e-06/8.4e-01/ 9/ 22) | MHC class I receptor activity (1.5e-03/3.2e-01/ 5/9) | Type I diabetes mellitus (1.3e-04/1.1e+00/ 9/26) | ||
| 1038 | 2/2 | 577 | 4 | regulation of signal transduction (9.8e-03/2.4e+01/ 43/ 371) | plasma membrane (8.7e-05/9.0e+01/131/1409) | cytokine binding (2.2e-03/3.2e+00/ 13/50) | |||
| 1039 | 2/1.8 | 460 | 8 | nuclear division (4.7e-04/8.4e+00/ 24/ 173) | microtubule cytoskeleton (4.7e-02/1.6e+01/ 28/ 321) | calcium ion binding (4.5e-02/1.9e+01/ 34/390) | |||
| 1040 | 2/1.8 | 454 | 7 | system process (3.7e-11/2.1e+01/ 60/ 445) | extracellular region (1.3e-10/3.3e+01/ 77/ 673) | transmembrane receptor activity (2.9e-12/1.5e+01/ 54/324) | Neuroactive ligand-receptor interaction (3.0e-05/3.9e+00/17/78) | ||
| 1041 | 2/1.8 | 474 | 9 | cell cycle phase (5.3e-17/1.6e+01/ 60/ 285) | chromosomal part (6.1e-07/1.1e+01/ 33/ 198) | DNA binding (7.3e-05/6.3e+01/102/1195) | DNA replication (1.1e-07/2.1e+00/15/33) | ||
| 1042 | 2/1.8 | 529 | 6 | regulation of signal transduction (7.7e-03/2.2e+01/ 41/ 371) | cytoplasmic vesicle (1.1e-05/1.8e+01/ 43/ 319) | protein binding (1.8e-03/2.7e+02/310/4505) | Pancreatic cancer (2.1e-02/4.4e+00/13/66) | ||
| 1043 | 2/1.8 | 517 | 6 | organ development (3.5e-02/4.0e+01/ 60/ 729) | extracellular region (1.5e-02/3.7e+01/ 57/ 673) | hormone activity (3.8e-02/1.5e+00/ 7/27) | |||
| 1044 | 2/1.8 | 407 | 6 | immune system process (7.2e-11/2.3e+01/ 62/ 466) | extracellular region (7.1e-12/3.1e+01/ 77/ 673) | signal transducer activity (5.9e-07/3.7e+01/ 76/780) | Complement and coagulation cascades (1.7e-04/1.8e+00/11/33) | ||
| 1045 | 2/1.8 | 437 | 5 | multicellular organismal process (1.2e-02/7.3e+01/101/1611) | integral to plasma membrane (9.5e-04/2.4e+01/ 45/ 535) | transmembrane receptor activity (3.1e-02/1.4e+01/ 28/324) | Neuroactive ligand-receptor interaction (2.3e-03/3.3e+00/13/78) | ||
| 1046 | 2/1.8 | 524 | 8 | inositol metabolic process (2.0e-02/3.8e-01/ 4/ 7) | sugar binding (2.3e-02/3.6e+00/ 12/65) | ||||
| 1047 | 2/1.8 | 527 | 6 | cell cycle phase (4.2e-42/1.7e+01/ 92/ 285) | chromosome (5.3e-20/1.5e+01/ 61/ 248) | ATP binding (1.3e-05/4.7e+01/ 85/801) | DNA replication (8.1e-11/2.2e+00/18/33) | ||
| 1048 | 2/1.8 | 489 | 11 | multicellular organismal process (2.6e-04/8.3e+01/122/1611) | intrinsic to membrane (7.6e-04/1.0e+02/142/2010) | calcium ion binding (1.8e-03/2.0e+01/ 41/390) | |||
| 1049 | 2/1.8 | 459 | 7 | morphogenesis of a polarized epithelium (2.8e-02/1.9e-01/ 3/ 4) | extracellular region (9.8e-06/3.4e+01/ 65/ 673) | glucuronosyltransferase activity (1.9e-02/5.9e-01/ 5/12) | Androgen and estrogen metabolism (3.7e-03/1.0e+00/ 7/21) | ||
| 1050 | 2/1.8 | 562 | 6 | cell cycle phase (5.2e-33/1.9e+01/ 86/ 285) | chromosomal part (2.5e-15/1.3e+01/ 50/ 198) | DNA binding (2.0e-06/7.5e+01/124/1195) | DNA replication (4.2e-12/2.5e+00/20/33) | ||
| 1051 | 2/1.8 | 335 | 6 | multicellular organismal process (3.0e-04/5.7e+01/ 89/1611) | trans-1,2-dihydrobenzene-1,2-diol dehydrogenase activity (6.5e-03/1.0e-01/ 3/3) | ||||
| 1052 | 2/1.8 | 324 | 8 | multicellular organismal process (1.2e-03/5.9e+01/ 89/1611) | proteinaceous extracellular matrix (1.3e-02/5.5e+00/ 15/ 153) | aldo-keto reductase activity (3.7e-03/3.9e-01/ 5/11) | |||
| 1053 | 2/1.8 | 446 | 7 | response to hexose stimulus (4.0e-03/2.6e-01/ 4/ 5) | membrane (1.2e-05/1.5e+02/202/3116) | GTPase activity (2.9e-03/6.3e+00/ 19/125) | Pancreatic cancer (2.0e-02/3.8e+00/12/66) | ||
| 1054 | 2/1.8 | 473 | 9 | response to external stimulus (2.3e-09/2.1e+01/ 56/ 364) | extracellular region (4.2e-12/3.8e+01/ 87/ 673) | cytokine activity (2.0e-07/3.8e+00/ 21/71) | Cytokine-cytokine receptor interaction (2.8e-05/7.9e+00/25/115) | ||
| 1055 | 2/1.8 | 424 | 10 | positive regulation of protein kinase activity (7.5e-03/4.8e+00/ 15/ 97) | vesicle (1.5e-06/1.6e+01/ 41/ 327) | cytoskeletal protein binding (3.4e-03/1.3e+01/ 29/263) | miR-320/320abcd (0.00748/22.5275/47/372) | ||
| 1056 | 2/1.8 | 467 | 9 | centromere complex assembly (1.1e-02/1.5e-01/ 3/ 3) | membrane part (2.6e-03/1.2e+02/153/2382) | adenosine deaminase activity (3.8e-02/2.0e-01/ 3/4) | |||
| 1057 | 2/1.6 | 492 | 8 | multicellular organismal process (3.3e-09/7.9e+01/134/1611) | integral to plasma membrane (4.2e-07/2.7e+01/ 60/ 535) | transmembrane receptor activity (1.8e-10/1.6e+01/ 52/324) | Neuroactive ligand-receptor interaction (5.8e-07/4.2e+00/20/78) | ||
| 1058 | 2/1.6 | 480 | 11 | activation of MAPK activity (6.8e-03/1.9e+00/ 9/ 37) | intrinsic to membrane (1.1e-03/1.0e+02/136/2010) | calcium ion binding (3.8e-02/1.9e+01/ 35/390) | MAPK signaling pathway (4.1e-02/9.3e+00/20/183) | ||
| 1059 | 2/1.6 | 490 | 9 | Golgi vesicle transport (1.0e-02/3.9e+00/ 13/ 74) | melanosome (7.8e-03/4.2e+00/ 13/ 77) | ECM-receptor interaction (2.4e-02/2.8e+00/10/58) | |||
| 1060 | 2/1.6 | 570 | 9 | cell cycle phase (4.7e-49/1.8e+01/103/ 285) | chromosome (3.0e-24/1.6e+01/ 70/ 248) | ATP binding (1.8e-05/5.1e+01/ 90/801) | Cell cycle (1.5e-13/7.3e+00/35/98) | ||
| 1061 | 2/1.6 | 503 | 13 | negative regulation of foam cell differentiation (1.9e-02/3.7e-01/ 4/ 7) | intrinsic to membrane (5.8e-03/1.1e+02/138/2010) | calcium ion binding (2.7e-03/2.1e+01/ 41/390) | |||
| 1062 | 2/1.6 | 538 | 9 | cell cycle phase (1.7e-34/1.8e+01/ 86/ 285) | condensed chromosome (6.3e-16/4.0e+00/ 29/ 66) | DNA binding (5.0e-05/7.1e+01/113/1195) | DNA replication (5.3e-09/2.4e+00/17/33) | ||
| 1063 | 2/1.6 | 449 | 11 | multicellular organismal process (4.8e-03/8.0e+01/112/1611) | extracellular region (4.1e-07/3.4e+01/ 70/ 673) | UDP-glycosyltransferase activity (1.8e-02/3.0e+00/ 11/61) | |||
| 1064 | 2/1.6 | 459 | 8 | MAPKKK cascade (2.1e-02/5.4e+00/ 15/ 112) | plasma membrane part (2.7e-04/4.1e+01/ 70/ 855) | Rap GTPase activator activity (1.3e-02/1.4e-01/ 3/3) | |||
| 1065 | 2/1.6 | 444 | 7 | signal transduction (9.3e-03/8.1e+01/111/1768) | plasma membrane part (2.0e-03/4.0e+01/ 65/ 855) | receptor binding (1.4e-02/1.8e+01/ 35/400) | |||
| 1066 | 2/1.6 | 454 | 9 | signal transduction (1.0e-02/8.1e+01/111/1768) | extracellular region (4.8e-06/3.2e+01/ 64/ 673) | Rap GTPase activator activity (1.3e-02/1.4e-01/ 3/3) | |||
| 1067 | 2/1.6 | 343 | 10 | immune system process (7.7e-12/1.9e+01/ 58/ 466) | extracellular region (1.3e-14/2.7e+01/ 75/ 673) | signal transducer activity (2.6e-07/3.1e+01/ 68/780) | Complement and coagulation cascades (4.9e-05/1.6e+00/11/33) | ||
| 1068 | 2/1.6 | 365 | 11 | multicellular organismal process (6.0e-08/6.3e+01/109/1611) | plasma membrane (6.7e-08/5.8e+01/102/1409) | signal transducer activity (1.2e-07/3.0e+01/ 68/780) | Cell adhesion molecules (CAMs) (1.7e-02/3.2e+00/11/70) | ||
| 1069 | 2/1.6 | 440 | 13 | signal transduction (3.5e-03/8.2e+01/114/1768) | 19 (1.5e-02/26.7868/49/570) | ||||
| 1070 | 2/1.4 | 458 | 13 | cell cycle phase (8.8e-41/1.5e+01/ 86/ 285) | chromosome (1.9e-19/1.3e+01/ 57/ 248) | DNA binding (7.2e-06/6.1e+01/104/1195) | DNA replication (2.3e-10/2.0e+00/17/33) | ||
| 1071 | 2/1.4 | 498 | 16 | multicellular organismal process (9.9e-07/7.9e+01/126/1611) | integral to plasma membrane (1.4e-08/2.7e+01/ 63/ 535) | transmembrane receptor activity (2.0e-09/1.6e+01/ 50/324) | Neuroactive ligand-receptor interaction (2.7e-06/4.1e+00/19/78) | ||
| 1072 | 2/1.4 | 519 | 12 | cell cycle phase (9.5e-38/1.6e+01/ 86/ 285) | chromosome (1.4e-20/1.4e+01/ 61/ 248) | microtubule motor activity (3.2e-05/2.1e+00/ 13/37) | DNA replication (5.2e-09/2.1e+00/16/33) | ||
| 1073 | 2/1.4 | 465 | 17 | positive regulation of JUN kinase activity (6.9e-04/7.6e-01/ 7/ 16) | neuron projection (2.5e-02/3.1e+00/ 10/ 65) | 19 (3.0e-03/28.3805/54/570) | |||
| 1074 | 2/1.4 | 463 | 14 | activation of MAPK activity (5.4e-03/1.8e+00/ 9/ 37) | caveola (2.7e-03/7.8e-01/ 6/ 16) | adenosine deaminase activity (3.7e-02/1.9e-01/ 3/4) | MAPK signaling pathway (4.1e-02/9.3e+00/20/183) | ||
| 1075 | 2/1.4 | 509 | 16 | multicellular organismal process (3.6e-09/8.2e+01/138/1611) | plasma membrane (6.0e-10/7.5e+01/131/1409) | transmembrane receptor activity (4.7e-13/1.6e+01/ 58/324) | Neuroactive ligand-receptor interaction (1.6e-07/4.4e+00/21/78) | ||
| 1076 | 2/1.4 | 427 | 12 | response to external stimulus (1.0e-11/1.9e+01/ 57/ 364) | extracellular space (1.9e-10/1.2e+01/ 41/ 237) | cytokine activity (2.2e-07/3.5e+00/ 20/71) | Cytokine-cytokine receptor interaction (4.8e-05/7.0e+00/23/115) | ||
| 1077 | 2/1.4 | 592 | 13 | cell cycle phase (7.6e-27/1.9e+01/ 79/ 285) | chromosome (1.5e-16/1.7e+01/ 60/ 248) | microtubule motor activity (2.8e-03/2.4e+00/ 11/37) | DNA replication (1.6e-12/2.4e+00/20/33) | ||
| 1078 | 2/1.4 | 476 | 14 | homophilic cell adhesion (7.4e-03/1.9e+00/ 9/ 37) | intrinsic to membrane (2.6e-03/1.0e+02/136/2010) | calcium ion binding (3.1e-04/2.0e+01/ 43/390) | |||
| 1079 | 2/1.4 | 581 | 13 | cell cycle phase (2.8e-32/2.0e+01/ 87/ 285) | chromosome (2.2e-20/1.7e+01/ 66/ 248) | cytokine activity (1.7e-07/4.6e+00/ 23/71) | DNA replication (7.5e-13/2.7e+00/21/33) | ||
| 1080 | 2/1.4 | 534 | 11 | cell cycle phase (3.8e-23/1.8e+01/ 73/ 285) | chromosomal part (1.9e-12/1.2e+01/ 45/ 198) | growth factor activity (1.3e-05/5.5e+00/ 22/91) | DNA replication (8.2e-09/2.5e+00/17/33) | ||
| 1081 | 2/1.4 | 391 | 10 | immune system process (6.4e-10/2.1e+01/ 57/ 466) | extracellular region (2.3e-11/3.0e+01/ 73/ 673) | signal transducer activity (2.7e-08/3.4e+01/ 76/780) | Complement and coagulation cascades (1.1e-04/1.7e+00/11/33) | ||
| 1082 | 2/1.4 | 350 | 13 | multicellular organismal process (1.3e-07/6.0e+01/105/1611) | plasma membrane (4.3e-09/5.6e+01/103/1409) | receptor activity (1.6e-06/1.9e+01/ 48/519) | Allograft rejection (9.1e-03/8.1e-01/ 6/21) | ||
| 1083 | 2/1.4 | 423 | 11 | ectoderm development (2.2e-02/3.2e+00/ 11/ 70) | extracellular region (4.9e-06/3.2e+01/ 63/ 673) | extracellular matrix structural constituent (4.4e-02/1.9e+00/ 8/42) | Androgen and estrogen metabolism (3.7e-03/1.0e+00/ 7/21) | ||
| 1084 | 2/1.2 | 558 | 19 | cell cycle phase (1.3e-43/1.8e+01/ 96/ 285) | chromosome (7.1e-25/1.6e+01/ 70/ 248) | ATP binding (6.5e-06/4.9e+01/ 89/801) | DNA replication (5.9e-14/2.3e+00/21/33) | ||
| 1085 | 2/1.2 | 456 | 23 | signal transduction (3.7e-04/8.4e+01/122/1768) | extracellular region (2.6e-03/3.2e+01/ 54/ 673) | ||||
| 1086 | 2/1.2 | 444 | 16 | vesicle-mediated transport (4.8e-03/1.8e+01/ 36/ 355) | cytoplasmic vesicle (7.6e-06/1.6e+01/ 39/ 319) | protein binding (1.4e-02/2.2e+02/259/4505) | miR-320/320abcd (0.00525/22.8559/48/372) | ||
| 1087 | 2/1.2 | 399 | 13 | inflammatory response (1.8e-05/6.4e+00/ 23/ 150) | extracellular space (1.3e-05/9.9e+00/ 29/ 237) | cytokine activity (1.9e-05/3.0e+00/ 16/71) | Cytokine-cytokine receptor interaction (4.2e-05/4.9e+00/19/115) | miR-17-5p/20/93.mr/106/519.d (0.01474/31.7394/58/633) | |
| 1088 | 2/1.2 | 488 | 18 | cell cycle phase (2.6e-52/1.5e+01/ 99/ 285) | chromosome (4.1e-27/1.4e+01/ 69/ 248) | ATP binding (2.2e-07/4.3e+01/ 86/801) | Cell cycle (2.2e-16/5.8e+00/35/98) | ||
| 1089 | 2/1.2 | 588 | 19 | DNA replication (1.1e-13/1.2e+01/ 47/ 180) | chromosome (2.1e-08/1.7e+01/ 46/ 248) | pattern binding (3.6e-02/3.9e+00/ 12/60) | DNA replication (4.5e-10/2.4e+00/18/33) | ||
| 1090 | 2/1 | 464 | 20 | regulation of transcription (1.5e-03/5.8e+01/ 89/1314) | DNA binding (2.7e-04/5.4e+01/ 88/1195) | Retinol metabolism (4.9e-02/8.0e-01/ 5/21) | |||
| 1091 | 2/1 | 468 | 33 | cell communication (1.5e-03/9.3e+01/129/1908) | plasma membrane (1.4e-03/6.6e+01/ 97/1409) | Natural killer cell mediated cytotoxicity (4.7e-02/3.7e+00/11/73) | |||
| 1092 | 2/1 | 571 | 25 | cell cycle phase (2.4e-40/1.8e+01/ 94/ 285) | chromosome (2.6e-20/1.6e+01/ 65/ 248) | ATP binding (4.3e-04/5.1e+01/ 85/801) | DNA replication (9.6e-15/2.5e+00/22/33) | ||
| 1093 | 2/1 | 465 | 33 | positive regulation of JUN kinase activity (6.7e-03/7.7e-01/ 6/ 16) | 19 (5.6e-06/28.4418/63/570) | ||||
| 1094 | 2/1 | 477 | 22 | MAPKKK cascade (1.1e-03/5.5e+00/ 18/ 112) | membrane (4.0e-02/1.5e+02/183/3116) | MAPK signaling pathway (6.3e-03/9.7e+00/23/183) |
